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Abstract 
While protein aggregation has been widely studied, it is still poorly understood. Protein 
aggregation is a complex process, resulting in heterogeneous populations of particles 
from a variety of mechanisms, which provides both intellectual and technical challenges.  
This thesis probes the mechanisms leading to protein aggregation by characterising the 
aggregation of two model proteins, lysozyme and bovine serum albumin, using a variety 
of chemical and biophysical techniques. 
 
High-throughput assays are commonly utilised for screening protein formulations. Two 
high-throughput assays were critically examined to assess the effectiveness and 
robustness of this approach for detecting protein aggregation after forced degradation (or 
accelerated aggregation testing). While these high-throughput assays do play a role in 
formulation and screening, careful consideration must be given to the interpretation of 
the analysis and the results must be viewed in context and as part of a wider 
characterization process. 
 
Chemical modification of protein structure via oxidation was also examined as a 
mechanism leading to aggregation. Oxidation of lysozyme and bovine serum albumin 
was induced with hydrogen peroxide. The secondary structure of both proteins were 
vulnerable to oxidative attack, resulting in a loss of native structure and the formation of 
both protein aggregates and protein fragments, the extent of which depended on both the 
specific protein chemistry and solution conditions.  
 
The mechanism of chemical unfolding was probed for both lysozyme and BSA with the 
addition of two denaturants; urea and guanidine hydrochloride. The mechanism by which 
each denaturant unfolds both proteins has been thoroughly studied in the past. Lysozyme 
is known to follow a two-state model, while BSA conforms to a two-step unfolding 
process via three transition states. We have demonstrated the sensitivity and reliability of 
second derivative UV analysis to characterise the unfolding states of both proteins. 
 
Finally, a monoclonal antibody, IgG1, was purified and characterised. Initial studies 
where carried out to assess the stability of this protein. Glyco-analysis was carried out to 
determine the glycan profile of the IgG1 protein and to ensure for consistency in product 
glycosylation. The stability of the glycoform was also examined in terms of length of 
storage under, different storage conditions.  
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 Protein aggregation 
Proteins are synthesized on ribosomes as a linear chain composed of 20 naturally 
occurring amino acids. The linear arrangement of these amino acids through peptide 
bonds makes up the primary structure of a protein; the basis of the polypeptide chain. The 
use of the term “protein folding” refers to the process whereby the newly synthesised 
polypeptide chain adopts a unique three-dimensional shape; the native conformation of 
the protein. This is a spontaneous process that gives the protein the shape necessary for it 
to function. This is achieved without the need for any other information beyond what is 
contained within the amino acid sequence and its surroundings (Anfinsen 1973; Dobson, 
Sali et al. 1998).  
Protein solutions are thermodynamically unstable and prone to the formation of 
protein aggregates, due to net-attraction between protein molecules. Environmental 
changes can lead to partial unfolding of the protein, and by different mechanisms to 
aggregation. Almost all proteins can aggregate in certain experimental conditions; 
however the degree to which they aggregate and the types of aggregates formed will vary 
depending on such conditions. The overall process of aggregation depends on several 
factors including temperature, solution pH, protein concentration and the presence of co-
solutes. The process of aggregation results from different interconnected mechanisms 
(Fink 1998; Manno, Emanuele et al. 1999; San Biagio, Martorana et al. 1999; Bondos 
and Bicknell 2003; Wang, Nema et al. 2010). Changes in protein structure, formation of 
intermolecular bonds, protein self-association and nucleation processes all contribute to 
the formation of protein aggregates. Despite extensive research both within academia and 
medicine, and in the biopharmaceutical industry, the complex processes that govern 
protein aggregation are still poorly understood. 
 The importance of understanding protein aggregation 
Protein aggregation is important in many different fields from biomedicine to 
biotechnology, and also many diseases associated with the deposition of amyloid 
aggregates (Dobson 2004; Ami, Natalello et al. 2013). Over 40 human diseases are 
commonly associated with protein aggregation, in particular neurodegenerative/ageing 
diseases such as Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, and 
other human diseases such as type II diabetes (DeToma, Salamekh et al. 2012). Protein 
aggregation in biopharmaceutical protein products is of growing concern, related to the 
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potential impact of aggregated protein particles on product quality, efficacy and safety. 
The increase in safety concerns stems from the suggestion that protein particles have been 
the cause of adverse events and immunogenic responses in patients (Rosenberg 2006; 
Zolls, Tantipolphan et al. 2012), yet a full understanding of the risk still remains unclear. 
How exactly particle size, morphology or molecular structure affects immunogenicity has 
not yet been established (Ripple and Dimitrova 2012). Consequently, manufacturers of 
therapeutic proteins are implementing various control strategies and continued 
improvements to minimise particle formation (Ripple and Dimitrova 2012). A better 
understanding of the aggregation risks associated with the manufacturing process, 
transportation, storage and clinical administration is required.  Recognising any potential 
for manufacturing processes to induce aggregation, along with improving the shelf-life 
of the product to ensure better stability of the formulations are some of the ways of 
managing and addressing the issues of protein aggregation (Cromwell, Hilario et al. 
2006). 
 Aggregation models and pathways 
The term “protein aggregation” has many definitions. “Protein aggregates” are here 
defined as any non-native protein species with a molecular weight higher than a protein 
monomer (i.e. dimers, oligomers, multimers…) that are formed by either physical or 
chemical changes and/or by covalent or non-covalent interactions (Mahler, Friess et al. 
2009). 
Protein aggregation can occur via numerous mechanisms, some that involve the interplay 
between different structural conformations of the protein (non-native), while others are 
not related to changes in protein structure (Fink 1998). The aggregation pathways of a 
protein are not exclusive, in that they can occur simultaneously within the same solution 
(Philo and Arakawa 2009). Protein aggregation depends strongly on the solution 
environment, as well as on the relative intrinsic thermodynamic stability of the protein 
native state. Different stress conditions can favour various aggregation pathways, leading 
to a number of mechanisms by which protein aggregation can occur leading to either the 
formation of amorphous aggregates or amyloid-type fibrils. 
 Mechanism 1 – Reversible association of the native monomer 
The surface of protein monomers are self-complementary, so that they readily self-
associate without the formation of an intermediate state, to form small oligomers which 
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are generally reversible. No structural change is required for mechanism 1. The number 
and variability of the surface patches has the potential to form multiple conformations 
and different patterns of oligomer growth. With time these oligomers can grow 
(dependent on protein concentration). Irreversible aggregates may occur through the 
formation of covalent bonds such as disulphide linkages (Philo and Arakawa 2009) within 
the non-covalent aggregate. 
 
Figure 1.1: Schematic of protein aggregation by Mechanism 1 modified from (Philo and 
Arakawa 2009). 
 
In 1970, Eisenberg suggested a reversible association mechanism for the aggregation of 
glutamate dehydrogenase (Reisler, Pouyet et al. 1970); 
 
𝑁 +  𝑁𝑛 ⇌  𝑁𝑛+1                                                   1.1 
 
where N is the native monomeric state, and Nn, is the polymerised species of length n. 
This was disputed by Thusius who claimed Eisenberg’s reversible association mechanism 
alone is not able to account for all the aggregation data in varying concentration ranges 
(Thusius 1975). They termed their mechanism the “random association mechanism” 
where by any two native protein units (N) of any size (mono- or polymeric) can associate 
together where i and j = 1, 2…..∞; 
 
𝑁𝑖  +  𝑁𝑗 ⇌  𝑁𝑖+𝑗                                                1.2 
 
Self-association of native protein is understood to be a result of non-covalent protein-
protein interactions (Wang, Nema et al. 2010). The primary step in protein condensation 
diseases stems from a loss in protein solubility due to the net attraction between the 
proteins (Benedek 1997; Annunziata, Ogun et al. 2003). An understanding of the 
molecular interactions that govern the conformation of proteins in solution goes some 
way to understanding the drive for a protein to self-associate and in determining its 
colloidal stability. In some solutions, for protein in their native state the repulsive forces 
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(table 1.1) are not sufficiently strong to overcome the attractive forces, and self-
association can occur through intermolecular interactions. 
Type Sign Strength Range 
Hydrophobic Attractive Strong Long 
Electrostatic Repulsive or 
attractive 
Weak → Stronga Short→ Longa 
Hydrogen bonding Attractive Weak Short 
Hydration Repulsive Strong Short 
Van der Waals Attractive Weak Short 
Steric repulsion Repulsive Strong Short 
Table 1.1: Types of molecular interactions between two similar proteins in aqueous 
solution.[ a depends on pH and ionic strength] (Bryant and Mcclements 1998). 
 
A structural change is not required, for this mechanism of aggregation, as shown in the 
case of human eye lens proteins (crystallins), where aggregation and phase transitions are 
thought to be driven by attractive inter-protein interactions (McManus, Lomakin et al. 
2007; Wang, Lomakin et al. 2010). Measuring the net interaction potential is a reliable 
way of predicting aggregation potential. George and Wilson (George and Wilson 1994) 
have shown that the thermodynamic parameter, the osmotic second virial coefficient (B22) 
can be used to assess the tendency of a protein to self-associate. B22 represents a 
Boltzmann-weighted average measure of protein-protein interactions; a positive B22 value 
indicates protein-protein net repulsion and favours protein-solvent interactions (proteins 
are collodially stable), while a negative value indicates protein-protein net attraction. 
Traditional methods to measure B22 values include static light scattering, dynamic light 
scattering, membrane osmometry (Tessier and Lenhoff 2003). B22 has been successfully 
used to directly quantify protein-protein interactions (Saluja, Fesinmeyer et al. 2010; 
James and McManus 2012). 
  Mechanism 2 – Aggregation of conformationally - altered monomer  
The key difference between mechanism 1 and 2 is that a conformational change or partial 
unfolding of the native state is required to form a non-native aggregate. Without this 
structural change/unfolding, the native monomer has a low propensity to aggregate 
through reversible interactions. Once it undergoes conformational changes or partial 
unfolding (forming an intermediate state)  associations typical of mechanism 1 are formed 
(Philo and Arakawa 2009). 
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Figure 1.2: Schematic of protein aggregation by Mechanism 2 modified from (Philo and 
Arakawa 2009). 
 
In order for a natively folded monomer to form structurally perturbed, higher order 
aggregates the native state needs to first undergo both a structural change and an assembly 
process which is generally irreversible once the aggregates get to a sufficient size (Chi, 
Krishnan et al. 2003).  This model of protein aggregation was first presented by Lumry 
and Erying in 1954 known as the Lumry-Eyring framework model (Lumry and Eyring 
1954), proposing that the native protein (N) undergoes an intramolecular transformation 
into a transition state (TS*) preceding the formation of an aggregation-competent 
intermediate (AI), followed by the irreversible assembly into aggregates. Am and Am+I are 
aggregates containing m and m + I protein molecules; 
𝑁 ⇌ 𝑇𝑆∗ →  𝐴𝐼                                                  1.3 
 
𝐴𝐼  + 𝐴𝑚  →  𝐴𝑚 +𝐼                                               1.4 
 
A representative reaction diagram for the irreversible association of non-native protein is 
shown in Figure 1.3. In this reaction the formation of Am is favoured thermodynamically 
and therefore has the lowest free energy. Each reaction proceeds through energy barriers. 
The maximum energy state is the formation of the TS*state and the free energy between 
this state and that of the native state (N) is the activation free energy (ΔG҂) (Chi, Krishnan 
et al. 2003).  
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Figure 1.3: Schematic reaction coordinate diagram of a protein aggregation mechanism 
of a structurally altered protein (mechanism 2). Modified from (Chi, Krishnan et al. 
2003). 
 
Much of the research in this area suggests that this is probably the most dominant 
mechanism of protein aggregation and the most problematic because it is encountered so 
routinely in protein formulation (Wang, Singh et al. 2012; Elvin, Couston et al. 2013). 
Many conformational diseases, also known as misfolding diseases, result from proteins 
with a mutated gene sequence whereby the protein cannot adopt a native folded 
conformation, structural modification or by an incorrect folding process leading to self-
association and subsequent aggregation e.g. prion, tau, alpha-synuclein and amyloid-
beta peptide (Moreno-Gonzalez and Soto 2011). Experimental examples and theoretical 
models suggest that fundamentally any protein can form non-native aggregates in solution 
if incubated for sufficient time without the intervention of other process such as chemical 
or proteolytic degradation (Roberts 2007). The aggregation of protein via this mechanism 
is promoted by numerous stresses such as heat, chemical unfolding or shear. 
 Mechanism 3 – Aggregates by chemically-modified product 
This mechanism is similar to mechanism 2, except that the aggregation proceeds from a 
covalent structural alteration (specific interaction) to the native state through a method of 
chemical degradation i.e. oxidation, deamidation, proteolysis, photo decomposition or 
disulphide bond shuffling. The non-native monomers are capable of inducing aggregation 
of native monomers by altering their physical properties such as their hydrophobicity or 
association tendency through the generation of sticky patches on their surface, or a 
reduction or change in the electrical charge in a way that reduces the electrostatic 
repulsion between monomers. They also induce changes to the secondary/tertiary 
structures of a protein. Aggregates formed through this pathway can be composed of 
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either chemically modified monomers, but can also have native monomers engaged in the 
aggregates (Philo and Arakawa 2009; Amani and Naeem 2013). 
 
 
Figure 1.4: Schematic of protein aggregation by Mechanism 3 modified from (Philo and 
Arakawa 2009). 
 
Chemical modification can result in cleavage of protein to yield lower-molecular weight 
products or cross-linkage of protein to yield higher molecular weight products. 
 Mechanism 4 – Nucleation-controlled aggregation  
Nucleation driven aggregation involves free monomers coming together to form a critical 
sized nucleus, which is followed by elongation steps via the irreversible addition of 
monomers. Once the nucleus is formed, it acts as a seed for further growth of the 
aggregate. Nucleation driven aggregation is generally preceded by some structural 
alteration to the protein (Moreno-Gonzalez and Soto 2011). Aggregation proceeds in two 
phases, nucleation and then growth. The formation of a critical nucleus is stochastic in 
nature and lag times before the appearance of aggregates can vary from days to years (Wu 
and Shea 2011; Cohen, Vendruscolo et al. 2012). 
 
 
Figure 1.5: Schematic of protein aggregation by Mechanism 4 modified from (Philo and 
Arakawa 2009). 
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The nucleation process is the rate limiting step for aggregates of this type i.e. the energy 
barrier results from the free energy required to create a new solid-liquid interface and 
depends on the size of the aggregate, once the size of the new phase is above a critical 
size (energy barrier is at its highest) the nucleus grows in size (Chi, Krishnan et al. 2003). 
Seeding, known as seeded polymerization, of protein solutions with preformed aggregates 
can also encourage nucleation driven aggregation. These can be made from homologous 
seeds (same as monomeric protein) or heterologous seeds (different to monomer i.e. non-
native). Because the addition of monomer to aggregates is strongly favoured by the 
thermodynamic stability of the aggregates, aggregates will dominate and recruit 
monomeric protein (Kopito 2000; Morales, Moreno-Gonzalez et al. 2013). 
Heterogeneous nucleation can also occur due to contaminants or impurities (foreign 
matter) within protein solutions acting as seeds for aggregation. Sources of contaminants 
can be manufacturing impurities such as silica particles shed by glass vials, or steel 
particles shed by piston filling pumps (Roberts and Wang 2010). 
 Mechanism 5 – Surface induced 
Protein aggregation can be mediated by undesirable adsorption to surfaces during 
purification, filtration, transportation and storage. This mechanism is closely related to, 
and can sometimes be considered alongside mechanism 4 where the surface acts as the 
critical nucleus. This aggregation pathway is initiated by reversible native monomer 
binding to surfaces inducing a conformational change in the protein structure. 
Aggregation will then propagate either on the surface or from the altered monomer 
released back into the solution. Partially unfolded protein can adsorb at interfaces directly 
(Philo and Arakawa 2009).  
 
 
Figure 1.6: Schematic of protein aggregation by Mechanism 5 modified from (Philo and 
Arakawa 2009). 
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This mechanism does not always result in structural change in the protein. The reversible 
absorption of rvPAF-AH was observed without detectable changes in the secondary or 
tertiary structure but resulted in extensive aggregation (Chi, Weickmann et al. 2005). The 
driving force behind the interactions will depend on the surface and on the solution 
conditions i.e. solution pH, salt concentration, temperature (Wang, Nema et al. 2010). 
Surface induced aggregation can also occur at air-water interfaces found in vials, syringes 
and tubing. This is generally driven by hydrophobic interactions (Amani and Naeem 
2013). The most reliable ways to measure protein adsorption and surface induced protein 
aggregation is to use fluorescent labelling to monitor changes in protein hydrophobicity 
(Yano 2012) or by monitoring loss of protein in the bulk solution (Roberts and Wang 
2010).  
 Solution conditions 
The aggregation behaviour of a protein relies on many factors, both intrinsic (protein 
structure) and extrinsic. The most significant extrinsic factor is the solution environment 
surrounding the protein, including pH, ionic strength, buffer species, excipients and 
contact materials (Mahler, Friess et al. 2009). Of these, pH is one of the most critical 
(Wang, Nema et al. 2010). Solution conditions for protein formulations need to be tightly 
controlled as proteins are expressed in an aqueous environment and many therapeutic 
proteins are in liquid form as they are typically administered by intravenous infusion or 
subcutaneous injection (Jiskoot, Randolph et al. 2012). 
 Solution pH 
Throughout this thesis, solution pH was varied as each mechanism has been 
systematically studied. The pH of a protein solution dictates the distribution of charge on 
the protein surface and is governed by differences in pKa values of the ionisable groups 
(Garcia-Moreno 2009). These charges can influence intramolecular folding interactions 
and also intermolecular protein-protein interactions. Proteins are generally only stable in 
a narrow pH range due to a delicate balance between these interactions. By simply altering 
the solution pH, the charge-charge interactions are altered (Wang, Nema et al. 2010). In 
general, protein aggregation is most likely to occur at the pI of a protein, as its solubility 
should be at its lowest due to the loss in protein charge-charge repulsive interactions. At 
                  
 
17 
 
extreme pH values, proteins are strongly charged. In some cases these dense charges on 
the protein surface greatly increase repulsive intramolecular and/or intermolecular 
interactions inducing partial unfolding of the protein exposing hydrophobic patches 
potentially increasing protein aggregation (Roberts and Wang 2010). However this is not 
the case for all proteins, some proteins can aggregate at a lower rate around their pI value 
(Majhi, Ganta et al. 2006). Solution pH can also play a role in the morphology of 
aggregates since the solution pH affects the type and density of charge on the surface and 
the degree of structural disruption (Krebs, Domike et al. 2009). 
 Characterising protein aggregates 
Protein aggregates can be categorised or classified into several different types (usually 
governed by the mechanisms mentioned in section 1.1.2), by the interactions involved in 
their formation, and their size (Ripple and Dimitrova 2012). Currently there is no 
universal method of nomenclature. The following system is a useful way of categorising 
aggregates (modified from (Mahler, Friess et al. 2009; Roberts and Wang 2010). 
 
1. Protein Conformation: predominantly native structure or non-native 
(significantly altered structure compared to native state/ partially unfolded) 
2. Linkage/type of bond: covalent (held through covalent links e.g. disulphide 
links, will not typically dissociate with chemical denaturant) or physical (held 
through non-covalent physical interactions e.g. electrostatic, hydrogen bonds, 
will typically dissociated with chemical denaturant) 
3. Reversibility: reversible (dissociates upon reversal of solution condition that 
initiated their formation) or irreversible (remain associated in higher order sate 
upon reversal of solution conditions that initiated their formation) 
4. Size: soluble (typically dimers, trimers, oligomers that are not visible under a 
microscope), subvisible (between 0.1 – 100 μm, can induce visible turbidity if 
present in high concentrations) or visible (larger than 100 μm, can be visualised 
with naked eye) 
 
The aggregation process can lead to aggregates ranging in size from nanometres to 
millimetres. For this reason, it is useful to categorise the particle types produced. Again 
there is no universal method, nor is there a consistent definition of what “soluble” or 
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“insoluble” aggregates refers to. Soluble aggregates are generally considered as those that 
are not visible as discrete particles, while insoluble aggregates are referred to aggregates 
that are often visible to the unaided eye (Cromwell, Hilario et al. 2006). The terms 
subvisible and visible are also used to discriminate between particle sizes (Ripple and 
Dimitrova 2012). Figure 1.7 is a representation of the size range of aggregates and their 
relevant terms of characterisation. 
 
Figure 1.7: Representation of the approximate size and characterisation terms for 
protein aggregates modified from (Mahler, Friess et al. 2009). 
 
 
The macroscopic attributes (morphology) of protein aggregates is highly variable but can 
be generalised into amorphous or fibrillar material depending on the protein and its 
environment (Mahler, Friess et al. 2009; Roberts and Wang 2010). 
 Fibrillar aggregates 
Fibrillar aggregates are frequently associated with amyloid plaque formation. 
Amyloidogenesis is a condition defined by the process of soluble protein turning into 
insoluble aggregates known as amyloid fibrils generally driven by a nucleation dependent 
pathway (Bhak, Choe et al. 2009). Some of the most-well known amyloid related diseases 
are neurodegenerative disorders such as Alzheimer’s diseases, Parkinson’s disease and 
Huntington’s diseases associated with the accumulation of these fibrils (Dobson 1999). 
The proteins and peptides associated with these diseases do not share primary amino acid 
sequences or structural homologies. There is no apparent structural link between them 
that may account for their tendency to form fibrils, yet regardless of the proteins initial 
conformation, they all share common fibril characteristics (Roberts and Wang 2010; 
Amani and Naeem 2013). Proteins not associated with these diseases states have also 
been shown to form fibril structures with the same properties as amyloid fibrils (Krebs, 
Bromley et al. 2005). 
 
Fibrils are so called after their long, thin, unbranched fibrous shape (figure 1.8). They can 
be quite diverse in their diameter, length and interconnection between amyloid stands. 
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They generally exhibit optical birefringence and increased fluorescence upon association 
of dyes such as Congo red and Thioflavin T, yet the mechanism of their association to 
such dyes is still largely unknown (Biancalana, Makabe et al. 2009; Biancalana and Koide 
2010). The pathways to fibril formation usually consists of a conformational change from 
random coil (no structure) or α-helix into β-strand. They lack alpha content but have 
considerable beta-sheet formation, with parallel strands orientated perpendicular to the 
fibre axis. Antiparallel sheet orientations have also been observed. Their formation is 
stabilised by backbone hydrogen bonding and hydrophobic interactions, rather than 
through specific interactions of different side chains (Chiti, Webster et al. 1999; Hou and 
Zagorski 2004). 
 
 
Figure 1.8: Schematic of fibrillar aggregate formation modified from (Booth, Sunde et al. 
1997). 
 Amorphous aggregates 
Amorphous aggregates (figure 1.9) lack long range order. Originally it was assumed they 
were composed of completely unfolded material held together by random associations 
between hydrophobic residues, since harsh denaturants (SDS, urea) were required to 
resolubilise them. Today amorphous aggregates have been shown to consist of various 
types of assemblies without ordered intermolecular interactions (Yoshimura, Lin et al. 
2012) and also by fully folded proteins without covalent interactions e.g. α-crystallin in 
patients with cataracts (Sugiyama, Fujii et al. 2010). They can be thought of as 
heterogeneous populations of aggregates, from subpopulations of reversible, native, 
unmodified aggregates and irreversible, unfolded disulphide cross-linked aggregates 
(Narhi, Schmit et al. 2012). Detailed information about the structure of amorphous 
aggregates is lacking as they tend to scatter light interfering with spectroscopic techniques 
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typically used to characterise structure, and also because of their heterogeneity they are 
hard to study (Roberts and Wang 2010). 
 
 
Figure 1.9: Schematic of amorphous aggregate formation. 
Many amorphous aggregates have increased beta-sheet structure and diminished alpha 
helicity compared to the native state. Some amorphous aggregates have been shown to 
associate with dyes such as Congo red and Thioflavin T, suggesting at least some level 
of ordered structural elements common with fibrillar aggregates (Biancalana and Koide 
2010). Insulin initially converted into reversible amorphous aggregates, undergoes 
structural reorganisation from α-helix to β-sheet structures capable of associating with 
ThT (Owczarz and Arosio 2014). It was also shown to associate with the hydrophobic 
pocket of human serum albumin devoid of cross β-structure characteristic of fibril 
structure (Sen, Fatima et al. 2009). ThT has been shown to associate with non-amyloid 
amorphous β-aggregates devoid of fibril morphology (Chang, Liao et al. 2009). 
 Methods to measure protein aggregation 
Aggregation of protein samples during formulation and production is a serious safety 
concern due to their adverse effects and immune response in patients (Cromwell, Hilario 
et al. 2006). Therefore there is a need to establish enhanced methods to detect and monitor 
protein aggregation during manufacturing during both upstream and downstream 
processing. Many forced degradation studies have been conducted to induce aggregation 
in protein solutions, to study the aggregation process and to identify the appropriate 
techniques to monitor aggregation (Hawe, Wiggenhorn et al. 2012). While these studies 
are useful, care must be taken when interpreting the results. Since there are several 
mechanisms by which aggregation can proceed, it must be clear from the stress applied, 
which particular mechanism is driving aggregation. Techniques or approaches suitable 
for studying the fibrillation process of proteins as a result of structural change are not 
necessarily applicable to the study of reversible aggregates, while techniques useful for 
measuring protein unfolding will not hold for detecting oxidation related modifications. 
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In the absence of any prior knowledge about the characteristic of the aggregated material, 
it is necessary to employ multiple techniques to obtain as much information as possible 
(Zolls, Tantipolphan et al. 2012).  As discussed in section 1.2, aggregates across a range 
of sizes (nm to μm) may be present, meaning no single technique can reliably characterize 
the full spectrum of aggregates present. A combination of several techniques is necessary 
(Narhi, Jiang et al. 2009). A range of the major analytical techniques used for aggregation 
analysis is shown in Figure 1.10 spanning the wide variety of particle sizes that may arise 
as a result of aggregation. 
 
Figure 1.10: Variety of analytical techniques used to measure protein aggregation over 
a range of length scales. 
 
The kinetics and products of protein aggregation have been measured using at least 20 
different analytical techniques, each having pros and cons, which should be carefully 
considered in designing or selecting a suite of techniques to monitor aggregation of 
protein. Table 1.2 lists such techniques modified from (Mahler, Friess et al. 2009; Roberts 
and Wang 2010; den Engelsman, Garidel et al. 2011). 
 
Method Application Size range Advantages Disadvantages 
SE-HPLC Size estimation and 
quantification 
(soluble aggregates) 
50 –1000 kDa Robust, sensitive, 
precise 
Sample dilution, limited 
resolution, limited particle 
size range 
Mass spectroscopy Size/charge 
estimation and 
quantification  
Atomic 
resolution - 
MDa 
Very high resolution, 
high accuracy, 
precision, detailed 
structural information 
Gas phase analysis, 
requires exchange into 
volatile buffer, costly and 
expertise training  
Electrophoresis 
- Native 
 
- SDS–PAGE 
 
Size estimation 
and to distinguish 
reducible 
covalent from 
non-covalent 
aggregates 
 
5 – 1000 kDa 
 
- Easy to preform, 
detect native 
aggregates 
- Differentiation 
disulphide linked, 
non-covalent 
 
- Does not detect non - 
covalent aggregates 
 
- Mobility depends on 
charge, size, size resolution 
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Capillary 
electrophoresis 
Size estimation 
and quantification 
(soluble 
aggregates) 
5 – 1000 kDa High resolution, 
quantification, fast 
separation 
Possible protein reactions 
with capillary, doesn’t 
detect non-covalent 
Microscopy 
- Light 
- Electron 
- Atomic force  
 
Size and shape 
estimation 
 
- > 1 μm - mm 
- nm – mm 
- nm 
(resolution 
0.01 nm) 
 
- Easy, size & shape-  
- Large size range, 
high resolution 
- Molecular resolution 
 
- Limited resolution-  
- Possible artifacts, not 
quantitative 
- Time consuming, 
expensive, limited 
representativeness 
Static light 
scattering 
Size and shape 
estimation 
20 nm – 2 mm Single particles 
detection, counting, 
characterisation 
Requires sample dilution 
Dynamic light 
scattering 
Size distribution 1 nm – 10 μm Easy to preform, non-
destructive, high 
sensitivity 
Complicated data analysis, 
low resolution, sensitivity 
to artifacts 
Analytical 
ultracentrifugation 
Size, shape 
estimation and 
quantification 
1 nm – 0.1 μm Absolute method, 
measurement of 
molecule size, shape, 
high resolution 
Strongly dependent on 
instrument quality, 
complex data analysis 
Light obscuration Size and 
quantification 
(insoluble 
aggregates) 
2 – 100 μm Rapid analysis, 
counting and 
clustering 
Large sample volume, no 
morphological information 
Coulter counter Size and number 
quantification 
(insoluble 
aggregates) 
0.4 – 1.2 mm Single particle 
detection, counting 
and characterisation 
Dilution of low 
conductivity samples into 
electrolyte solution 
Visible inspection Absence or 
presence of 
visible aggregates 
> 50 μm - mm Easy to perform, 
information on size 
and shape 
Low resolution, limited 
particle discrimination, 
subjective 
Turbidimetry, 
nephelometry 
Particle 
size/concentration 
100 nm – 
several μm 
Easy to perform, 
various designs and 
methodologies 
Observed signal depends 
on both size and 
concentration, no particle 
specific detail 
UV–Vis 
spectroscopy 
Soluble and 
insoluble 
aggregates; solution 
property (no 
quantification 
possible) 
N/A Easy to perform, non-
destructive, detection 
of particles outside 
absorption bands 
Complicated data 
interpretation, limited 
information on particle 
properties 
Circular 
dichroism 
Structural 
analysis 
N/A Non-destructive, easy 
to perform, low 
protein amount 
required, undiluted 
sample analysis 
possible 
Interference by light 
scattering, limited 
resolution, complicated 
data analysis 
Fluorescence 
spectroscopy 
Structural 
analysis 
nm - μm Non-destructive, 
comprises multiple 
fluorescent techniques 
Destructive when using 
extrinsic dyes, interference 
from excipients or 
impurities 
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combined with 
microscopic tools 
(FT-)infrared 
spectroscopy 
Structural 
analysis 
N/A Non-destructive, solid 
state analysis possible, 
little inference from 
scattering, 
microscopic tools 
Low sensitivity, protein 
concentration >1 mg/ml, 
possible artifacts 
Raman 
spectroscopy 
Structural 
analysis 
N/A Non-destructive, solid 
state analysis possible, 
little inference from 
scattering, 
microscopic tools 
Particle isolation can lead 
to artifacts 
Table 1.2: Overview of analytical methods used for detecting, measuring and 
characterising protein aggregates 
 Unfolding pathways 
Most of the knowledge we have about the forces that stabilise protein conformation comes 
from thermodynamic studies of folding/unfolding (Gomez, Hilser et al. 1995) (Pace 
1986). Protein conformational stability can be described in term of Gibbs free energy, 
ΔG, between the folded and unfolded state; 
 
Δ𝐺𝑈𝑁  =  𝐺𝑈  −  𝐺𝐹                                                     1.5 
 
where ΔGUN is the difference in Gibbs free energy upon unfolding, and GU and GF are the 
Gibbs free energies of the unfolded and folded state respectively (Sancho 2013). In order 
for proteins to maintain their folded native conformation against more stable aggregated 
conformations, a high energy barrier must be overcome. This energy barrier is related to 
the mechanical stability of a protein i.e. the resistance of native proteins to be unfolded 
by external forces (Sancho 2013). 
 
Two-state behaviour systems are the simplest models for protein unfolding (Pace 1986; 
Eftink 1994); the unfolded state (U) and the folded, native state (F) are the only two 
conformations and the equilibrium constant, Kun, is the ratio of unfolded protein to the 
folded native state; 
 
𝑈 
𝐾𝑈𝑁
⇌
𝐾𝐹
𝐹                                                        1.6 
 
𝐾𝑈𝑁 =  
[𝐹]
[𝑈]
                                                      1.7 
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which can be used to calculate the ΔGUN of unfolding: 
 
 
Δ𝐺𝑈𝑁 =  −𝑅𝑇 𝐼𝑛𝐾𝑈𝑁 =  ∆𝐻𝑈𝑁 − 𝑇 ∆𝑆𝑈𝑁                             1.8 
 
where ΔHUN and ΔSUN are the enthalpy and entropy associated with unfolding. 
 
A two-state model of protein unfolding is characterised typically by a linear plot of the 
natural logarithm of the rate constants for unfolding, In KUN, and refolding, In KF, versus 
denaturant concentration [D]. A non-linear plot of such parameters can result from the 
presence of a meta-stable intermediate on or off the folding pathway (Jackson 1998). For 
some proteins the initially unfolded protein rapidly adopts a limited set of conformations 
under refolding conditions before refolding is complete. These states are termed 
“intermediates” (I) (Creighton, Darby et al. 1996); 
 
𝑈 ⇌ 𝐼 ⇌ 𝐹                                                      1.9 
 
where there is evidence of one or more intermediates in the folding process, then the 
thermodynamic models become more complex; 
 
𝐾𝐹→𝐼 =
[𝐼]
[𝐹]
, 𝐾𝐹→𝑈 =
[𝑈]
[𝐹]
                                       1.10 
 
The corresponding rate constants need to be calculated for each intermediate state 
transition; ΔGF⟶I, ΔHF⟶I, ΔSF⟶I, ΔGI⟶U ΔHI⟶U, ΔSI⟶U. 
 
Intermediate states are generally less folded than the native state but more folded than the 
denatured state (Sancho 2013). Identifying the existence of intermediate states and 
characterising its spectral properties is a difficult challenge as it will depend on how 
extensively the intermediate state is populated and requires a significant difference in 
fluorescence properties of the three states (Eftink 1994). The kinetic importance of these 
states is still largely unknown, some believing they are off-pathway conformations that 
are kinetically trapped (Gruebele 1999). In order for the intermediate state to be deemed 
a productive and obligatory state through which the molecule must pass, a lag phase 
before the appearance of the native state is formed is required, corresponding to the time 
it takes for I to be generated. However this lag phase is generally undetectable (Creighton, 
Darby et al. 1996). Conventional free energy diagrams as in Figure 1.11 are commonly 
used to illustrate the folding/unfolding pathway of a protein. The wells portray the 
sequence and stability of intermediates and end states. 
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Figure 1.11: Free energy diagram illustrating the folding/unfolding of protein 
molecules. Change in the relative free energies for two-state or three-state 
(intermediate) folding. Thermodynamic states (U- unfolded, I- intermediate, F- folded). 
 Forced degradation and aggregation 
Tuning environmental conditions and stress mechanisms can result in the destabilisation 
of the native conformation of protein and also encourage protein-protein interactions 
leading to protein aggregation as discussed in section 1.1.2. This type of stress-testing/ 
forced-degradation studies (i.e. accelerated aggregation) are commonly used during the 
development of protein formulations (Hawe, Wiggenhorn et al. 2012). These practises 
are essential for obtaining information on potential degradation pathways, ensuring 
analytical methods are satisfactory and identifying potential stabilisers and optimal 
conditions are achieved (Hasija, Li et al. 2013). 
 Thermal stress – Mechanism 2 
Proteins have a limited temperature range where their structural integrity is maintained, 
outside of this range the protein is likely to denature. Thermal denaturation, is one of the 
most common stress mechanisms used for accelerated aggregation testing (Bischof and 
He 2005; Hawe, Wiggenhorn et al. 2012). Exposure of proteins to elevated temperatures 
perturbs their native conformation to such a degree that intermediate (partially unfolded) 
states are formed that can promote aggregation. The melting temperature (Tm) of a protein 
is often used to assess its thermal stability. Tm is expressed as the peak temperature where 
a protein molecule is half way through the unfolding process (temperature where half the 
protein is denatured) and therefore proteins often rapidly aggregate near their Tm (Cooper 
1999; Wang, Nema et al. 2010). The prediction of protein aggregation on Tm is not wholly 
reliable, a higher Tm does not ensure a lower tendency of a protein to aggregate by other 
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mechanisms, and instead it is the actual solution conditions that control protein 
aggregation (Blumlein and McManus 2013). The thermal unfolding of IL-Ira mutant (Tm 
=63 ○C) did not lead to immediate aggregation, and was reversible measured by CD 
(Myers, Pace et al. 1995). To accurately interpret thermal scans, a prior knowledge or 
assumptions of the relative enthalpy and heat capacity values of the aggregates being 
formed are required. Tm values should only be used for qualitatively ranking of solution 
conditions where aggregation is likely to occur (Weiss, Young et al. 2009). 
 
After thermal denaturation, during cooling and refolding of the protein there are 
competing pathways leading to either the native state or an aggregated state. These are 
governed by attractive and repulsive forces brought about by the solution environment 
surrounding the protein. At pH values close to the pI of a protein, there is a shift from net 
repulsion between the protein molecules to attraction. Therefore repulsive interactions are 
essentially screened and there is an overall attraction between the molecules increasing 
the chance of aggregation as the protein is thermally unfolded at elevated temperatures. 
The screening of the repulsive charges, is coupled with the exposure of hydrophobic 
residues on the protein surface thus increasing the probability of protein aggregation 
through either specific or non-specific interactions between hydrophobic regions of 
different molecules (Goldberg, Rudolph et al. 1991; Calamai, Canale et al. 2005). 
 
Several methods can be used to measure thermal denaturation of protein. Differential 
scanning calorimetry (DSC) is commonly applied to monitor the thermal behaviour of 
protein solutions as it is the only technique that can measure the calorimetric effect 
associated with the protein structural change. It can also directly quantitate protein 
unfolding. It measures the specific heat of a sample as temperature is increased and can 
detect the heat absorbed during transition from a native to a denatured state, thus 
determining the relative amounts of each state (Freeman, Borrelli et al. 1999). Numerous 
groups have followed the calorimetric events associated with protein structural change as 
a result of their structural environment, altering parameters such as protein concentration, 
pH, ionic strength, presence of co-solutes and ion type (Garbett, Mekmaysy et al. 2009; 
Luo, Wu et al. 2011; Blumlein and McManus 2013) 
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 Chemical denaturation induced unfolding – Mechanism 2 
The native state of a protein is characterised by its tightly folded and highly ordered 
conformation. With the use of chemical denaturants (urea, guanidine hydrochloride), this 
folded native stated can be induced to unfold the polypeptide chain, resulting in the 
protein adopting a largely disordered structure. The formation of these partially unfolded 
states can induce protein aggregation through interactions detailed in Table 1.1. (Roberts 
and Wang 2010).  
 
The chemical unfolding of a protein using denaturants has been carried out in countless 
studies (Dill and Shortle 1991; Street, Courtemanche et al. 2008). Despite their 
widespread use, the molecular basis for urea and guanidine hydrochloride induced protein 
denaturation remains unknown and is under intense investigation (Cao and Li 2008; 
Constatinescu, Herrmann et al. 2010; Gao, She et al. 2010; Buchner, Murphy et al. 2011). 
Both “indirect” and “direct” mechanisms are proposed. The ‘indirect’ mechanism 
suggests that the denaturant alters the solvent environment by disruption of the water 
structure, weakening the hydrogen bonds between water and the protein to facilitate the 
exposure of residues in the hydrophobic core. One such model was proposed by Frank 
and Franks whereby urea only interacted with the disordered state of water, pulling it 
away the more ordered state and thereby indirectly “breaks” the water structure (Frank 
1968). 
 
In recent years, the general consensus falls to the ‘direct’ mechanism which suggests that 
the denaturant unfolds the protein through direct interactions with the protein by 
displacement of water molecules from the protein. It directly binds to and stabilises the 
denatured state favouring unfolding. Kumaran and Ramamurthy used several urea 
derivatives to show direct hydrogen-bonding interaction of the N-H moiety of urea with 
the hydrogen bonding functional groups of BSA to induce unfolding (Kumaran and 
Ramamurthy 2011). Schellman (Schellman 1994) reported that one urea replaces one 
water molecule, a view not supported by Lim et al. who proposed the idea that since urea 
is approximately three times larger than a water molecule, that a single urea molecule 
should replace three water molecules (Lim, Rosgen et al. 2009). A third view believes 
that both mechanisms might play a role in chemical unfolding of protein. Daggett and co-
workers (Bennion and Daggett 2003) showed both direct urea interactions consisting of  
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hydrogen bonding to the polar moieties of the protein, while also promoting indirect 
unfolding by altering the water structure and dynamics. 
 Chemical alteration – Mechanism 3 
Chemical modifications of proteins are complex and do not appear to be solely dependent 
on the amino acid affected but also on sequential and structural neighbours (Reubsaet, 
Beijnen et al. 1998). Several spontaneous and induced chemical alterations such as 
oxidation, deamidation, hydrolysis, β-elimination and racemisation can affect protein 
degradation and aggregation resulting in fragmentation and aggregation of the protein 
(Roberts and Wang 2010). The oxidation of proteins will be discussed in more detail 
below. 
 Oxidation 
Aerobic organisms constantly produce small amounts of free radicals. Free radicals are a 
reactive chemical species that have an odd number of electrons rendering them highly 
active with relatively short lifetimes (Davies and Pryor 2005). Oxidative stress (OS) can 
occur within organisms when their defence mechanisms designed to protect themselves 
are unable to adequately remove these free radicals, or they are generated in such excess 
beyond the ability of the defence to cope with. OS can result is several metabolic 
dysfunctions; peroxidation of membrane lipids, depletion of nicotinamide nucleotides, 
rises in intracellular free Ca²⁺ ions, cytoskeleton disruption and DNA damage (Jomova, 
Vondrakova et al. 2010). 
 
Free radicals are formed via biochemical processes that involve the generation of reactive 
oxygen and nitrogen species (ROS and RON), as a by-product from normal cellular 
metabolism (Kaur, Kaur et al. 2014). ROS are molecules that contain one or more 
unpaired electrons and singlet oxygen, rendering them highly reactive and damaging to 
cells. They are formed by the consecutive intracellular reduction of molecular oxygen to 
produce the superoxide anion radical (O2⦁⁻), hydrogen peroxide (H2O2) and hydroxyl 
radical (⦁OH) (Liu, Fiskum et al. 2002). O2⦁⁻ is the primary free radical and is produced 
as a side product in the mitochondria during energy transduction reactions. O2⦁⁻ is a short 
lived radical and the major proportion of it is converted into H2O2 and molecular oxygen 
by superoxide-dimustase (SOD), an enzyme that catalyses the partitioning of the toxic 
O2⦁⁻ radical (Henkler, Brinkmann et al. 2010); 
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𝑆𝑂𝐷 +  4𝑂2⦁
− + 4𝐻+  →  𝑆𝑂𝐷 +  2𝐻2 𝑂2  +  𝑂2                            1.11 
 
Hydrogen peroxide is a harmful by-product of many normal metabolic processes. To 
prevent damage, it must be quickly converted into other, less dangerous substances. H2O2 
is a strong oxidant and can be further reduced into the hydroxyl radical ⦁OH, the neutral 
form of hydroxide ion and is a highly reactive radical with a half-life of nanoseconds 
(Sies 1997). Among the many types of free radicals generated, the hydroxyl radical is one 
of the most potent. It is formed via the Haber-Weiss reaction by oxidation of superoxide 
anion radical; 
 
     𝑂2⦁
−  +  𝐻2 𝑂2  →   ⦁𝑂𝐻 +  𝑂𝐻
−  + 𝑂2                             1.12 
 
The oxidation of proteins is believed to be a relatively rapid process as the changes in 
conformation exposes more susceptible residues. For example, the nitration of tyrosine to 
form peroxynitrite (ONOO-) from the reaction of NO- with superoxide, NO⦁ and O2⦁⁻ 
occurs in k = 6.7 x 109 M-1 s-1 (Huie and Padmaja 1993), while peroxiredoxin has been 
shown to reaction with H2O2 with a rate constant of k = 1.3 x 10
7 M-1 s-1 (Peskin, Low et 
al. 2007). In excessive cases, massive protein damage can result in the formation of large 
aggregates that cannot be degraded themselves. In excessive cases, massive protein 
damage can result in the formation of large aggregates that cannot be degraded 
themselves. There are numerous mechanisms for the induction of protein oxidation as 
highlighted in Table 1.3. All of the amino side chains can become oxidatively modified 
making them more susceptible to oxidation (Shacter 2000). The rate of protein oxidation 
can be affected by both intrinsic (flexibility of the peptide backbone and overall structure) 
and extrinsic factors (pH and buffer type). It can also be broken down into two categories; 
site specific (metal catalysed oxidation (MCO)) or non-site specific (photooxidation and 
free radical cascades) (Manning, Chou et al. 2010). 
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Modification Amino acids involved Oxidising source* 
Disulfides, glutathiolation Cys All, ONOO- 
Methionine sulfoxide Met All, ONOO- 
Carbonyls (aldehydes, ketones) All (Lys, Arg, Pro, Thr) All 
Oxo-histidine His γ-Ray, MCO, 1O2 
Dityrosine Tyr Tyr γ-Ray, MCO, 1O2 
Chlorotyrosine Tyr HOCl 
Nitrotyrosine Tyr ONOO- 
Tryptophanyl modifications 
(N-formyl)kynurenine 
Trp γ-Ray 
Hydro(pero)xy derivatives Val, Leu, Tyr, Trp γ-Ray 
Chloramines, deamination Lys HOCl 
Lipid peroxidation adducts 
(MDA, HNE, acrolein) 
Lys, Cys, His γ-Ray, MCO (not HOCl) 
Amino acid oxidation adducts Lys, Cys, His HOCl 
Glycoxidation adducts Lys Glucose 
Cross-links, aggregates, fragments Several All 
Table 1.3: Oxidative modifications of proteins (modified from (Shacter 2000)) 
*MCO-metal catalysed oxidation; All = γ-ray, HOCL, ozone, 1O2. 
 
 
 
Figure 1.12: Commonly observed oxidative modifications of protein amino acids caused 
by reactive oxygen species (ROS) modified from (Moller, Jensen et al. 2007). 
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The most common oxidative protein modifications of amino acids residues are shown in 
Figure 1.12. These include cysteine, methionine and tryptophan. Peroxide molecules can 
be introduced into a formulation by trace amounts of impurities in the added excipients 
such as surfactants. As a result, oxidation of proteins in a forced condition of excess H2O2 
is one of the most commonly used models in order to understand protein oxidation in 
solutions. The oxidation of protein can be limited with more efficient packing and storage, 
lessening the likelihood for photooxidation or less exposure to oxygen by decreasing the 
deal volume in vials. The addition of additives into the formulation has shown to improve 
oxidation levels (Manning, Chou et al. 2010) 
 Model proteins 
Throughout this thesis, lysozyme and bovine serum albumin have been used as model 
systems to examine how protein aggregation proceeds for each mechanism. These two 
proteins were selected since they are available in high purity, at a reasonable cost and the 
properties of these proteins have been well established through many studies. Some of 
their structural features are listed in Table 1.4 
 
Protein 
Mw 
(Da) 
Secondary 
structure 
pI S-S 
bridges 
Chromophores Tm 
Lysozyme 14,307 4 α‐helices 
5 β-sheets 
random coil 
11 4 Phen - 3 
Tyr - 3 
Trp - 6 
>75 ○C 
 
BSA 66,000 67% α‐helices 
16 % β-sheets 
29% random coil 
5.1 17 Phen - 27 
Tyr - 20 
Trp - 2 
>65 – 70 ○C 
 
Table 1.4: Properties of lysozyme and BSA. 
 Lysozyme 
Lysozyme in an enzyme found in bodily secretions (nasal, tears, saliva, serum). Hen egg 
white lysozyme (HEWL), is a natively monomeric protein made up of 129 amino acids 
that fold into a compact globular structure with a molecular weight of 14, 307 Da. This 
structure was first sequenced in 1963 by enzymatic digestion of reduced 
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carboxymethylated HEWL (Canfield 1963; Jolles, Jauregui Adell et al. 1963). It is 
composed of two domains, alpha (green features) and beta (red features) (figure 1. 13). 
 
Figure 1.13: A) Ribbon representation of the crystal structure of and B) the amino acid 
sequence(PDB code: 3LZT) (ProteinDataBank). 
 
The α-domain (residues 1 – 35, 85 – 129) comprises four α-helices, and a single short 310-
helix. Within the α-domain there is a core of hydrophobic side-chains that are packed 
closely together. Its β-domain (residues 36 – 84) is made up of a triple–stranded 
antiparallel β-sheet, a long loop and a 310-helix. There is no core hydrophobic region, 
instead hydrogen bonds and a number of small hydrophobic clusters are believed to be 
responsible for maintaining the tertiary structure. There is also a long exposed loop region 
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(Schwalbe, Grimshaw et al. 2001). Four disulphide bonds formed between eight cysteine 
residues (6:127, 30:115, 64:80 and 76:94) also contribute to the folded conformation. The 
disulphide bond between cysteine residues 76:94 supports both domains. The ratio of 
tryptophan to tyrosine is 2:1. There are 6 tryptophan residues from which the intrinsic 
fluorescence dominates (Trp-28, -62, -63, -108, -111 and -123). Of these Trp-62, -63 and 
-108 are located in the active site, from which the bulk fluorescence comes from Trp-62 
and -108 (Imoto, Forster et al. 1972; Formoso and Forster 1975). 
 Bovine serum albumin 
Serum albumin is one of the most abundant proteins in plasma and aids in maintenance 
of circulating fluid within the vascular system, acting to transport a variety of endogenous 
and exogenous compounds (Zilg, Schneider et al. 1980). Bovine and human serum 
albumin are commonly used in experimental studies. The structure of serum albumins 
have been extensively studied (Peters 1985). Both are very similar globular proteins 
performing the same functions and sharing high sequence homology with the major 
difference being their number of amino acids; HSA is made up of 585 with BSA having 
582. 
 
BSA has a molecular weight of 66,000 Da. It is a multi-domain monomer protein made 
up of three homologous domains (I, II, III) which are divided into nine loops giving it an 
overall heart-like shape. The secondary structure consists of 55% α-helix, 16% β-sheet 
and 29% disordered structure. Each domain displays specific structural functional 
characteristics and is composed of two further subdomains; subdomain A containing six 
helices and subdomain B with four helices. It contains 35 cysteine residues of which 17 
are involved in disulphide bonds stabilising its tertiary structure, with one free thiol group 
at position 34 (Reed, Feldhoff et al. 1975; Peters 1985; Carter, He et al. 1989; Bujacz 
2012). It’s believed that this free thiol group may not be essential in the formation of large 
aggregates, but is likely to play a role in the intermolecular cross-links between 
aggregates (Hillier, Lyster et al. 1980; Matsudomi, Rector et al. 1991; Boye, Alli et al. 
1996) and in the thermal aggregation pathways of BSA (Militello, Casarino et al. 2004). 
Despite numerous methods to determine its tertiary structure, its three dimensional 
molecular structure has remained largely under debate (Ferrer, Duchowicz et al. 2001; 
Huang, Kim et al. 2004). Based on hydrodynamic experiments (Bloomfield 1966; Wright 
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and Thompson 1975) and low angle X-ray scattering (Bloomfield 1966), serum albumin 
was postulated to be an oblate ellipsoid. NMR studies have indicated it’s a heart shaped 
structure (Bos, Labro et al. 1989).  Bujacz recently determined the crystal structure of 
BSA at 2.47 Å resolution (figure 1.14) exhibiting only 75.8% homology to HSA with 
differences in surface structure, the binding pockets and charge distribution (Bujacz 
2012). 
 
Figure 1.14: A) Crystal structure of BSA. B) Domain division of BSA (I – blue, II – 
purple, III – cyan). C) Charge distribution on the surface of BSA; molecules in the 
orientation with domain I on the left and further domains arranged anticlockwise. 
D) Charge distribution on the surface of BSA; domain I is on the right and the domains 
are arranged clockwise. E) The amino acid sequence (PDB code:1AO6 ) 
(ProteinDataBank ; Bujacz 2012). 
 
BSA has several conformational transformations induced by pH changes (figure 1.15). 
BSA is natively folded between pH 4.5 to 7. Lowering the pH to 3.5 – 2 creates the fast 
form (F, fast migration in gel electrophoresis) and the expanded form (E). Raising the pH 
from 7 to 9 introduces the basic form (B) and finally the expanded form at pH 11.5 
(Michnik, Michalik et al. 2005) 
 
Figure 1.15: BSA structural conformations related to pH changes 
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 Therapeutic Proteins 
Aggregation of bio-therapeutics is a major issue for the advancement of products to 
market. With numerous monoclonal antibodies already on the market and many more in 
development, understanding the factors that affect their efficiency and safety is greatly 
significant (Schellekens 2003; Bhogal 2010; Tovey and Lallemand 2011; Arvinte, Palais 
et al. 2013). Development of stable formulations is of upmost importance for the success 
of protein drugs. Various factors contribute to the aggregation of therapeutic proteins 
including temperature, light, solution conditions (pH, buffer type, concentration, and 
ionic strength), protein concentration, process and purification steps, and storage 
conditions meaning that control of protein stability is a challenging task for many 
pharmaceutical companies. Protein aggregation can result in reduced biological activity, 
but most importantly it can result in immunogenicity and/or cellular toxicities (Demeule, 
Gurny et al. 2006). Compromised immunoglobulin formulations have been shown to 
cause serious renal failure, and anaphylactoid reactions such as headache, fever and chills 
(Nydegger and Sturzenegger 1999; Aghamohammadi, Farhoudi et al. 2003). Despite the 
numerous advancements in improving therapeutic formulations, novel drug modifications 
are also helping to overcome these issues. These can either be genetic or chemical 
modifications; site-specific mutagenesis, PEGylation, sialyation, lipid based vehicles, 
hyperglycosylation and protein fusion (Pisal, Kosloski et al. 2010). Key steps in all such 
modifications is preservation of protein activity and stability as all can result in reduction 
and/or complete loss in protein activity (Roberts and Wang 2010). 
 Production of therapeutic proteins – monoclonal antibodies 
Antibodies (also known as immunoglobulins) are glycoproteins made up of 3 – 12% 
carbohydrates at conserved N-glycosylation sites (Leibiger, Wustner et al. 1999), 
produced naturally in the body by plasma cells in response to an invasion of foreign 
substances (antigens). They are the body’s first natural defence system (Paul 1993; Pathak 
and Benita 2012). The advent of hybridoma technology by Georges Köhler and Cèsar 
Milstein in 1975 (Kohler and Milstein 1975) has enabled the production of monoclonal 
antibodies. Monoclonal antibodies (mAbs) are the fastest growing category of 
therapeutics entering clinical study, primarily in development for treatment of cancer and 
immunological disorders (Nelson, Dhimolea et al. 2010; Casi and Neri 2012). The use of 
glycoengineering to produce antibodies with specific glyco forms can increase the 
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therapeutic efficiency of mAbs (Zheng, Bantog et al. 2011). Transfected cell lines are 
used to synthesize a wide range of compounds that can be extracted and purified for use 
as biopharmaceuticals. It also makes it possible to generate cells lines that can produce 
molecules to be easily engineered to optimise their therapeutic properties (Paul 1993). 
The predominant cell line used for human recombinant protein production is the Chinese 
Hamster Ovary (CHO) cell line (Chusainow, Yang et al. 2009). This cell line has been 
approved and licensed for the synthesis of therapeutic products including glycoproteins 
(Hossler, Khattak et al. 2009). It is the most commonly used cell line for antibody 
expression and has been shown to produce glycosylation patterns compatible with the 
human immune system (Shukla and Thommes 2010). 
 Antibodies 
Antibodies are dived into 5 classes based on their differing structure IgA, IgD, IgE, IgM 
and IgG (figure 1.16). Generally antibodies are Y-shaped molecules, either singular 
(monomeric) or in a combination (dimers, pentamers). They can be divided into two 
regions; the variable (V) region has the defining antigen binding properties, while the 
constant (C) region interacts with effector cells and molecules. They are divided into 
classes based on their C regions (Beale and Feinstein 1976). 
 
Figure 1.16: Structure of 5 classes of antibodies and their molecular formation. 
 Immunoglobulin G 
Immunoglobulin G (IgG) is the most abundant serum immunoglobulin with 
concentrations of approximately 10–15 mg/ml and also the majority of marketed mAbs 
belong to the IgG class (Weiner, Surana et al. 2010). They have two identical heavy 
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chains (H, 50 kDa) and two identical light chains (L, 25 kDa) and can be further sub-
divided into four different subclasses (IgG1, IgG2, IgG3 and IgG4) depending on the 
number and location of interchain disulphide bonds and the length of the hinge region of 
the heavy chain, named γ1, γ2, γ3 and γ4. There is also variation in the light chain giving 
rise to two types- lambda (𝜆) and kappa (κ). Each IgG molecule is bi-functional. The 
variable region of both chains mostly consists of the first 110 amino acids and forms the 
antigen-binding fragment (Fab) that recognizes the respective antigen targets. These can 
be further sub-divided into three hypervariable sequences (HV1, HV2 and HV3) on both 
the heavy and light chains and provides the structural basis for the enormous 
immunological diversity in antibodies. The rest of the sequence consists of the Fc region 
that works to interact with receptors on effectors cells (Amzel and Poljak 1979; Schroeder 
and Cavacini 2010; Weiner, Surana et al. 2010). 
 
 
Figure 1.17: Line structure of immunoglobulin G along with crystal structure 
representation of IgG2a monoclonal antibody as per the protein data bank (1ight), 
created using Chimera 1.8.1. 
 
 Glycosylation 
A glycoprotein is one that contains an oligosaccharide chain covalently attached to the 
polypeptide side chain. This process, known as glycosylation, is one of the most complex 
post-translational modifications. There are two major types; the covalent attachment of 
oligosaccharides through the amide side-chain nitrogen of an asparagine (Asn) residue 
(N-linked), or though the oxygen side chain of serine or threonine (O-linked) of a 
polypeptide chain (figure 1.18). 
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Figure 1.18: Structure of N-linked and O-linked glycans. 
 
Glycosylation is carried out in a step-wise, highly ordered, site specific manner in the 
Golgi apparatus, where the activity of each enzyme is dependent upon the completion of 
the previous enzymatic reaction. The structure of the oligosaccharides (the glycan chain) 
is determined in part by the conformation of the polypeptide chain in the immediate 
vicinity of the amino acid residue being processed and the availability of different 
glycoemzymes to complete the glycan structure (Schwarz and Aebi 2011).  
 
There are five different N-glycosidic linkages, with N-acetylgucosamine to asparagine 
(GlcNa-Asn) being the most common. This linkage was discovered by biochemical 
analyses of immunoglobulins (Stanley, Schachter et al. 2009). Not all asparagine residues 
can accept an N-glycan, the minimal sequence must contain the sequon (Asn-Xaa-
Ser/Thr) where Xaa is any amino acid accept proline. All N-glycans share a mutual core 
sugar sequence, Manα1-6(Manα1-3)Manβ1-4GlcNacβ1-4GlcNacβ1-Asn-Xaa-Ser/Thr 
and can be classified into three types as shown in Figure 1.19. 1) Oligomannose - only 
mannose residues are attached at the core, 2) Complex - antennae initiated by N-
acetylglucosaminyltranferases (GlcNAcTs) are attached at the core and 3) Hybrid - only 
mannose residues are attached to the Manα1-6 arm of the core and one or two antennae 
are on the Manα1-3 arm. Researchers in this field use pictorial diagrams such as those in 
Figure 1.17, composed of small geometric symbols to represent individual constituent 
monosaccharides to aid in describing the structures of many carbohydrates. 
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Figure 1.19: Structural diversity in the three classes of N-linked glycans (Stanley, 
Schachter et al. 2009). N-glycans added to protein at Asn-Xaa-Ser/Thr sequons and each 
contains the common core Man3GlcNAc2Asn which can be then elongated with the 
addition of other monosaccharides. 
 
 Glycosylation of immunoglobulins 
All immunoglobulins are glycosylated with an inherent set of glycoforms which can differ 
in number, type and glycosylated site. IgG is the least glycosylated with just two glycan 
attachment sites, N-linked to the conserved Asn297 on both heavy chains (Arnold, 
Wormald et al. 2007). These attachments are ~2 kDa each and help to maintain the 
structure and stability of the Fc fragment of IgG. This associated sugar domain is not 
exposed on the surface of IgG, but buried within the hydrophobic core between the two 
heavy chains, impacting the Fc structure. Each of the Asn-297 sites contains one family 
of glycans that can be assigned to three subsets, IgG -G0, -G1 and -G2 depending on the 
number of galactoses present. Figure 1.20 outlines the basic glycan structure found in 
IgG. The oligosaccharide found in the Fc region is a biantennary complex made up of a 
core block of sugars (blue boxes) (Asn 297 -GlcNac -GlcNac –mannose (α1-6-/α1-3) -
[mannose -GlcNAc]2), where GlcNac is N –acetylglucosamine. Variations to this pattern 
include (red boxes) attachment of terminal sialic acid, a third GlcNac arm (a bisecting 
GlcNac), terminal galactosylation and core fucosylation (Teillaud 2005).  
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Figure 1.20: The oligosaccharides found in immunoglobulin G (IgG) attached to the Fc 
fragment of the heavy chain through N-linkage to the Asn297 (Jefferis 2009). 
 
Engineering glycoforms to increase the biological activity of mAbs allows optimisation 
of their roles and enhances the functional diversity of the proteins. Glycosylation achieves 
this as every aspect of glycosylation can be modified from the glycosidic linkage, the 
glycan composition, structure and shape. Figure 1.21 outlines just a few of the glycan 
variations of the glycoforms of IgG. Each heavy chain may bear one of a total of 32 
unique oligosaccharides and random pairing of heavy side glycoforms could generate 
~500 glycoforms. 
 
Figure 1.21: Structural variations of the glycoforms of IgG (Teillaud 2005). 
 
The activity, solubility and immunogenicity of monoclonal antibodies can be influenced 
by glycosylation (Yamada 2011; Costa, Rodrigues et al. 2013). Glycan heterogeneity can 
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be altered by many cell cultural factors including the choice of cell line. The function of 
a particular glycan can be as important and complex as the function of an amino acid. 
Thus there is a requirement to monitor the impact cell cultural variables will have in order 
to ensure consistent glycosylation of monoclonal antibodies (Hossler, Khattak et al. 
2009). 
 Thesis motivation 
The motivation for this work was to further our understanding of the mechanisms by 
which proteins aggregate. Most of the previous studies in this area have been conducted 
in isolation e.g. a specific protein under a specific condition with a specific stress. Here, 
an inclusive, broad ranging comparative study, using two different proteins, lysozyme 
and BSA, for a fixed range of solution conditions was conducted. After forced 
degradation we measured and characterised their response to three specific stresses 
(thermal unfolding, chemical unfolding and chemical modification) with a collection of 
high-throughput and orthogonal techniques to meet the following objectives; 
1. To understand the molecular interactions governing the aggregation process 
for each mechanism. 
2. To measure the degree of structural change associated with each aggregation 
pathway. 
3. To relate the aggregation behaviour to specific solution conditions. 
4. To assess if certain types of aggregate forms (amorphous/fibril) are associated 
with a specific mechanism. 
 
The second aspect of this work was the isolation and characterisation of a monoclonal 
antibody, IgG. Specifically, the stability of the glycosylated form of this protein was 
assessed. The effects of short and long term storage conditions of the glycosylation 
pattern were also explored. 
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 Experimental 
techniques and data analysis 
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 Preparation of Reagents and Materials 
 Preparation of buffers 
The buffer salts used were analytical grade and were prepared in Milli-Q water (ultra-
pure). The pH of the buffer solutions was adjusted using concentrated sodium hydroxide 
or hydrochloric acid (HCl) solutions as appropriate. Stock buffer solutions were filtered 
through 0.45 μm, 47 mm nylon membranes using a Millipore filter assembly under 
vacuum (Merck Millipore). All buffers for SE-HPLC use were of HPLC grade, filtered 
using the above method and degassed using an online system degasser. All buffers for gel 
electrophoresis were also filtered as per above and degassed using a vacuum pump. 
 Sodium phosphate  
To prepare sodium phosphate buffer at the desired pH, firstly stock solutions of 
monobasic 1 M NaH2PO4 and dibasic 1 M Na2HPO4 were prepared and mixed in 
appropriate volumes as per Table 2.1 to achieve the desired pH. To prepare the stock 
solutions, 11.998 g of NaH2PO4 (Mw = 119.98) and 14.196 g of Na2HPO4 (Mw = 141.96) 
were each dissolved in Milli-Q water and made up to 100 ml. 
 
 
pH 
Vol (ml) of 1 M 
NaH2PO4 
Vol (ml) of 1 M 
Na2HPO4 
Final vol (ml) 
5.8 8.0 92.0 100 
6.0 12.3 87.7 100 
7.0 61.0 3.9 100 
7.8 91.5 8.5 100 
Table 2.1: Sodium phosphate pH guide. 
 
The 1 M solutions were then diluted as necessary i.e. to make a 50 mM, 1L solution, 50 
ml of the 1M stock was diluted into 950 ml of Milli-Q water. 
 Tris-HCl 
To prepare a 1 M Tris-HCl buffer stock solution, appropriate weight of Tris solid (Fisher) 
was dissolved in Milli-Q water. The pH was adjusted using HCl. 
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 10% SDS 
To prepare a 10% SDS stock solution, 1 g of SDS solid (Fisher) was dissolved in 10 ml 
Milli-Q water in a volumetric flask. 
 Preparation of reagents. 
 Preparation of denaturants 
Urea (U) and Guanidine hydrochloride (GdmHCl) [Calbiochem] were made up as stock 
solutions to a maximum concentration of 11 M and 8 M respectively. Denaturants were 
fully dissolved in appropriate buffer in volumetric flasks and prepared directly before use. 
 Standardizing hydrogen peroxide 
Hydrogen peroxide (Calbiochem) was purchased as a 30% (v/v) solution. Hydrogen 
peroxide decomposes over time into water and oxygen. Before each use, H2O2 was 
standardised against potassium permanganate (KMnO4) to obtain the absolute 
concentration by titration against a known concentration of KMnO4. 
 
Firstly, a 2 mM solution KMnO4 was made up in Milli-Q water (0.03 g in 100 ml). Solid 
KMnO4 contains traces of other impurities, so to determine the exact concentration of the 
KMnO4, it was titrated against oxalic acid (H2C2O4) in the presence of excess 6 M 
sulphuric acid (H2SO4). By using the stoichiometry of the standardization reaction, the 
exact concentration of the KMnO4 solution can be determined; 
 
2𝑀𝑛𝑂4− + 5𝐻2𝐶2𝑂4 + 6𝐻
+ → 2𝑀𝑛2+ + 10𝐶𝑂2 + 8𝐻2𝑂              2.1 
 
The standardised solution of KMnO4 was then titrated against the unknown concentration 
of Η2Ο2, in the presence of excess 6 M sulphuric acid (Η2SΟ2). In acidic solutions, 
potassium permanganate reacts with hydrogen peroxide as follows; 
 
2𝐾𝑀𝑛𝑂4 + 6𝐻
+  + 3𝐻2𝑆𝑂2 + 5𝐻2𝑂2 → 2𝑀𝑛𝑆𝑂4 + 𝐾2𝑆𝑂4 + 2𝑂2 + 8𝐻2𝑂       2.2 
 
Once a permeant pink colour change was detected the titration was stopped and the molar 
concentration of Η2Ο2 was calculated. Hydrogen peroxide was standardised in this way 
directly before each use. 
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 Preparation of protein stock solutions 
Chicken egg white lysozyme [Calbiochem, Lot # D00140217] and bovine serum albumin 
[Sigma Aldrich, Lot # SLBL2871V] were used without further purification. Protein was 
dissolved in sodium phosphate buffer, 50 mM pH 5 – 8 or sodium acetate buffer pH 5 – 
8, then washed of co-precipitated salts by repeated ultrafiltration using Amicon Ultra-4 
MWCO 10 kDa (lysozyme) or 30 kDa (BSA) centrifugal devices at 4000 × g. Both 
lysozyme and BSA concentrations were determined spectrometrically by UV/Vis 
absorbance using the extinction coefficients, 2.64 ml mg− 1 cm− 1 and 0.66 ml mg− 1 cm− 1 
respectively. [See section 2.5] 
 Mechanisms of aggregation 
 Thermal denaturation 
Thermal denaturation is achieved by heating the protein solution beyond its melt 
transition temperature Tm. Upon heating and cooling of the protein, it begins to unfold 
and refold. The overall structural stability of the protein solution during this process is 
dependent on many factors such as protein concentration, pH, ionic strength, presence of 
co-solutes and ion type. The degree of structural change caused by thermal denaturation 
can very much depend on the solution conditions (Wang, Nema et al. 2010). 
 Temperature induced unfolding 
A thermal denaturation assay was developed to suit a 96 well plate format. Prepared 
protein samples were aliquoted in triplicate into a 96 well plate. Solution conditions were 
varied including, protein concentration (0.5 – 20 mg/ml), buffer type (50 mM sodium 
phosphate) and pH of buffer solution (range from pH 5 – 8). Stock solutions of protein 
were prepared and diluted to the desired concentration using buffer to a total volume of 
200 μl, below the maximum well volume of 300 μl. The multi-well plate was covered 
using sealing tape (Thermo Scientific) and a plate lid. The proteins were thermally 
denatured by incubation at 80○C, (beyond the Tm of the protein) for 20 minutes to allow 
sufficient time for the protein to fully denature and then cooled on the bench at room 
temperature (20 – 24°C). 
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 Oxidation 
The hydroxyl radical (⦁OH) is the most powerful oxidizing species among several reactive 
oxygen radicals (ROS), and is known to oxidize proteins (Shacter 2000). Therefore 
hydrogen peroxide (H2O2) was chosen to act as a ROS to induce oxidation and the 
associated conformational rearrangements within the protein structure. 
 Oxidant induced de-stabilisation of protein 
Stock protein solutions were prepared and diluted in 50 mM sodium phosphate buffer and 
hydrogen peroxide to give the final protein concentration of 10 mg/ml. (BSA was 
examined in pH 7 buffer, while lysozyme was examined over the pH range 5 – 8.) Η2Ο2 
ranging from 0.01 mM to 5 M was added to the protein solutions to a total volume of 300 
μl. Η2Ο2  is sensitive to light and can readily decompose to water and oxygen. Therefore 
protein solutions after addition of Η2Ο2 were stored in amber glass vials sealed with 
parafilm and wrapped in aluminium foil. Glass syringes were used to transfer Η2Ο2 
solutions to avoid leaching from plastic pipette tips which may have impacted on the 
aggregation study. Identical protein solutions not treated with Η2Ο2 were also prepared 
under the same conditions to be used as a reference. 
 Chemical unfolding 
Chemical denaturants (urea and guanidine hydrochloride) were used to induce protein 
unfolding. Stock protein solutions of lysozyme (0.5 mg/ml) and BSA (1 mg/ml) were 
prepared in 50 mM sodium phosphate buffer, pH 8. In microcentrifuge tubes, the stock 
protein solutions were diluted with appropriate amounts of buffer and denaturant. The 
total volume was fixed at 1 ml in every sample. The concentration of denaturant ranged 
from 0.5 – 10.5 M for urea, and 0.5 – 7.5 M for guanidine hydrochloride. Protein samples 
without denaturant at the same protein concentration and final sample volume were used 
as a control. 
 
 SE-High Performance Liquid Chromatography 
 Description of the technique 
High performance liquid chromatography (HPLC) is an analytical technique and physical 
separation method in which the components to be separated are selectively distributed 
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between two immiscible phases. The liquid mobile phase carrying the molecules to be 
separated is forced under pressure through a stationary phase bed, held in a column. The 
size exclusion HPLC (SE-HPLC) principle of separation is based on molecular size 
(figure 2.1). Larger molecules will move more quickly through the packing material of 
the column and elute first, while the smaller molecules will take longer as they are slowed 
down by passing through the pores in the packing material. The time taken for a molecule 
to travel through the column and reach the detector is known as the retention time (tR) 
(Hamilton and Sewell 1982). 
 
Figure 2.1: Schematic diagram of the three phases of SE-HPLC. A representative 
chromatogram is shown indicating two elution peaks (one for each particle size) and 
their corresponding retention times (tR). 
 
In SE-HPLC, the stationary phase generally consists of gel particles having a porous 
matrix with a closely controlled pore size. A schematic of the main components of 
required for an effective SE-HPLC system is shown in Figure 2.2.  
 
Figure 2.2: Schematic of components of SE- HPLC system 
. 
 Instrumentation 
SE-HPLC was carried out using a Shimadzu SPD HPLC system. Shimadzu LC solution 
software was used to run the instrument. Before each use the HPLC system has all its 
lines purged of trapped air or gas bubbles to ensure no damage to the system or column. 
A steady baseline was achieved by running mobile phase at 0.75 ml/min for 30 – 60 
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minutes before a sample injection. The column used was a Superdex 200 10/300 GL SE-
HPLC column (GE Healthcare). This column allows for high resolution analytical 
separations of protein molecules with molecular weights between 10 and 600 kDa. 
Protein was detected using a diode array detector (DAD) at 190 – 800 nm for each 
measurement. 
 Running a sample 
For HPLC, samples were placed in Chromacol glass vials (Lennox) with a crimp cap with 
a pre-fitted seal. Samples were introduced to the column via the instrument autosampler. 
Typical conditions used to run a SE-HPLC sample are given in Table 2.3. All SE-HPLC 
measurements were carried out at room temperature. 
SE-HPLC sample run  
Mobile phase 50 mM sodium phosphate, pH 5 - 8 
Pump flow rate 0.75 ml/min 
Analysis run time 45 minutes 
Sample injection volume 20 – 30 μl 
Sample concentration 0.5 – 20 mg/ml 
Pressure ~ 11 bar 
 
Table 2.3: Typical conditions used to run a protein sample using 
Superdex 200 10/300 GL column. 
 
 Calibration of the column 
A mixture of proteins with different molecular weights, within the resolution range of the 
column were prepared. Each protein was dissolved in 50 mM sodium phosphate buffer 
and filtered through 0.22 μm syringe driven filters (Milli-pore Durapore) to remove 
particulates. All proteins were run individually (1 mg/ml, sample injection volume 20 μl, 
flow rate 0.75 ml/minute) to obtain a characteristic chromatogram for that protein and 
assign a retention time as per Table 2.4. 
 Peak # Protein tR M W  
Conc. 
mg/ml 
Injection 
vol. (μl) 
1 Gama Globulin dimer 10.40 300    
2 Gamma globulin 13.20 150  1 20 
3 Bovine serum albumin dimer 14.09 133.4    
4 Bovine serum albumin 16.30 66.7  1 20 
5 Chicken serum albumin 17.53 44.2  1 20 
6 Myglobulin 21.06 16.7  1 20 
7 Lysozyme 23.29 14.7  1 20 
 
Table 2.4: Proteins used for the calibration of Superdex 200 10/300 GL column. 
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Figure 2.3: Calibration of Superdex 200 column using a range of different molecular 
weight proteins.  
 
A mixture of all proteins was then prepared keeping each individual protein concentration 
at 1 mg/ml; 200 μl of each protein sample at 5 mg/ml, made up to a total mixture volume 
of 1 ml. 20 μl  of this protein mixture was then loaded on to the column (figure 2.3A). A 
calibration curve was then created (figure 2.3B). 
 Determination of protein concentration by SE-HPLC 
Calibration curves of protein over a range of concentrations were prepared allowing 
conversion of the area under a chromatic peak to a protein concentration (figure 2.4). 
Protein samples were prepared at concentrations from 0.5 – 20 mg/ml and the 
concentration was confirmed by UV absorbance. The sample volume was 20 μl in each 
case and detection was at 280 nm. Using OriginPro 9.1 software, the chromatogram at 
each conentration was baseline subtracted and then the area under all peaks were 
intergrated to give a total peak area per mg/ml of protein.  
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Figure 2.4: SE-HPLC for A) lysozyme and B) BSA at increasing concentrations. 
Relationship between peak area and protein concentration of each is also shown. 
 
 Electrophoresis 
 Description of the technique 
Electrophoresis is an analytical method used to separate, identify and purify 
biomolecules. Under the influence of an electric field, charged molecules will migrate in 
the direction of the electrode bearing an opposite charge. Due to the varying charges and 
masses on the molecules, they will migrate at different rates and thus be separated into 
single fractions. This technique is typically used for proteins, peptides, sugars and nucleic 
acids. It can be used for qualitative characterisation of samples, quantitative 
determination and assessment of purity, and preparative purposes (Hames and Rickwood 
1981; Westermeier 2001). The speed at which a protein will migrate in an electric field 
will be characteristic of that protein under defined conditions (pH, ionic strength, 
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temperature and voltage). The electrophoretic mobility (μ) of a protein molecule can be 
defined as; 
 
𝜇 =  
𝑑
𝐸𝑡
                                                              2.3 
 
where d is the distance travelled from the origin (cm), E is the strength of the electrical 
field (V/cm) and t is the duration of electrophoresis (seconds) (Keren 2003). 
 
Polyacrylamide gel was first used for electrophoresis by Raymond and Weintraub 
(Raymond and Weintraub 1959). PAGE gels consist of an electrically neutral matrix of 
pores to separate proteins according to size (molecular weight) and conformation. They 
can resolve proteins between 5 and 400 kDa. The clear gel is formed by chemical co-
polymerisation of acrylamide monomers with a cross-linking reagent, usually 
bisacrylamide. The reaction is started with ammonium persulphate (APS) acting as a 
polymerising agent with TEMED (N,N,N,N'-tetramethylenediamine) providing the 
tertiary amino groups to release the free radicals by APS (Westermeier 2001). The pore 
size of the gels is inversely related to the amount of acrylamide used and can be controlled 
by the amount of acrylamide (T) and the degree of cross-linking (C) 
 
𝑇 =  
(𝑎+𝑏)×100
𝑉
 [%],   𝐶 =  
𝑏 ×100
𝑎 + 𝑏
 [%]                                 2.4 
 
where a is the mass of acrylamide, b is the mass of cross-linker and V is the volume 
(Westermeier 2001).  
 Types of PAGE electrophoresis 
 Native polyacrylamide gels 
Native or non-denaturing polyacrylamide gels are used for separation and characterisation 
of protein depending on the net charge, size and shape of the protein in its native state. 
Samples are prepared in a non-reducing, non-denaturing sample buffer, which maintains 
the protein secondary structure and native charge density. Proteins migrate through the 
gel matrix as the majority will have a net negative change in the alkaline buffer used. The 
higher the negative charge density, the faster the protein will migrate. The frictional force 
of the gel matrix also acts like a sieve, restricting the mobility of proteins by their size 
and shape (Westermeier 2001). 
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 SDS polyacrylamide gels  
SDS-PAGE is a method of separating proteins exclusively on the basis of molecular 
weight. The structural complexity of the protein is reduced and a uniform charge to mass 
ratio is applied. Sodium dodecyl sulphate (SDS) is an anionic detergent that binds to most 
proteins in constant weight ratio, giving it an overall negative charge density. The tertiary 
and secondary structures are also disrupted through the breakage of hydrogen bonds 
causing the protein to unfold. This type of gel is commonly referred to as a “non-
reducing” SDS-PAGE. “Reducing” SDS-PAGE involves breakage of the disulphide 
bonds between the cysteine residues of the protein. This is achieved by a thiol reducing 
agent such as 2-mercaptoethanol or dithiothreitol. The protein migrates in the electric 
field towards the positive anode, separating according to their size with the smaller 
proteins migrating faster (further) than the larger protein (Westermeier 2001). 
 Protocol 
 PAGE 
A 4-gel electrophoresis tank (Bio-Rad) was used for all separations. Gel plates rinsed 
with Milli-Q water, followed by ethanol and air-dried. Once dried, plates were assembled 
as per manual. Gel solutions were prepared with the following components:  
 
Resolving Gel (12%) 
Milli-Q water 
Acryl amide: Bis solution (37.5:1) (Bio-Rad) 
1 M Tris-HCL pH 8.8 
10% SDS (w/v) 
Mixed and degased for 15 minutes 
10% (w/v) ammonium persulfate (prepared fresh, added just before use) 
TEMED (added just before use) 
 
Stacking Gel (4%) 
Milli-Q water 
Acryl amide: Bis solution (37.5:1) 
0.5 M Tris-HCL pH 6.8 
10% SDS 
Mixed and degased for 15 minutes 
10% (w/v) ammonium persulfate (prepared fresh, added just before use) 
TEMED (added just before use) 
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Sample buffer 
Milli-Q water 
0.5 M Tris-HCL (pH depending on sample) 
Glycerol (0.8 ml) 
10% SDS (w/v) 
Bromophenol Blue (0.5 mg) 
 
Running buffer 
10X Tris-glycine (Bio-Rad, diluted 1/10)  
 
Protein Molecular weight markers 
Molecular weight markers were purchased from Bio-Rad (figure 2.5). Markers were 
diluted in SDS reducing sample buffer and stored at -20○C. Markers were thawed and 
boiled at 95○C just before use. 
 
 
Figure 2.5: Bio-Rad molecular weight markers. A) Low range and B) High range. 
 
Gel preparation 
Appropriate amounts of both separating gel and stacking gel were prepared as described 
above. Just before casting the gel, the ammonium persulfate and TEMED were gently 
mixed into the gel mixture. Using Pasteur pipettes the separating gel solution was slowly 
pipetted into the gap between the glass casting plates, to about 2/3 full. A small amount 
of tert-amyl alcohol was used to cover the gel solution while the gel was setting. The gel 
was left for 40 – 45 minutes to set. Once set, the tert-amyl alcohol was washed off the gel 
with Milli-Q water and residual water was wiped away. The stacking gel was then added 
and the well combs inserted. A further 40 – 45 minutes was allowed for the stacking gel 
to set before running samples. 
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Sample preparation 
Samples were prepared by mixing appropriate amounts of sample and sample buffer. The 
maximum loading capacity for each well was 30 μl. Samples were heated to 90 - 95○C 
for 5 minutes (for SDS PAGE only). 
Running the gel 
Gels were run using an external power source at 200 V (400 mA) until the visual running 
band was 1 cm above the end of the glass plates. 
Gel staining 
Gels were stained for 1+ hour in Coomassie Brilliant Blue R-250 staining solution 
(Biorad). Gels were then de-stained in a mixture of Milli-Q water, methanol and acetic 
acid in a ratio 50/40/10 (v/v/v). The protein molecular weight was determined by 
comparing the migration of the protein band to the molecular weight standards. 
 Modifications to the PAGE protocol 
The protocol described above is an example of a non-reducing SDS 12% gel. This type 
of gel is ideal for identifying the molecular weight of a protein. Modifications to this 
protocol were needed for a number of different reasons. 
 Native PAGE  
For native PAGE the protein samples were prepared without the addition of reducing or 
denaturing sample buffer and without heat treatment. The electrophoresis was also run 
without SDS in the running buffer. 
 Reducing SDS-PAGE 
Reducing gels were prepared by adding 2-mercaptoethanol to SDS sample buffer just 
before use allowing for identification of disulphide linked aggregates or reduction of 
proteins that were disulphide inked. 
 Gel concentration 
By varying the percentage of cross-linker, the pore size of native and SDS-PAGE gels 
were optimised to yield the best separation and resolution of the protein of interest. The 
gel concentration was adjusted according to Table 2.5 by varying the amount of cross-
linker in the resolving gel solution. 
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Acrylamide % MW Range Vol Acrylamide (ml) Vol Milli Q water (ml) 
7% 50 – 500 kDa 2.3 5.1 
10% 20 – 300 kDa 3.3 4.1 
12% 10 – 200 kDa 4 3.4 
15% 3 – 100 kDa 5 2.4 
Table 2.5: Optimum acrylamide gel composition for the resolution of different Mw 
proteins. Volume of acrylamide and Milli-Q water needed to achieve each gel 
composition (keeping the total resolving gel solution at 10 ml). 
 
 Spectroscopy 
Spectroscopy deals with the production, measurement, and interpretation of spectra 
arising from the interaction of radiation with matter. When radiation interacts with matter 
a number of processes can occur; absorbance, fluorescence/phosphorescence, reflection 
and scattering. Radiation is characterised by energy, E, that is related to the frequency, v, 
or wavelength, λ, of the radiation by the Planck relationship; 
 
𝐸 = ℎ𝑣 = ℎ𝑐/𝜆                                                    2.5 
 
where c is the  speed of light (2.998 x 108 cm/s) and h is Planck’s constant (6.625 x 10-27 
J-s). 
 Absorption spectroscopy 
The absorbance of light is due to the interaction of an oscillating electromagnetic field of 
radiation with the charged particles in an atom (Hammes 2005). The principle is based on 
the ability of a molecule to absorb photons of light. When UV-visible light is absorbed 
by a molecule, energy from the light can promote an electron from a bonding or non-
bonding orbital into one of the empty anti-bonding orbitals. The process of absorption is 
extremely fast occurring in about 10-15 s. Electrons in the excited state equilibrate with 
the surroundings and returns to the ground electronic state in a decay process. This occurs 
with either the production of heat (non-radiative decay) or the emission of light (radiative 
decay) with an energy equal to or less than that of the absorbed radiation (figure 2.6). 
This process is known as fluorescence and will be discussed in more detail in section 
2.5.2.  
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Figure 2.6: Absorption and emission of light. 
 
The potential energy of a molecule can be represented as the sum of its electronic, 
vibrational and rotational energies; 
 
𝑬𝒕𝒐𝒕𝒂𝒍 =  𝑬𝒆𝒍𝒆𝒄𝒕𝒓𝒐𝒏𝒊𝒄 + 𝑬𝒗𝒊𝒃𝒓𝒂𝒕𝒊𝒐𝒏𝒂𝒍  + 𝑬𝒓𝒐𝒕𝒂𝒕𝒊𝒐𝒏𝒂𝒍                   2.6 
 
The amino acids that make up the backbone of protein are connected by peptide bonds. 
This gives rise to two characteristic absorption bands in the far-UV region (λ = 190 – 
250 nm): π  π* transition at 190 nm and a weaker, broader n   π* transition at 210 
nm. A π orbital is formed between two p atomic orbitals overlapping laterally, resulting 
in a π bond. A π electron can be promoted to an antibonding orbital, π*, with the 
absorption of sufficient energy. This is known as a π  π* transition. Non-bonding 
electrons, can be promoted to an antibonding orbital and this transition is denoted by n   
π* transition. A σ orbital can also be formed between two s atomic orbitals, between two 
p atomic orbitals or from one s and one p atomic orbital, forming a σ bond (Valeur 2002). 
Figure 2.7 shows the different types of electronic transitions and their energy is generally 
in the order; 
 
n   π* <  π  π* <  n  σ* <  π  σ* <  σπ* <  σ σ*           2.7 
 
Of these six transitions, only the two of lowest energy occur in absorbance and 
fluorescence spectroscopy (200 – 800 nm spectrum) for small molecules.  
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Figure 2.7: Electronic transitions and their corresponding orbitals. 
 
The ability of a protein to absorb UV-visible light is based on the presence of 
chromophores such as amide bonds in the peptide backbone and the aromatic amino acids. 
For proteins, there are three amino acid residues that absorb light in the UV region: 
phenylalanine (Phen), tyrosine (Tyr) and tryptophan (Trp) due to their conjugated π bonds 
in the non-polar side chains (figure 2.8). 
 
Figure 2.8: Aromatic residues found in protein: Phenylalanine, tryptophan and tyrosine 
contain aromatic side chains, which allow them to absorb UV light (A) and emit 
fluorescence (E) from (Lakowicz 2006). 
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Absorbance spectroscopy is a commonly used tool to estimate protein concentration, 
according to the Beer-Lambert equation; 
 
𝐴 =  𝜀𝑐𝑙                                                            2.8 
 
where A is absorbance, ε  is the extinction co-efficient of the protein (1 dm3 mol-1 cm-1), 
c is the concentration of the protein (mol dm-3) and l is the path length of light (1 cm). 
 UV-Vis measurement 
UV measurements were performed on a Perkin Elmer Lambda 35 UV/VIS spectrometer 
using Hellma Analytics precision quartz cells with a 1 cm path length. Spectra were 
collected between 200 – 500 nm at the scan speed 240 nm/min with a data interval 0.1 
nm. Air was used as a reference sample. Spectra for buffer solutions were acquired in the 
same way and manually subtracted from the protein spectra. 
 Fluorescence Spectroscopy 
Fluorescence is the emission of a photon associated with transition of a molecule from a 
higher excited state to a lower ground state accompanied by radiation. When light of an 
appropriate energy is absorbed by a molecule with electrons of opposite spin, the 
electronic state of the molecule changes from the ground state singlet energy level, S0, to 
one of many vibrational levels in one of the excited states (S1, S2…). All electrons are 
paired in singlet states so that their spins are in opposite directions. This is known as a 
singlet-singlet transition. Decay can occur via numerous process; non-radiative decay or 
radiative decay. Non-radiative decay occurs to the ground vibrational energy level, S1, 
generally in the form of heat. Electrons upon returning to the ground state, S0, via 
radiative decay from the first excited singlet state emit fluorescence. They can also move 
to a triplet state (T1,T2…) having two unpaired electrons, known as intersystem crossing. 
The process of electrons returning to the ground state, S0, from a triplet state is known as 
phosphorescence. This is generally shifted to longer wavelengths (lower energy) relative 
to fluorescence. 
 
Within each electronic state there are also vibrational energy levels more closely spaced 
than the electronic energy levels, due to the vibration of atoms within the molecule. 
Molecules are generally in their ground electronic state are in their lowest vibrational 
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energy level. Once excited to the next electronic energy level, they can be found in many 
different vibrational energy levels. The molecules rapidly decay (10-13 s or less) to the 
lowest vibrational level of the second electronic energy level by non-radiative decay. 
Electrons in this level will then decay to the ground state. The Perrin-Jablonski diagram 
(figure 2.9) is a useful way of visualising these processes. (Valeur 2002; Hammes 2005; 
Lakowicz 2006). 
 
 
Figure 2.9: Perin-Jablonski diagram and illustration of the relative positions of 
absorption, fluorescence and phosphorescence spectra (Valeur 2002). 
 
Fluorescence data is mostly presented as emission spectra. The emission spectrum 
depends on the chemical structure of the fluorophore, the surrounding environment and 
the wavelength of excitation (Lakowicz 2006). There are two classes of fluorophores; 
extrinsic fluorophores are added to a sample that doesn’t display the desired spectral 
properties and intrinsic fluorophores that occur naturally. Proteins are examples of 
intrinsically fluorescent molecules. The fluorescence of proteins originates from the 
aromatic residues; phenylalanine, tyrosine, and tryptophan residues (figure 2.8). However 
fluorescence is dominated by the contribution of tryptophan and tyrosine residues as their 
absorbance at wavelength excitation and their quantum yield of emission are considerably 
greater than for phenylalanine. Emission of both tyrosine and tryptophan residues is 
observed when proteins are excited at 280 nm. Excitation at 295 nm results in an emission 
spectrum for tryptophan only. The emission spectra of intrinsic fluorophores are highly 
sensitive to the solvent/environmental conditions. 
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 Fluorescence Measurements 
Intrinsic fluorescence measurements were conducted using Molecular Devices 
SpectraMax M2e (Molecular Devices, USA) with Hellma Analytics fluorescent precision 
quartz cells. Protein solutions were excited at 280 nm (excitation of tyrosine and 
tryptophan residues) and 295 nm (tryptophan excitation mainly) and fluorescence 
emission spectra were recorded in the range 200 – 500 nm with a data interval of 1 nm. 
The blank was a buffer solution, which was manually subtracted from the protein spectra. 
From each fluorescence spectrum both the fluorescence intensity and lambda max (λmax) 
of fluorescence were recorded and used for analysis.  
 Derivative spectroscopy 
Derivative spectroscopy is useful for extracting both qualitative and quantitative 
information from spectra composed of unresolved bands. It allows for the enhancement 
of the resolution of overlapping peaks, and the elimination or reduction of background or 
matrix absorption (Aligent Technologies, 2000 ; Rojas, Ojeda et al. 1988; Ojeda and 
Rojas 2004). A single absorbance band with a broad maximum and unresolved individual 
features occurs for proteins, due the overlap in absorbance in the 280 nm region for the 
aromatic three amino acids; tyrosine, tryptophan and phenylalanine. The differentiation 
of zero order spectra allows more spectral detail to be observed and results in more 
accurate determination of the wavelengths of broad peak maximum, for peaks which 
appear only as shoulders, as well as for the isolation of small peaks from an interfering 
large background absorption (Grum, Paine et al. 1972) (figure 2.10). Finite differences 
between adjacent data points can be determined by calculating the derivative of a 
spectrum (Saakov, Drapkin et al. 2012). A typical spectrum is expressed as absorbance A 
as a function of wavelength 𝜆. The derivative of absorbance spectra are: 
 
Zero order                                               𝐴 = 𝑓(𝜆)                                                         2.9 
 
First order                                                 
𝑑𝐴
𝑑𝜆
 =  𝑓′(𝜆)                                                       2.10 
 
Second order                                         
𝑑2𝐴
𝑑𝜆2
 =  𝑓′′(𝜆)                                                  2.11 
 
The first derivative spectrum starts and ends at zero, it passes through zero at the same 
wavelength as 𝜆max of the absorbance band. The second derivative spectrum reveals a 
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negative band that crosses the x-axis at the point of maximum slope and with a minimum 
the same wavelength as the maximum on the zero-order band which is a significantly 
sharper band  (Mark and Workman 2007). 
 
 
 
Figure 2.10: Simulation of the effects of first order and second order derivatisation on 
the absorbance spectra (Aligent Technologies, 2000). 
 
Differentiation progressively increases the signal-to-noise ratio (S/N) of the original zero 
order spectrum with higher orders (Rojas, Ojeda et al. 1988). It is important to remove or 
significantly minimize the S/N, yet maintaining the underlying spectral data. To achieve 
this a certain amount of mathematical smoothing must be performed either before or after 
differentiation. This method of spectral averaging results in the reduction in random noise 
(figure 2.11). The Savitzky-Golay smoothing filters are the most frequently used digital 
smoothing filters in spectroscopy. The Savitzky-Golay filter method essentially performs 
a local polynomial regression to determine the smoothed value for each data point. This 
method is superior to adjacent averaging because it tends to preserve features of the data 
such as peak height and width, which are usually 'washed out' by adjacent averaging 
(Chen, Liu et al. 2004). 
 
Figure 2.11: Smoothening of a second derivative absorbance spectra of BSA using the 
Savitzky – Golay filter method. 
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 Second derivative absorbance spectroscopy measurement 
Figure 2.12 illustrates how second derivative operations on the zero order spectrum 
allows deconvolution of this single band into distinct peaks representing each individual 
aromatic amino acid residue. 
 
Figure 2.12: UV zero order absorbance spectrum of BSA (solid black line) indicating 
the single absorbance band attributed to the three aromatic amino acids. The 
corresponding second derivative spectrum of BSA (broken blue line) clearly showing the 
individual signals from the three aromatic amino acids. 
 
Protein solutions had their zero order absorbance spectra recorded as per section 2.5.1.1. 
Data for each sample was analysed using Origin Pro 9.1. Second derivative operations 
were performed on each spectrum. The Savitzky-Golay algorithm was used for smoothing 
after differentiation. In the second derivative spectra, the distinctive peaks were assigned 
to phenylalanine (Phen), tyrosine (Tyr) and tryptophan (Trp). The presence of 
phenylalanine in proteins is generally recognised as weak ripples or shoulders within the 
absorbance spectra between 250 – 270 nm region (Schmid 2001). Due to this, 
phenylalanine shows as several negative bands within the second derivative spectrum 
within this region  (Balestrieri, Colonna et al. 1978). However it is the strongest band at 
259 nm that is monitored for evaluation purposes (Ichikawa and Terada 1977; Mach, 
Thomson et al. 1991; Lucas, Ersoy et al. 2006).  For each of the three residue peaks the 
wavelength value at the peak minima was recorded. 
 Second derivative fluorescence spectroscopy 
Fluorescence derivative methods can be used to attain structural and functional 
information about transitions taking place in the environments of aromatic residues 
(Mozo-Villarias 2002). It can be used as a technique to monitor and characterise relatively 
                  
 
63 
 
small changes and subtle alterations that may not be seen in the zero order fluorescence 
spectra. When proteins are excited at 280 nm, the signal arises from both the tryptophan 
residue and tyrosine residue. Using second derivative operations on the zero order 
spectrum can allow deconvolution of this single fluorescence signal into the two 
individual peaks representing each individual amino acid residue (figure 2.13). Any 
overlapping peaks and shoulders can be resolved into distinct peaks. 
 
 Figure 2.13: Intrinsic fluorescence zero order spectrum of BSA (solid line) indicating 
the single absorbance band attributed to the tyrosine and tryptophan residues. The 
corresponding second derivative spectrum of BSA (broken line). 
 
All fluorescence measurements were performed as per section 2.5.2.1. Differentiation of 
the normalised spectrum was performed using Origin Pro 9.1. The Savitzky-Golay 
algorithm was used for smoothing after differentiation. The criteria for smoothing was 
that the overall shape and intensity of the zero order emission spectrum is not affected, 
and that the peak and shape of the bands in the second derivative is preserved and excess 
noise is removed. In the second derivative spectra, the distinctive peaks were assigned to 
both tyrosine (Tyr) and tryptophan (Trp). For each peak both the intensity and wavelength 
values of the minimum negative band were recorded. 
 High throughput assays 
High throughput screening assays were carried out using a multi-platform plate reader, 
Molecular Devices SpectraMax M2e and are performed in a 96 well-plate format.  
 Turbidity assay 
Changes in protein sample turbidity is in general associated with protein aggregation 
(provided other phase transitions associated with increased turbidity, including liquid-
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liquid phase separation are not occurring). If the process of aggregation produces a 
relatively high concentration of small particles or a smaller number of larger particles, 
this leads to light scattering and opacity. The turbidity, or light scattering by precipitates 
can be detected at non-absorbing wavelengths (≥ 400 nm) to detect protein aggregates.  
 Protocol 
Samples were measured in triplicate, in a 96 well plate format using UV-Star microplate 
96 well, f-bottom, µClear (Greiner Bio-One). These plates have a specialised optical 
window that allows for measurement of samples within the UV range (down to 230 nm), 
ideal for measuring protein concentrations at 280 nm. No pre-treatment of the plate 
surface was carried out. Stock protein samples were diluted in the chosen buffer to a 
protein concentration range of 0.5 – 20 mg/ml. The total volume of samples was fixed at 
200 μl. Solution turbidity was determined spectrometrically by measuring the change in 
absorbance at 450 nm. The extent of turbidity was calculated using percentage (%) 
transmission. The variation in transmitted light through a turbid solution can be seen as 
an increase in sample absorbance. This change in absorbance can be related to the 
percentage of light transmitted though the sample i.e. the more turbid the sample, the 
higher the scattering and thus the % transmission is low. The absorbance at 450 nm is 
related to a percentage transmittance (% T) using the following relationship; 
 
𝐴 = 2 −  𝑙𝑜𝑔10(%𝑇)                                                  2.12 
 
% 𝑇 =  10(2−𝐴)                                                    2.13 
 
Measurements were taken every 20 minutes until no further changes in % T were detected. 
Buffer solutions at the appropriate salt concentration and pH were used as blanks, and 
manually subtracted from the protein data. Average % T data from the three replicates 
was averaged and error calculated as the standard deviation. 
 Thioflavin T assay 
Thioflavin T (ThT) is a benzothiazole dye traditionally used as an indicator for the 
presence of amyloid structures (figure 2.14). It exhibits enhanced fluorescence upon 
association amyloid fibrils (extrinsic fluorescence). Due to the specificity of ThT to 
associate amyloid fibrils, it has found many applications such as diagnosis of amyloid in 
tissue sections using fluorescence microscopy, monitoring extracted amyloid and in vitro 
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amyloid fibril formation using fluorescence spectroscopy (Khurana, Coleman et al. 
2005). 
 
Figure 2.14: Chemical structure of Thioflavin T. 
 Protocol 
ThT (Fisher) stock solutions were prepared at a concentration of 2 mM in Milli-Q water 
(3.18 mg in 5 ml), covered in foil and stored at 4○C for up to one month. ThT was mixed 
with protein and buffer (at appropriate concentrations) to give a total volume of 300 μl 
and a final ThT concentration of 200 μM in NUNC 96 black Polypropylene MicroWellTM 
plates. A sample containing ThT and protein in buffer was used as a reference. Excitation 
at 435 nm and emission between 465 nm and 565 nm or at a single wavelength of 485 nm 
were recorded (figure 2.15). In the presence of amyloid fibrils, the intensity of ThT 
fluorescence at 485 nm increases sharply. The average of three identical samples was 
determined and errors calculated as the standard deviation. 
 
Figure 2.15: Thioflavin T assay spectrum indicating the increase in fluorescence peak at 
485 nm attributed to ThT association with fibrillar material. 
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 Phase separation 
 Removal of large (precipitated) aggregates 
The formation of large aggregate particles during denaturation (or other aggregation 
pathway) is a common occurrence. To further characterise either the aggregates or the 
supernatant, samples were centrifuged (15,000 x rpm/20 minutes) to allow for the 
separation of precipitated aggregates from the bulk protein solution (the supernatant) 
(figure 2.16). The protein supernatant was then carefully pipetted from the aggregated 
pellet of protein and the concentration of the supernatant re-determined as per 2.5.1.1 to 
establish the loss in protein to aggregated particles.  
 
Figure 2.16: Separation of precipitated aggregates from bulk protein solution by 
centrifugation. 
 Characterisation of supernatant 
Once the precipitated aggregates have been removed, the supernatant can be characterised 
using PAGE or HPLC. These techniques can be used to identify the quantity of 
monomeric protein retained after aggregation and/or the formation of small, oligomeric 
(soluble) aggregates in the supernatant. The protein remaining in the supernatant can also 
be assessed over a prolonged time period to evaluate the stability of the remaining protein. 
This was done using SE-HPLC. 
 
 Microscopy 
As protein aggregates, particles can become large enough to be accessible to different 
microscopic techniques. Numerous microscopy methods can be used to image large 
protein aggregates (larger than ~1 μm). The major challenge in microscopy is isolation 
and preparation of the protein sample. It is important that these procedures don’t impact 
on the structure of the particle. It is also important that a sample aliquot is representative 
of the sample as a whole (Mahler and Jiskoot 2012).  
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 Light microscopy imaging protocol 
In order to visualise protein particles within a solution, the sample was pipetted gently up 
and down to ensure mixing of the sample so an adequate representation of the sample 
could be obtained. Samples for analysis were prepared on microscope slides and a 
coverslip was placed on top. Where thick precipitated protein aggregates were formed, 
these were gently transferred onto the microscope slide with a spatula and a small (~10 
μl) amount of buffer was pipetted over the sample to ensure it would not dry out. Protein 
aggregates were observed using an Olympus BX61 microscope, equipped with a digital 
imaging system with magnification to up 100X. Images of the viewed structures were 
viewed and recorded using CellF software. Microscopy images had their contrast and 
brightness adjusted so that the morphology of the structures could be best viewed and 
evaluated. 
 Polarised microscopy imaging protocol 
Polarised light microscopy is used to generate contrast in birefringent sample 
components, indicative of structural order. For example, it allows for the determination 
of the optical crystallographic properties of crystals. The polariser functions to convert 
light from the light source, which vibrates in random directions, into linearly polarised 
light. When the linearly polarised light passes through a birefringent sample, it is divided 
into ordinary and extraordinary rays, with different speeds and refraction indexes. When 
the polariser and the analyser are aligned orthogonally only the light modified by 
birefringent sample can pass through. Polarising microscopy can be used for quantitative 
and qualitative analysis of protein aggregate species, proving information on properties 
such as morphology, refracting index, dichroism and interference figures (Weaver 2003). 
Protein aggregates were assessed for their ability to show birefringence using the same 
protocol as in section 2.8.1, using the same optical microscope equipped with a polariser 
(located before the sample) and an analyser (located between the sample and camera). 
Images of the viewed structures were viewed and recorded using CellF software. 
Microscopy images had their contrast and brightness adjusted so that the morphology of 
the structures could be best viewed and evaluated. 
                  
 
68 
 
 Transmission electron microscopy 
Transmission electron microscopy (TEM) uses a high voltage beam of highly energetic 
electrons sent through a thin slice of sample to create an image of the sample, the resulting 
interference pattern. It allows for better resolution than light microscopy as the beam of 
electrons have a far smaller wavelength. The electron source is an electron gun (tungsten 
cathode) that emits an electron beam accelerated by an anode (40 – 400 keV). The beam 
is then focused by electrostatic and electromagnetic lenses and transmitted through the 
sample. Depending on the density of the material present, some of the electrons are 
scattered from the beam. Based on the degree of scattering and interaction with the 
sample, the electron beam carries information about the structure of the sample and is 
magnified by an objective lens. CCD cameras can be coupled to the device to take images 
(Mahler and Jiskoot 2012). The resolution limit of TEM is approximately in the range of 
100 μm to 0.05 nm.  
 TEM Protocol 
TEM work was carried out in The Royal College of Surgeons, Ireland with the help of 
Mr. Brenton Cavanagh. The instrument used was a Hitachi H-7650 Transmission 
Electron Microscope. Samples for examination were prepared using an ‘inverted droplet 
method’. This consisted of gently pipetting up and down the sample for analysis to ensure 
a homogenous mixture. The mixed sample was then pipetted (~ 20 μl) onto parafilm and 
a metal grid (300 mesh thin bar copper grids; 3.05 mm diameter) was placed on top (figure 
2.17). These were left for 30 minutes to allow sufficient time for sample to adhere to the 
grid while avoiding large protein aggregates sticking to and blocking up the grid. The grid 
was removed from sample and excess solution evaporated off. The grid was then inserted 
into the electron column in the microscope and into the beam path. The beam strength 
was 100 kV. Microscopy images had their contrast and brightness adjusted so that the 
morphology of the structures could be best viewed and evaluated. 
 
Figure 2.17: Method of sample preparation for TEM.  
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 Isolation of monoclonal antibody IgG1 
 Expression and purification of IgG1 from CHO DP-12 
Cell culture medium with expressed IgG1 was kindly provided by Professor Ian 
Marison’s laboratory, Dublin City University. The antibody was expressed in the CHO 
(DP12v2) cell line. Two batches of protein were received. Batch 1 was grown in shake 
flasks and Batch 2 was grown in a 2.5 L bioreactor. The bioreactor conditions used were; 
temperature 37○C, pH: 7.2 and dissolved oxygen: ~95%. The cells were cultured in 
ExCell CHO CD3 media which was supplemented with 4 mM L-glutamine, 1 μM MTX, 
10 mg/L insulin and 0.1% antifoam. The medium was stored at -80○C. 
 Purification of monoclonal antibody 
IgG1 was purified from the cell culture medium using a 5 ml HiTrap™ Protein A HP 
column (GE Healthcare). Before purification, the cell culture medium was defrosted 
slowly at room temperature. Defrosted material was then centrifuged at 8,500 rpm for 2 
hours to remove large particles and any remaining cellular material. The supernatant was 
then separated from the pellet. The supernatant was syringed through 0.22 µm filters prior 
to being loaded onto the separation column. 
 
A series of buffers were prepared for the purification of the IgG1 from the medium; 
1. Binding buffer – 20 mM sodium phosphate, pH 7.0 
2. Elution buffer – 0.1 M citric acid, pH 3.5  
3. Neutralisation buffer – 1 M Tris-HCl pH 9.0 
 
Collection tubes were primed by adding 100 μl of neutralisation buffer per 9 ml of fraction 
to be collected. The HiTrap™ column was washed with 10 column volumes of binding 
buffer at a flow rate of 5 ml/min. Prepared sample was loaded on to the column at a flow 
rate of 1 ml/min. The column was again washed with at least 10 column volumes of 
binding buffer (or until no material appeared in the effluent) at a flow rate of 5 ml/min. 
Protein was eluted from the column with 2 to 5 column volumes of the elution buffer at 
a flow rate of 1 ml/min into the collection tubes. The column was then washed with 5 
column volumes of 20% ethanol to prevent bacterial growth and for storage purposes. 
Peak fractions from the purified IgG1 were pooled and washed into a 50 mM phosphate 
buffer, pH 8 using Amicon ultra 0.5 ml 10 kDa cut off membrane centrifugal filter units 
(Merck Millipore). Purified antibody was aliquoted into microcentrifuge tubes and kept 
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at - 80○C. The concentration of purified IgG was measured by UV absorbance using the 
extinction coefficient 1.40 cm2/mg as a guide (Neergaard, Nielsen et al. 2014; Hoger, 
Mathes et al. 2015; Molloy, Fesinmeyer et al. 2015). This is to be officially determined. 
 
The protein was analysed using SE-HPLC (as described in 2.3) to ensure purity. The 
column used for all IgG1 work was TSK-GEL® 3000 SWxl column (Tosoh Bioscience). 
The columns packing material is made up of 5 µm silica particles with 250Å pores, 
making it ideal for the separation of IgG1, a relatively large protein (150 kDa). The 
column resolution ranges from 10 – 500 kDa. The mobile phase used was 50 mM sodium 
phosphate, pH 8 at a flow rate of 1 ml/min with a 45 μl injection volume. The purity of 
the protein was also assessed using PAGE. Native PAGE was used to insure the correct 
molecular weight protein was isolated and purified. Reduced SDS-PAGE was used to 
separate the IgG into its heavy and light chain.  
 Identifying the glycoform of IgG1 
Glycoanalysis was performed in the laboratory of Professor Pauline Rudd, NIBRT. All 
immunoglobulins are glycosylated. Glycosylation is post-translational modification that 
involves the attachment of sugars (glycans) to the antibody. The quantity and quality of 
glycosylation depends both on the protein itself and also on the cell type expressing the 
protein. Changes in the IgG glycoforms can alter their function and stability. 
 
Sugars were enzymatically cleaved from the IgG1 using the enzyme PNGase F, capable 
of removing most N-Glycans and is the most reliable and easiest approach (Huhn, Selman 
et al. 2009). PNGase F is an amidase that cleaves the N-linked glycan from the Fc portion 
of IgG. It removes all asparagine-linked oligosaccharides with high yields by cleaving 
the bond between the GlcNAc and asparagine yielding a glycan with a free reducing 
terminus. This mechanism is not yet fully understood, but believed to occur via an initial 
β-elimination step prior to a reaction with hydrazine derivate (Merry, Neville et al. 2002). 
 Extraction of glycan from IgG1 
The heavy chain fragment of the IgG was isolated using reducing SDS-PAGE, cut out 
and chopped into 1 mm sections using a sterile knife. 1 ml of acetonitrile was added to 
the gel pieces in a microcentrifuge tube and rotated/shaken for 10 minutes to cause the 
gel pieces to expand. All liquid was removed from gel pieces. 1 ml of 20 mM sodium 
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bicarbonate (NaHCO3) was added and rotated/shaken for 10 minutes to remove the 
coomassie blue stain from the gel pieces. The stain contains SDS that will interfere with 
steps further in the process. These steps were repeated until all dye was removed. 2 µl of 
Peptide -N-Glycosidase F (PNGase F) enzyme and 48 µl of buffer (NaHCO3) were added 
to the gel pieces. Gel pieces were left to swell and soak up the solution, and kept topped 
up with solution to prevent them drying out. Samples were then left in an incubator 
overnight (at least 16 hours) at 37○C. Samples were then washed using 200 µl of water, 
vortexed and sonicated for 15 minutes. All liquid was removed into labelled 
microcentrifuge tubes and retained. This process was repeated with 200 µl water followed 
with 200 µl acetonitrile two more times with all liquid retained (1000 µl total). Liquid 
samples were completely dried in a vacuum centrifuge (~ 50 µl liquid/ 30mins, total time 
~10 hours). Once dry, samples were stored at – 20○C. 
 Labelling of glycan 
Glycans do not absorb in the UV region and don’t contain any fluorophores. They require 
derivatization to add a chromophore or fluorophore, allowing for detection after 
separation (Ruhaak, Zauner et al. 2010). IgG1 was derivatized using the fluorescent label 
2-aminobenzamide (2-AB). Samples were removed from the freezer (-20°C) and 5 µl of 
2-aminobenzamide (2-AB) labelling mixture (LudgerTag 2AB labelling kit) is added to 
each tube, agitated for 5 minutes to ensure thorough mixing and incubated for 30 minutes 
at 65○C. Samples were agitated for a further 5 minutes and incubated for a minimum of 
1.5 hours at 65○C. This approach is advantageous as it gives 1:1 stoichiometric attachment 
of one label per glycan, allowing accurate and direct quantification based on fluorescence 
or UV-absorbance intensity. This is carried out in excess to ensure complete 
derivatization of the released sugars. 
 Label clean up – paper chromatography 
Paper chromatography was used after reductive amination to remove excess label. 3 mm 
Whatman chromatography paper was cut, washed three times in Milli-Q water (2 
minutes/wash) and dried in an oven at 65○C. 5 µl of sample placed on the dried paper. 
Acetonitrile was used as the mobile phase. This was left for 30 minutes or until a clear 
separation could be seen with a UV lamp. The paper was dried for 15 minutes and the 
spot containing the sample was cut out. The paper piece was then washed into a 
microcentrifuge tube using a Millex Syringe Driven non-sterile, low protein binding, 
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hydrophilic filter (Millipore). First the paper was soaked in 500 µl of Milli-Q water for 
15 minutes, then 400 µl Milli-Q water was added, and washed through. This process was 
repeated 3 times, waiting 15 minutes between each wash. Samples were placed into a 
Speed Vac to dry overnight. 
 Separation of glycoforms 
 Undigested Samples 
After labelling, glycan samples were separated using ultra performance liquid 
chromatography (UPLC). The remaining pellet was diluted in 50 µl Milli-Q water. 5 µl 
of sample was added to acetonitrile in a LC vial and mixed. Samples were then run using 
ACQUITY® UPLC H-class 4 on an Acquity® UPLC BEH Glycan 1.7 µm, 2.1 x 50 mm 
column (both Waters) designed for HILIC-mode separations of 2-AB labelled glycans. 
The mobile phase was 30% 50 mM NH4 HCOOH pH 4.4, 70% acetonitrile, flow rate 
0.561 ml/min for 30 minutes, sample injection was 20 µl, and Milli-Q water was used as 
a blank and a gradient separation with increasing amounts of aqueous phase was 
performed. 
Digested Samples 
20 µl of sample was digested into fragments using specific enzymes known as 
exoglycosidases, and a denaturing buffer (10X; 0.5% SDS, 40 mM DTT) according to 
Table 2.6. Each enzyme cleaves a different part of a glycan structure breaking it down 
into individual sugar units to allow identification of the full glycan structure. The sample 
was mixed with the components and left in oven overnight at 37○C. 
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10X 
buffer 
(µl) 
ABS 
(µl) 
BTG 
(µl) 
BKF 
(µl) 
GUH 
(µl) 
JBM 
(µl) 
Milli-Q 
H2O (µl) 
TOTAL 
(µl) 
UND 1 - - - - - 9 10 
ABS 1 1 - - - - 8 10 
ABS+BTG 1 1 2 - - - 6 10 
ABS+BTG+BFK 1 1 2 1 - - 5 10 
ABS+BTG+BKF 
+GUH 
1 1 2 1 2 - 3 10 
ABS+BTG+BFK 
+GUH+JBM 
1 1 2 1 2 1 2 10 
Table 2.6: Reagents and enzymes used to digest the glycan structure 
Arthrobacter ureafaciens sialidase (ABS), Bovine kidney alpha-fucosidase (BFK), 
Bovine testes β-galactosidase (BTG), Β-N-acetylgucosaminidase (GUH), Jack Bean α(1-
2,3,6)-Mannosidase (JBM) 
 
Figure 2.18 details the order of exoglycosidases used to digest our IgG1 glycan. Starting 
with our undigested sample, successive enzymes were added to cleave off different 
elements of the glycan structure to aid in identifying the glycan profile. 
 
Figure 2.18: Exoglycaosidases used to achieve glyco profiling of our IgG1 and where 
they specifically cleave. 
 
After the glycan structure had been completely digested into individual sugar units, the 
remaining enzyme was neutralized by placing the sample into an oven at 65○C for 5 
minutes. Nanosep 10 kDa MWCO centrifugal filters (OMEGA) (washed x2 with 500 µl 
Milli-Q water at 13,000 rpm for 5 minutes) were used to wash the sample from the 
microcentrifuge tube. Addition of water to the tube and then to the filter is repeated three 
times to ensure all sample is removed. The sample was then placed into the Speed Vac 
and dried down. 
 
The dried pellet was dissolved in 5 µl Milli-Q water & added to 80 µl acetonitrile plus 20 
µl of Milli-Q water (total 105 µl). Samples were run on Normal Phase HPLC (Waters) 
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using a TSKgel Amide 3 µm (150 x 4.6 mm) column (Anachem). Mobile phase was 30% 
50 mM NH4 HCO2 pH 4.4, 70% acetonitrile, flow rate 0.4 ml/min, sample injection was 
95 µl. A 2-AB labelled dextran ladder was also run as a standard. The dextran ladder is a 
characteristic ladder profile made up monomeric glucose. Each peak is expressed as a 
glucose unit (GU) used to assign GU values released in the glycan pool.  
 
Elution properties were carried out by performing a standardization/calibration using a 
dextran hydrolysate ladder (Royle, Campbell et al. 2008). This is a characteristic ladder 
profile from monomeric glucose. Each peak is expressed as a glucose unit (GU) used to 
assign GU values released in a glycan pool. Elution peaks are expressed in terms of (GU). 
The GU for each glycan is then directly related to the number and linkage of its constituent 
oligosaccharides; the larger the glycan, the higher its GU. Therefore, the removal of 
sugars by exoglycosidase digestion results in movement of the peak to a lower GU. 
 Peak assignment 
Interpretation of data and structural assignment of peaks from UPLC and NP-HPLC 
profiles was carried out via a web-based database bioinformatic tool-GlycoBase 3.0+ to 
establish the glycan composition of our IgG1. 
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 High-Throughput 
Approach to Measure Protein 
Aggregation 
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 Introduction 
 Background 
The pharmaceutical industry has invested billions of dollars in the development of new 
drug targets and leads over the last 20 years. Despite this large investment, the industry 
is in a decline. Since 2010 the number of FDA-approved new molecular entities (NMEs) 
has dramatically decreased and it has been argued that improved target selection is the 
key to tackling this challenge (Bunnage 2011). The growing number of biopharmaceutical 
therapeutic proteins coming to market are more challenging to analyse than small 
molecules because of their inherent complexity; numerous molecular weights, variable 
conformations, solubility and stability, and post-translational modifications (Crommelin, 
Storm et al. 2003). The manufacturing of such protein formulations requires a greater 
number of batches (>250 vs. <10), a larger number of product quality tests (>2000 vs. 
<100) and larger process data entries (>60,000 vs. <4000) (Rathore 2011). This means 
more powerful analytical techniques and complex approaches to screening are necessary 
to obtain detailed characterisation of the protein product (Staub, Guillarme et al. 2011). 
Forced degradation (FD) studies or accelerated tests are an essential step in formulation 
development. They are carried out early in the development stage to establish the most 
suitable conditions for protein formulations and define optimal conditions for long term 
storage (Hasija, Li et al. 2013). They also give insight into potential degradation pathways 
and ensure that analytical methods are able to detect degradation products for stability 
assays and to set up screening protocols (Hawe, Wiggenhorn et al. 2012). The 
international Conference on Harmonisation (ICH) provides scientific and regulatory 
guidelines on how to approach FD studies for the pharmaceutical industry in USA, 
Europe and Japan. The ICH Guideline Q5C on stability testing in biotechnological 
products advises that drug manufacturers provide information on product stability, 
including information on numerous external conditions that may affect the quality of the 
product (ICH 1998). 
 The problem 
Currently, drug discovery and formulation stability measurements can be time-
consuming, require high concentrations of pure product and can be costly. The high 
expense in producing protein formulations means manufacturers often do not commit to 
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the production of large quantities of material until positive screening results are achieved 
(Capelle, Gurny et al. 2007). The time cycle for introducing new targets now averages 
over 13 years from project inception to market costing as much as €1 billion. Roughly 4 
years is spent in preclinical trials and on average it takes 9 years for a drug candidate to 
progress through the clinical phases of development (Bunnage 2011).  
 High-throughput as a solution 
For this reason it is often advantageous to screen a large number of solution conditions in 
order to assess the quality/stability of the protein in solution. The main factors driving the 
competitive biopharmaceutical market are; ‘first to market’, product quality and cost-
effectiveness of the product production. Phrases such as ‘hit generation’, lead generation’ 
and ‘lead optimization’ are used in the rapid discovery and selection of new 
candidates/products (Roberts 2001). The ability to measure numerous parameters in 
development processes in a rapid, cost-effective fashion to screen samples for production 
and to aid in design and formulation development is the key to achieving this (Capelle, 
Gurny et al. 2007). This is fuelling the need for improved high-throughput screening 
(HTS). HTS is a technology widely used in the pharmaceutical and biotechnology 
industry. Only in the past 10 years have HTS scientists been able to bring together 
sophisticated automated equipment, robust assays, validated targets with high quality 
compound libraries, useful data analysis tools and a better understanding of how to use 
HTS. These technologies are now the primary tool to monitor protein product degradation 
including aggregation and precipitation (Pereira and Williams 2007; Xia and Wong 
2012). Essential to obtaining high-precision data is the use of fully automated platforms 
coupled with robotics with benefits such as miniaturisation and parallelisation. This 
benefits the cost-effectiveness of the process and run times. The challenge is in finding 
the right drug/protein formulation while concurrently optimising the screening of targets 
at a minimal cost per sample, through quality detection with a high degree of confidence 
(Mayr and Bojanic 2009; Xia and Wong 2012). 
 Advancements in high-throughput technologies 
Various technologies have been developed that take advantage of assay miniaturisation, 
lab automation and robotics to aid in the development of HTS (Pereira and Williams 
2007; Mayr and Bojanic 2009). Since the first microtitre plate was invented in 1951 by 
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Dr. Guyla Takatskay, a revolution in the technologies for HTS has occurred and has 
advanced rapidly with instruments now capable of preparing and/or analysing large 
numbers of samples with low or no personal assistance in relatively short time periods 
(Sundberg 2000). By the late 1990s, a shift from the assay systems and robotics that were 
capable of screening thousands of samples per day, saw the rise in the development of 
ultra high-throughput screening methods (uHTS). These have increased the number of 
assays per day from several thousands to 100,000 or more per day (Hertzberg and Pope 
2000). The goals of HTS and uHTS are automation, miniaturisation and high-throughput 
with emphasis on the development of assay formats coupled to highly sensitive detection 
methods. The trend towards miniaturisation and automation was also driven by the need 
to reduce development and operating costs, thus reducing the amount of biological and 
chemical reagents used per assay, facilitating higher throughput assay formats by 
enabling the use of parallel sample approaches and multiplexed detection modes (Gomez-
Hens and Aguilar-Caballos 2007). uHTS has evolved in the areas of assay automation, 
miniaturisation and detection methodologies. Assays while initially adopting a 96-well 
microplate format, have now advanced towards 384- and even 1536-well microplate 
assays. The next goal is in designing plate-based formats with higher well densities and 
smaller volumes. There is also a trend towards microfabricated devices designed to 
perform continuous flow assays and advanced chip technology capable of handling 
nanoliter samples (Sundberg 2000; Mayr and Bojanic 2009). 
 HTS methodology 
Numerous automated processing steps are involved in in HTS including using liquid and 
power handling systems, barcode readers, stackers, shakers, cooling or heating systems, 
incubators, centrifuges, filtration stations, plate sealers, washers and a variety of detection 
systems. It is of vital importance that any of these systems do not induce any stress on the 
protein that might disrupt its stability. A variety of techniques can then be employed to 
analyse the protein quantitatively or qualitatively i.e. fluorescence, absorbance, 
luminescence (Gomez-Hens and Aguilar-Caballos 2007). HTS can be classified into two 
groups; invasive (calorimetry, chromatography, mass spectrometry) and non-invasive 
(UV-Vis absorbance, fluorescence and luminescence) depending on the technique used 
and the possibility of recovering the protein after characterisation. (Capelle, Gurny et al. 
2007). Figure 3.1 introduces a schematic representation of several components involved 
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in HTS from sample preparation in a multi-well plate format using automated handling 
systems to detection and interpretation of results and how this can feed back into a loop 
for designing new experiments. Assays in microarray formats can be carried out to either 
asses the same target in multiple wells with different concentrations to assess its potency, 
or one sample per well gaining multiple measurements from a single sample to increase 
information about their properties (Gomez-Hens and Aguilar-Caballos 2007). Typically 
just a single measurement of each sample is obtained in an initial primary screen. This is 
evaluated for biological relevance by a counter screen and confirmed as a hit by a 
secondary screen that may test fewer samples. -Marginal hits on the first screen may fail 
to validate on the second screen because of measurement or procedural error (Malo, 
Hanley et al. 2006). 
 
 
Figure 3.1: Schematic of HTS process from sample preparation, applying a stability 
stress to detection and analysis of results. 
 
The most important factors in HTS are minimising the amount of sample and products 
needed, selecting the correct assay, integrating multiple automated techniques, 
continuous evaluation of the data and flexibility in designing new experiments (Capelle, 
Gurny et al. 2007).  
 Scepticism of HTS 
However there are some that believe the balance between increasing the throughput to a 
maximum level of assays per day, versus higher quality screening is askew. Analysis has 
shown that in fact HTS have hindered the productivity of the pharmaceutical industry as 
it undermines creativity and critics of HTS feels it is not worth the return on investment 
(Lahana 2003; Garnier 2008). As there is a push for quantity and higher throughput, there 
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needs to be careful consideration that this is not at a downfall of higher quality data that 
can provide more information and leads that can become clinical candidates (Macarron, 
Banks et al. 2011). 
A problem with HTS methodologies is that with increasing throughout there is usually a 
greater chance that good or bad properties of a sample will be wrongly categorised. The 
generation of “false-positives” (sample that wrongly pass a particular minimum 
requirement) and “false-negatives” (samples that should have passed) are a major point 
of concern for HTS. Roberts (Roberts 2001) states of these outcomes; false-negative are 
of more concern as de-selection during screening can lead to exclusion of promising 
candidates. The quality of analytical results depends critically on the precision and 
accuracy of the HTS device (Wolcke and Ullmann 2001). Sometimes a screen may be 
sufficient for one set of conditions, but not another. Microplates stored for prolonged time 
before measuring can result in sample evaporation. Water in sealed versus non-sealed 
microplates have shown increased evaporation at the corners and borders compared to the 
centre leading to potential errors in measurement (Berg, Undisz et al. 2001). This study 
also showed that while automated pipetting into microplates of higher density (384+) was 
more efficient then manual pipetting in time, effort and accuracy, the accuracy and 
precision of HTS liquid handling systems depended on many factors from the medium 
handled, the plate type used, the delivery methods and methods of detection (Rhode, 
Schulze et al. 2004). Bertrand et al. believe that while progress with HTS methods has 
been achieved, progress has moved too fast with automated systems being established 
before we have fully mastered the handling of the vast amounts of data produced 
(Bertrand, Jackson et al. 2000). There is a lack of universal procedures for processing and 
extracting knowledge from screens or any standardised method of the ‘hit’ identification 
process (Malo, Hanley et al. 2006). There is also a considerable lack of literature reporting 
the limitations and pitfalls that have been identified from HTS methods that might 
highlight errors and incorrect interpretation of data recovered. 
 The end goal 
More interaction between chemists and biologists creating multidisciplinary teams with 
design plans can improve efficiency and quality. Improvements in both hit specificity and 
sensitivity need to be met by the technologies running and operating the systems, along 
with data analysis methods to achieve the full potential of HTS (Malo, Hanley et al. 
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2006). However the industry is still growing and improving the quality and validation of 
their targets and leads, industrialising and streamlining their HTS laboratories and 
increasing communication and integration with other drug discovery groups (Macarron 
2006). 
The combination of forced degradation studies with high-throughput assays is of great 
importance as it will aid in identifying more robust formulations while being more 
economic and less time consuming (Hawe, Wiggenhorn et al. 2012). However, careful 
consideration of the quality of data must be given to ensure that speed is not valued over 
quality and this will be explored in this chapter. 
 
 Aims of the study 
Quantification of protein aggregation is regularly carried out in in the pharmaceutical 
industry using expensive techniques such as the Coulter method, microscopic techniques 
or by light obscuration, that either need high concentrations of material, are time 
consuming, require manual counting of particles or limited by detection of particle size 
(Roberts and Wang 2010). Any process that can reduce the amount of time and resources 
involved while still reaching acceptable outcomes are preferred (Capelle, Gurny et al. 
2007). Therefore optimisation of screening assays using low concentrations of protein, 
straightforward particle size characterisation and rapid turnaround times are 
advantageous. 
 
The purpose of this investigation was to assess the effectiveness of a high-throughput 
approach to measure protein aggregation after forced degradation. Thermal denaturation 
(Mechanism 2) was used as a model stress as it is well known to induce elevated levels 
of aggregation and is one of the most common stress mechanisms (Bischof and He 2005; 
Hawe, Wiggenhorn et al. 2012). The mechanism of thermally induced aggregation in our 
model proteins is well established and studied; lysozyme (Raccosta, Manno et al. 2010) 
and BSA (Militello, Vetri et al. 2003). The aggregation of both proteins is known to be 
sensitive to solution conditions and so could be tuned to ensure protein aggregation 
occurred for both proteins at concentrations suitable for our high-throughput assay. 
 
A protein high-throughput formulation platform was designed based on the use of 
microplates using specific methods developed to investigate physical and chemical 
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properties of the protein formulations. The aggregation of both proteins was assessed 
using a combination of characterisation techniques, including, visual changes in solution, 
turbidity measurements, and Thioflavin T (ThT) fluorescence utilising a 96 well multi-
plate format and a microplate reader for detection. By detecting changes in solution 
turbidity and ThT fluorescence, an assessment of the degree and type of protein 
aggregation could be determined. These results were then compared to other more robust, 
higher resolution techniques to establish if the high-throughput approach was accurate in 
the detection and characterisation of protein aggregation. It is important that HTS assays 
are complemented with other techniques (often referred to as orthogonal techniques) 
typically applied to analyse protein stability. Ideally the strengths and weakness of any 
HTS method should be validated so that the method can then be applied when and where 
it will be most useful and predictive.  
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 Results 
 High-throughput assay - Turbidity 
 Lysozyme 
The HTS assays were conducted in a 96 well-plate format. Lysozyme (0.5 – 20 mg/ml) 
in the chosen buffer and within the pH range selected, is collodially stable i.e. no visible 
solution aggregation occurs in the absence of the applied stress, in this case, heat (figure 
3.2A). After thermal denaturation of lysozyme at 80○C, a visible change in many of the 
samples could be seen (figure 3.2B). An opaque precipitate was observed in several of 
the plate wells. 
 
Figure 3.2: 96-multiwell plates A) before and B) after thermal denaturation of lysozyme 
in 50 mM sodium phosphate for a range of pHs and protein concentrations. 
 
The change in solution turbidity was measured by % transmission at 450 nm before (t = 
-20 mins) and after (t = 20 mins) thermal denaturation (figure 3.3A). Based on the 
measured turbidity levels after denaturation and the visual appearance of the samples, a 
relative aggregation scale was created to establish a “phase diagram” as a way of 
indicating the level of precipitated material detected (figure 3.3B). Three divisions on the 
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relative scale were used; samples that showed high level of turbidity (visible particles), 
moderate levels of turbidity (subvisible particles, indicated by the absence of visible 
aggregates, but a decrease in % transmission) and samples that were both visually 
transparent and indicated no decrease in % transmission (free from large particles). 
 
Figure 3.3: A) Turbidity measurement for thermally denatured lysozyme in solution pH 
5, 6, 7 and 8 at t = 20 min. B) Phase diagram of lysozyme turbidity after thermal 
denaturation (X=No turbidity, Y=Moderate turbidity and Z=Visible turbidity). 
 
Lysozyme in sodium phosphate buffer at pH 5 and pH 6, showed almost no decrease in 
% transmission, compared to lysozyme at pH 7 and pH 8, which aggregated to a 
significant degree. Only in the lower concentration range for both solution conditions (pH 
7 < 2 mg/ml, pH 8 < 0.5 mg/ml), did the samples not indicate a measured change in 
turbidity after thermal denaturation. 
 BSA 
The same assay and conditions were used for BSA. Again, before heating, all samples 
were colloidially stable and after thermal denaturation at 80○C, a visible change in the 
protein solutions was observed (figure 3.4A and B). The % transmission was recorded for 
each sample (figure 3.4C). The turbidity measurements indicated that only at pH 5 did 
the BSA solution turn visibly turbid. The other solution conditions (pH 6, 7 and 8) showed 
no change in solution appearance or in % transmission. The samples appeared to be free 
of large particles which would give rise to turbidity. This is represented as a phase 
diagram (figure 3.4D). 
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Figure 3.4: 96-multiwell plates A) before and B) after thermal denaturation of BSA in 50 
mM sodium phosphate, pH 5, 6, 7 and 8. C) Turbidity measurement for thermally 
denatured BSA at t = 20 min. D) Phase diagram of BSA turbidity after thermal 
denaturation (A=No turbidity, B=Moderate turbidity and C=Visible turbidity). 
 
 Solution turbidity over time 
After the initial measurement at t = 20 min, further absorbance measurements were made 
each hour thereafter until no further changes in turbidity were detected. Figure 3.5 shows 
the difference in % transmission values recorded at t = 20 min and t = 180 min for both 
lysozyme (figure 3.5A) and BSA (figure 3.5B). For both proteins the calculated 
difference in the % transmission recorded between the two time points varied, up to 12% 
in some cases. In the majority of cases the change in % transmission appears (strangely) 
to indicate that less turbidity is observed over time. The variation was greater for the 
samples had turned visually turbid (BSA, pH 5 and lysozyme pH 7 - 8). 
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Figure 3.5: Change in % transmission between t = 20 mins and t = 180 mins. 
A) Lysozyme and B) BSA. 
 
The question is then if there has been a genuine decrease in the level of protein 
aggregation or if the decrease has some other explanation. As Figure 3.6 shows, visually 
there was a difference in the sample appearance between t = 20 min and t = 180 min. 
Visual inspection of the sample indicates that all of the aggregated material sediments 
within the 180 minute timeframe. This leads to heterogeneity in the distribution of the 
particles at the bottom of the well, and therefore a difference in the % transmission 
measured for the same sample (which is only read at one point). 
 
Figure 3.6: 96-multiwell plates containing BSA at pH 5, after thermal denaturation at t 
= 20 min and t = 180 min showing the sedimentation of the precipitated material. 
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 Analysis of the supernatant 
To determine the amount of protein material that had precipitated as a result of thermal 
denaturation for each solution condition, the precipitated material was separated from the 
bulk solution by centrifugation. The concentration of protein remaining in the supernatant 
was then determined. Table 3.1 shows the concentration of lysozyme (mg) in the 
supernatant after removal of the precipitated material. 
 
Initial 
Lysozyme 
conc 
 (mg/ml - mg) 
pH 5 
(mg) 
wt.% 
loss 
pH 6 
(mg) 
wt.% 
loss 
pH 7 
(mg) 
wt. % 
loss 
pH 8 
(mg) 
wt. % 
loss 
0.5 - 0.1 0.098 2.00 0.098 2.00 0.088 12.00 0.086 14.00 
1 - 0.2 0.196 2.00 0.194 3.00 0.172 14.00 0.162 19.00 
2 - 0.4 0.394 1.50 0.396 1.00 0.310 22.50 0.316 21.00 
4 - 0.8 0.796 0.50 0.794 0.75 0.596 25.50 0.594 25.75 
6 - 1.2 1.196 0.33 1.192 0.67 0.982 18.17 0.954 20.50 
8 - 1.6 1.592 0.50 1.594 0.38 1.250 21.88 1.282 19.88 
10 -2.0 1.990 0.50 1.992 0.40 1.460 27.00 1.588 20.60 
12 - 2.4 2.394 0.25 2.384 0.67 1.966 18.08 1.820 24.17 
15 - 3.0 2.980 0.67 2.994 0.20 2.330 22.33 2.172 27.60 
20 - 4.0 3.990 0.25 3.980 0.50 3.042 23.95 2.806 29.85 
 
Table 3.1: Concentrations of lysozyme (mg) in the supernatant after thermal 
denaturation for a range of solution pHs. The wt. % loss in protein is also shown. 
 
At each pH, the proportion of protein lost to precipitation of protein aggregates was only 
weakly dependent on the protein concentration. At pH 5 and pH 6, the reduction in protein 
concentration was very small and unlikely to be due to aggregation, but rather a loss of 
protein due to non-specific surface absorption (Mechanism 5) on the micro-well plate 
polystyrene surface, and through material transfer steps, since the amount of material lost 
as a proportion of the total amount decreases with increasing protein concentration. The 
opposite behaviour would be observed for aggregation, as is observed at pH 7 and pH 8 
where a larger % wt. loss in protein can be seen, consistent with the turbidity data. 
 
However, the lower concentration samples at pH 7 (0.5 – 4 mg/ml) that appeared visually 
free from precipitates and showed no decrease in % transmission after thermal 
denaturation, also have a relatively high material loss (12 – 25%). This indicates the limit 
of sensitivity of the high-throughput assay to detect aggregation in either low 
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concentration samples, or in higher concentration samples with low levels of aggregation. 
Lysozyme at pH 7 at 6 mg/ml was the lowest concentration to show a measured change 
in solution turbidity (89% transmission), with a calculated 18% wt. loss in protein, 
accounting for a 218 μg total loss in protein to aggregates large enough to be detected by 
the turbidity assay, indicating the limit of detection for the turbidity assay for aggregation. 
While lysozyme 4 mg/ml at pH 7, with 95% transmission but had a 25% loss in protein 
accounting for a 204 μg total loss in protein to aggregates that the turbidity assay did not 
detect. Comparatively, lysozyme at pH 8, 1 mg/ml had a 38 μg loss of protein to 
aggregation and showed a % transmission of 81%. Thus indicating the assays inability to 
differentiate between small amounts of large aggregates or high amounts of small 
aggregates. 
 
The assay also fails to fully quantify the degree of turbidity in highly aggregated samples. 
Lysozyme at pH 8, between 4 – 20 mg/ml all showed between 1 – 5% transmissions, yet 
the total loss of protein in the 4 mg/ml sample was 206 μg, for 10 mg/ml the protein loss 
was 412 μg, while at 15 and 20 mg/ml samples there was a loss of 828 μg and 1.19 mg 
respectively, of protein to aggregation. The assay is able to detect the change in samples 
due to aggregation, but is unable to differentiate the amount of protein lost per sample 
once a certain level of turbidity is reached. Similarly, BSA remaining in the sample 
supernatant (mg) was also calculated (Table 3.2) along with the wt. % loss of protein as 
a result of thermal denaturation. 
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Initial 
BSA conc 
 (mg/ml - mg) 
pH 5 
(mg) 
wt.% 
loss 
pH 6 
(mg) 
wt.% 
loss 
pH 7 
(mg) 
wt. % 
loss 
pH 8 
(mg) 
wt. % 
loss 
0.5 - 0.1 0.026 74.00 0.096 4.00 0.094 6.00 0.094 6.00 
1 - 0.2 0.084 58.00 0.184 8.00 0.182 9.00 0.184 8.00 
2 - 0.4 0.198 50.50 0.396 1.00 0.348 13.00 0.362 9.50 
4 - 0.8 0.278 65.25 0.794 0.75 0.744 7.00 0.756 5.50 
6 - 1.2 0.514 57.17 1.192 0.67 1.102 8.17 1.114 7.17 
8 - 1.6 0.594 62.88 1.594 0.38 1.530 4.38 1.460 8.75 
10 - 2.0 0.634 68.30 1.992 0.40 1.826 8.70 1.894 5.30 
12 - 2.4 0.842 64.92 2.384 0.67 2.294 4.42 2.254 6.08 
15 - 3.0 0.978 67.40 2.994 0.20 2.754 8.20 2.894 3.53 
20 - 4.0 1.686 57.85 3.980 0.50 3.638 9.05 3.790 5.25 
 
Table 3.2: Concentrations of BSA in the supernatant after thermal denaturation a range 
of solution pHs. The wt. % loss of protein is also shown. 
 
For BSA again the amount of aggregate detected visually and with the turbidity assay did 
not always correlate with the wt. % loss established from the concentration of protein 
remaining in the protein supernatant, with less aggregation detected by % transmission, 
then by simply measuring the concentration of protein in the supernatant (which may of 
course still contain smaller aggregates). Samples that remained visually free from 
precipitated material (pH 5, 0.5 – 2 mg/ml) showed a decrease in protein concentration 
corresponding to a % wt. loss comparable to samples that had turned turbid (pH 5, 4 – 20 
mg/ml). The 2 mg/ml sample at pH 5, was the last sample to show a measured change in 
% transmission, where again 202 μg loss to large aggregates was the limit of detection. 
Solutions at pH 6, 7 and 8 all show between 2 and 13% loss in protein. We know from 
visual inspection and the turbidity assay that this loss in protein was not through the 
formation of precipitated material. This loss accounts for up to 360 μg of total protein. 
This was mostly likely lost through the formation of aggregates not large enough to be 
detected by a change in % transmission but large enough to be removed through 
centrifugation at 15K rpm. 
 Further Screening 
Both lysozyme and BSA samples, initially heat treated to 80°C and cooled were then 
treated to two further heat cycles as a method of secondary screening to assess if marginal 
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hits on the first screen failed to validate on the second screen i.e. to see if any more 
aggregation occurred upon the addition of further heat stress in samples that appeared 
stable initially. While certain protein formulations may have no immediate response to 
the stress condition applied, this doesn’t mean stability has not been compromised. From 
the time point of the last turbidity measurement at heat cycle 1 (t = 180 min), without 
removing the precipitated material from the plate wells, changing or altering the samples, 
the multi-well plate was again heated for 20 minutes at 80○C. Figure 3.7 shows a multi-
well plate containing the lysozyme samples after heat cycle 2 and heat cycle 3. 
 
Figure 3.7: 96-multiwell plates showing thermal denaturation of lysozyme after heat 
cycles 1, 2 and 3. 
 
For lysozyme, at pH 5 the overall turbidity of the solution remained low with minimal 
change in % transmission between successive heat cycles observed across the full 
concentration range (figure 3.8A). For lysozyme at pH 6, the lower concentration samples 
(0.5 – 6 mg/ml) only showed minimal change in % transmission with each successive 
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heat cycle (figure 3.8B). However the higher concentration samples (8 – 20 mg/ml) 
showed a noticeable increase in turbidity by cycle 2, and a more significant decrease in 
% transmission for the 15 and 20 mg/ml samples by cycle 3. Lysozyme pH 7 (0.5 – 12 
mg/ml) and pH 8 (0.5 – 6 mg/ml), both showed a marked decrease in % transmission 
recorded between the first and second heat cycle, but none thereafter (figure 3.8C and D).  
 
Figure 3.8: The % transmission of lysozyme with successive heat cycles. 
A) pH 5. B) pH 6. C) pH 7. D) pH 8. 
 
The BSA samples were also treated in this manner (microplates not shown). No 
substantial change in any of the samples could be visually observed after heat cycles 2 or 
3, except for those that had already turned visually turbid after the first heat cycle. In these 
samples a slight increase in visual turbidity after the second and third heat cycles did 
occur. 
 
The measured % transmission after successive heat cycles of BSA is shown in Figure 3.9. 
For BSA at pH 6 – 8, the level of turbidity remains low. A relatively small decrease in % 
transmission (0.5 – 5%) was measured after each heating cycle consistent across all BSA 
concentrations apart from the highest concentration (20 mg/ml) where % transmission 
decreases to 90% (figure 3.9 B – D). For BSA at pH 5, all samples showed a decrease in 
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% transmission with each successive heat cycle, especially in the 1 – 10 mg/ml samples 
after the second heat cycle, when compared to the initial heat cycle.  
 
 
Figure 3.9: The % transmission of BSA with successive heat cycles. 
A) pH 5. B) pH 6. C) pH 7. D) pH 8. 
 
If the data for both BSA and lysozyme are summarized based on the % transmission data 
alone at two concentrations, we see that for both proteins, the stability against thermal 
denaturation decreases as the protein approaches its pI (figure 3.10). This is consistent 
with previous work on both lysozyme (Bonincontro, De Francesco et al. 1998) and BSA 
(Tobitani and Murphy 1997). In the case of lysozyme it appears that the protein is 
thermally stable at pH 5 – 6, however between pH 7 – 8, stability decreases. While BSA 
remained virtually free from precipitation between pH 6 – 8, and precipitated at pH 5, 
indicating aggregation.  
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Figure 3.10: Turbidity assay data of lysozyme (red) and BSA (blue) at 2 mg/ml and 10 
mg/ml indicating that both proteins are most stable against thermal denaturation at pHs 
far from their pI values. 
 
 Aggregate morphology 
 Appearance of the protein aggregates 
Lysozyme formed an opaque, thick, dense, solid aggregate after denaturation that did not 
break up after the application of shear. The BSA opaque aggregate was a less solid 
material that remained free in suspension and could easily be pipetted. Figure 3.11 shows 
both the lysozyme and BSA aggregate pellet formed by thermal denaturation of a 20 
mg/ml sample, after centrifugation. 
 
Figure 3.11: Thermally denatured aggregate pellet of A) lysozyme pH8, B) BSA pH 5. 
 
The precipitated material for both lysozyme and BSA was examined in more detail using 
optical microscopy. This was to establish the morphology of the aggregated protein 
produced by thermal denaturation. The precipitated material from both proteins was 
visually different (figure 3.12). Lysozyme formed large clumps of spherical aggregated 
units stuck together, compared to free floating spherical structures in formed BSA. 
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Figure 3.12: Optical micrograph of A) lysozyme and B) BSA for a 4 mg/ml thermally 
denatured aggregate. 
 
 Polarised light microscopy 
Both amorphous aggregates and amyloid type material can be formed after thermal 
denaturation of proteins (Khurana, Gillespie et al. 2001; Vetri, Canale et al. 2007), and 
polarization light microscopy can be used to detect the presence of amyloid material, 
which can help to distinguish both of these aggregate types. The lysozyme aggregates 
indicated some degree of optical birefringence, suggesting that amyloid-type aggregates 
may have formed after denaturation (figure 3.13). This phenomenon was not observed 
with the BSA aggregates.  
 
Figure 3.13: Micrographs of aggregated protein material produced after the thermal 
denaturation of lysozyme (4 mg/ml, pH 8). A) Phase contrast image B) Polarisation 
microscopy image. 
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 High-throughput assay – Thioflavin T 
The use of a Thioflavin T (ThT) assay is another convenient tool for high-throughput 
screening, based on the extrinsic fluorescence of a dye bound to an amyloid-type protein 
aggregate. The fluorescence intensity of Thioflavin T increases significantly when bound 
to the cross β-structure specific to amyloid fibrils. However small increases in 
fluorescence intensity can occur when bound to hydrophobic sites of amorphous 
aggregates and to amorphous aggregates showing β-cross structure but lacking fibril 
morphology (Chang, Liao et al. 2009; Sen, Fatima et al. 2009; Biancalana and Koide 
2010). A ThT assay for both lysozyme and BSA was performed under the same conditions 
used for the % transmission measurements. ThT fluorescence was monitored over time 
for all protein samples after thermal denaturation. 
 
For lysozyme in sodium phosphate buffer, pH 8, ThT fluorescence increased relative to 
protein samples at pH 5. Only in the higher protein concentration range (10 – 20 mg/ml) 
did the samples at pH 5, show an increase in ThT fluorescence (figure 3.14). 
 
Figure 3.14: Thioflavin T assay measurements (normalised) of thermally denatured 
lysozyme. A) pH 5. B) pH 8. 
 
BSA samples also showed increased ThT fluorescence after thermal denaturation at all 
protein concentrations (figure 3.15). Higher ThT fluorescence intensities were measured 
for protein at pH 5 than at pH 8. At pH 5, the measured ThT fluorescence intensity 
increases with increasing protein concentration. The data was normalized such that the 
intensity is divided by the protein concentration and represents the ThT fluorescence per 
milligram of protein, hence the increase in fluorescence intensity was related to the 
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association of ThT to aggregates beyond those expected by an increase in protein 
concentration. 
 
Figure 3.15: Thioflavin T assay measurements (normalised) for thermally denatured 
BSA. A) pH 5. B) pH 8. 
 
Lysozyme and BSA both showed the highest increase in ThT fluorescence in the samples 
that also had the biggest change in % transmission (figure 3.16). This was also related to 
the solution condition and pI of each individual protein. 
 
Figure 3.16: Thioflavin T fluorescence (normalised) of A) lysozyme and B) BSA, after 
thermal denaturation (t = 180 min). 
 
 SE-HPLC 
SE-HPLC was chosen as a technique to compare the effectiveness of the high-throughput 
assays in characterising and detecting protein aggregation after thermal denaturation. The 
bulk precipitated aggregates were removed from the protein samples by pelleting them 
from the protein solution by centrifugation. The remaining protein in the supernatant was 
examined using SE-HPLC. 
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 SE-HPLC of lysozyme 
The supernatant of lysozyme samples after one heat cycle were subjected to SE-HPLC 
on day 1 (after separation from the pellet) and also on days 3 and 7, at solution pH 5 
(figure 3.17A). At this pH, the protein was relatively collodially stable and no aggregation 
after thermal denaturation was detected using either % transmission measurements or the 
ThT assay. 
 
Figure 3.17: SE-HPLC data for the lysozyme supernatant (2, 5, 10, 15 and 20 mg/ml) at 
pH 5, after one cycle of thermal denaturation on day 1, 3 and 7. A) Lysozyme 
chromatograms showing the monomer peak and no indication of higher molecular 
weight species. B) Percentage recovery of lysozyme monomer. 
 
Plotted alongside each thermally denatured sample is a corresponding lysozyme control 
sample (data in black). This represents a chromatogram for a lysozyme sample of equal 
concentration to the protein sample before thermal denaturation for comparison. No 
higher molecular weight species were detected on the column. A clear monomer peak 
was detected at 26.3 minutes in all samples. Figure 3.17B plots the percentage recovery 
of monomer (calculated from area under each chromatogram peak) on each day. Also 
plotted for comparison is the percentage recovery of lysozyme control solutions (pH 5) 
at each concentration that wasn’t subjected to any sort of stress or denaturation on day 7. 
From this graph on day 1, for all concentrations, almost 100% of lysozyme at pH 5 was 
recovered from the supernatant (i.e. there is no precipitation) after thermal denaturation, 
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which is consistent with the data from the turbidity measurements. With time, the 
percentage of lysozyme monomer decreased but the same amount of material was lost in 
the non-stressed sample. This is likely to be as a result of a decrease in colloidal stability 
over time. This data indicates that after thermal denaturation, the recovery of lysozyme 
monomer at pH 5 was very high and that the stability of the recovered protein did not 
appear in any way to be diminished or affected by the imposition of a thermal stress. 
Table 3.3 shows the recovery of protein (mg/ml) in the supernatant (column 1) and the 
calculated recovery of monomer lysozyme (mg/ml) recovered (column 2; as per area 
under the SE-HPLC chromatogram). This confirms that the recovery of protein by SE-
HPLC was consistent with what was recovered in the supernatant and that almost no 
lysozyme was lost to aggregation by thermal denaturation. A small amount of lysozyme 
was unaccounted for (column 3), but is within the experimental error (~1%).  
 
Initial 
Lysozyme 
conc (mg/ml) 
Lysozyme 
supernatant  
SE-HPLC 
monomer 
Lysozyme 
unaccounted/ 
 > 600 kDa 
2 1.97 1.97 0.03 
5 4.92 4.91 0.1 
10 9.95 9.96 0.05 
15 14.9 14.86 0.1 
20 19.95 19.90 0.05 
Table 3.3: Lysozyme pH 5, concentration of lysozyme monomer resolved by SE-HPLC 
and in the supernatant (per UV measurement) (mg/ml) after thermal denaturation day 1. 
 
The supernatant of lysozyme at pH 8 was also analysed using SE-HPLC (figure 3.18). 
Both the turbidity and ThT measurements indicated significant protein aggregation at this 
pH, while a 15 – 30% loss to aggregation was measured by calculating the concentration 
of protein remaining in the supernatant. The lysozyme monomer can be identified as the 
main peak at 26.3 minutes, and again there was no indication of higher molecular weight 
species. The chromatograms in black represent control samples of lysozyme not subjected 
denaturation at this pH. 
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Figure 3.18: SE-HPLC data of lysozyme supernatant (2, 5, 10, 15 and 20 mg/ml) at pH 8 
after one cycle of thermal denaturation on day 1, 3 and 7. A) Lysozyme chromatograms 
showing monomer peak and no indication of higher molecular weight species. B) 
Percentage recovery of monomer. 
 
There was a significant loss in monomeric protein in the thermally stressed samples 
compared to non-stressed samples. The recovery of monomer was lower than expected 
since the concentration of protein in the supernatant indicated 70 - 85% recovery of 
protein. The quantity (mg/ml) of lysozyme recovered by SE-HPLC and in the supernatant 
did not match up. Table 3.4 shows the recovery of protein (mg/ml) in the supernatant 
(column 1) and the calculated recovery of monomer (mg/ml) recovered (column 2; as per 
area under the SE-HPLC chromatogram). The concentration difference suggested a 
population of lysozyme aggregates too large to be resolved on the column (> 600 kDa) 
but too small to be observed by the turbidity assay (< 1 μm) or removed by centrifugation 
(column 3). The quantity of lysozyme precipitate was calculated as the difference between 
lysozyme recovered in the supernatant and the initial lysozyme concentration (column 4). 
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Initial 
Lysozyme 
conc 
Lysozyme 
supernatant 
SE-HPLC 
monomer 
 
>600 kDa, <1 
μm 
Lysozyme 
precipitate 
 > 1 μm 
2 1.58 1.20 0.38 0.42 
5 3.67 0.84 2.86 1.33 
10 7.94 0.57 7.37 2.06 
15 10.86 0.67 10.19 4.14 
20 10.03 0.91 9.12 9.97 
Table 3.4: Lysozyme pH 8, concentration of monomer resolved by SE-HPLC and in the 
supernatant (per UV measurement) (mg/ml) after thermal denaturation day 1. 
 
 SE-HPLC of BSA 
BSA in its native, unstressed form has a SE-HPLC chromatogram with two peaks; a 
monomer peak with a retention time of 18.9 minutes (~88% of total protein content) and 
a small portion of dimer with a retention time of 16.39 minutes (~12% of total protein 
content) (figure 3.19).  
 
Figure 3.19: SE-HPLC of a BSA (10mg/ml, 50 mM NaPo4, pH 8) sample showing the 
proportion of monomer to dimer. 
 
SE-HPLC was performed on the supernatant of BSA samples after one heat cycle on day 
1 (after separation from pellet) and also on day 3, day 5 and day 7, for samples at pH 5 
(figure 3.20A). A non-stressed BSA sample is also plotted at each concentration (black 
chromatograms). All the BSA supernatant samples showed a decrease in monomer 
protein, very low levels of dimer species (less than 1%) and no evidence of higher 
molecular weight aggregates within the column resolution. The % recovery of monomer 
(calculated from the area under each chromatogram peak) for each day is shown in Figure 
3.20 B. Also plotted for comparison is the percentage recovery of lysozyme control 
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solutions (pH 5) at each concentration that wasn’t subjected to any sort of stress or 
denaturation on day 7. 
 
 
Figure 3.20: SE-HPLC data of BSA supernatant (2, 5, 10, 15 and 20 mg/ml) at pH 5, 
after one cycle of thermal denaturation on day 1, 3, 5 and 7. A) Chromatograms showing 
monomer peak and dimer peak at 16.39 minutes. B) Percentage recovery of monomer 
BSA. 
 
The supernatant of BSA shows between 30 – 50% recovery of monomeric protein after 
thermal denaturation. There does not appear to be any further loss in the recovered 
monomer after separation from the bulk aggregated material up to 7 days later indicating 
good stability of the recovered monomer. The proportion of monomer loss was also 
consistent across all BSA concentrations. The amount of BSA recovered by SE-HPLC 
was compared to the amount recovered in the supernatant. Table 3.5 shows the calculated 
recovery (mg/ml) of BSA recovered in the supernatant (column 1) and the recovery of 
protein by SE-HPLC (column 2 and 3; as per area under the SE-HPLC chromatogram). 
Initial 
BSA conc 
BSA 
supernatant 
SE-HPLC 
monomer 
SE-HPLC  
≥ dimer, 
< 600 kDa 
 
>600 kDa, 
<1 μm 
BSA 
precipitates 
2 0.99 0.88 0 0.11 1.01 
5 2.05 1.84 0.02 0.19 2.95 
10 3.17 3.02 0.06 0.09 6.83 
15 4.89 4.24 0.10 0.55 10.11 
20 8.43 7.36 0.33 0.74 11.57 
Table 3.5: BSA pH 8, concentration of lysozyme monomer resolved by SE-HPLC and in 
the supernatant (mg/ml) after thermal denaturation day 1. 
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From this table it appears that while SE-HPLC does detect very low levels of dimer, a 
very small proportion of BSA (< 0.55 mg/ml) has formed a population of aggregates 
outside the limits of detection for SE-HPLC and the detection range of the turbidity assay 
(column 4), with the greatest proportion of BSA at pH 5, going on to form large 
precipitated aggregates as detected by the turbidity assay (column 5). 
 
BSA samples at pH 8 was analysed in the same manner (figure 3.21A). A relatively small 
amount of monomer was detected in the supernatant by SE-HPLC, while a range of higher 
molecular weight peaks were observed, up to the maximum size resolution of the column 
(600 kDa). As little as 10 - 15% monomer was measured in the supernatant at all BSA 
concentrations after thermal denaturation (figure 3.21B).  
 
Figure 3.21: SE-HPLC data of BSA supernatant at pH 8 after one cycle of thermal 
denaturation on day 1, 3, 5 and 7. A) Chromatograms showing a monomer peak and 
higher molecular weight species to the left of the monomer. B) Percentage recovery of 
monomer. 
 
Again the proportion of each BSA species (mg/ml) was calculated as per Table 3.6. The 
recovery of monomer and the proportion of higher molecular weight species (< 600 kDa) 
from SE-HPLC (column 2 and 3) was compared to the recovery of protein in the 
supernatant (column 1). Since no visual aggregation was detected it was assumed that the 
majority of the protein aggregates were  smaller than ~1 μm accounting for a very small 
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proportion of aggregates out-side the detection limit of the column (column 4), but the 
majority of BSA in pH 8 that aggregated by thermal denaturation formed aggregates 
between 130 and 600 kDa (column 3). 
 
Initial 
BSA conc 
BSA 
supernatant 
SE-HPLC 
monomer 
SE-HPLC 
≥ dimer, 
< 600 kDa 
 
>600 kDa, <1 
μm 
2 1.81 0.24 1.04 0.58 
5 4.83 0.65 4.07 0.11 
10 9.47 1.04 7.17 1.26 
15 14.47 1.27 11.88 1.22 
20 18.95 1.57 14.63 2.75 
Table 3.6: Lysozyme pH 8, concentration of lysozyme monomer resolved by SE-HPLC 
and in the supernatant (mg/ml) after thermal denaturation day 1.  
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 Discussion 
High-throughput screening assays used in this study enabled the testing of large numbers 
of protein samples and solution conditions, to gauge their response to a thermal stress. In 
this study we verified whether the high-throughput assays used here were capable of 
detecting the levels and types of aggregation induced by the thermal denaturation of two 
model protein, lysozyme and BSA. 
 
The first assay assessed was the turbidity assay. After samples were subjected to heat 
denaturation (Mechanism 2), protein aggregation occurred. A number of the protein 
solutions turned visibly turbid, indicating the presence of large protein aggregates which 
was confirmed with optical microscopy. This change was measured as a marked decreases 
in % transmission coinciding with the samples that also showed a visual change in 
solution appearance. The degree to which the turbidity assay could differentiate between 
levels of turbidity was broken down into three categories; a large decreases in % 
transmission coinciding with visually high levels of turbid material (1 – 80% % T), a 
slight decreases in % transmission accounting for low levels of subvisible particles (80 – 
98% % T) and no loss in % transmission indicating no change in solution appearance. 
This shows that the turbidity assay is useful as a HTS assay for establishing a “phase 
diagram” for a range of solution conditions. 
 
The % transmission data for the range of solution conditions examined is consistent with 
previous work. This pH-dependent association of lysozyme observed has been well 
documented (Bruzzesi.Mr, Chiancon.E et al. 1965; Hampe 1972; Mine, Noutomi et al. 
1990; Goldberg, Rudolph et al. 1991; Ibrahim, Higashiguchi et al. 1996; Price, Tsuchiya 
et al. 1999; Cao, Wang et al. 2002; Raccosta, Manno et al. 2010; James and McManus 
2012). 
 
Many aspects of BSA thermal denaturation have been examined, indicating solution-
dependent unfolding related to solution conditions including ionic strength and pH (Ross, 
Finlayson et al. 1984; Shrake, Finlayson et al. 1984; Yamasaki, Yano et al. 1990; Michnik 
2003; Michnik, Michalik et al. 2006). This work is in general consistent with our 
measurements. 
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However, the turbidity assay does not give any detailed information about the type, size 
or quantity of aggregation and was actually misleading for several samples (on the basis 
of further analysis). It was found that within the region where a large decreases in % 
transmission were recorded for lysozyme at pH 8, did not correlate well with the actual 
loss of protein to aggregation. Additionally, once the % transmission reaches zero (the 
saturation point), no further changes in aggregation behaviour can be detected, even when 
further aggregation continues to occur over time. Hence, the technique is only appropriate 
for a range of relatively low concentration samples. In fact, determination of the protein 
concentration in the sample supernatant after removal of bulk aggregates was much more 
informative than the turbidity assay. The measured values were a more accurate 
representation of the actual loss of protein to aggregation. Additionally, heterogeneity 
within the sample is not captured by the measurement, since % transmission is assessed 
at a single point. 
 
The assay also seemed limited to only detecting large aggregates. A small proportion of 
large aggregates in lysozyme at 2 mg/ml was detected, but a higher concentration of 
aggregates in a 4 mg/ml indicated no aggregation by % transmission. The limits of the 
assay to differentiate between the sizes of aggregates was most apparent for BSA. Since 
the turbidity assay clearly had limits of detection, it was compared to other orthogonal 
techniques to further assess its sensitivity at detecting aggregation of protein samples. 
BSA at pH 6 – 8, that remained visually transparent even with almost 50% of the material 
was detected as small aggregates by SE-HPLC. 
 
As a stand-alone method of detection, % transmission measurements would suggest that 
for lysozyme at pH 5 – 6, was resistant to aggregation relative to the thermally unstable 
pH range (pH 7 and 8). If this is coupled with the SE-HPLC analysis, we were able to 
establish that stability is in fact only maintained at pH 5. From the SE-HPLC analysis of 
both proteins it become obvious that the not only does the turbidity assay not detect large 
amounts of small aggregates, it is unable to detect high levels of protein aggregates in 
higher concentration samples (i.e. once aggregation is sufficient to bring the % 
transmission to zero). Unlike the turbidity assay, SE-HPLC can quantitatively detect 
different forms/sizes of protein and when coupled to the measurement of protein 
concentration in the supernatant of separated samples, provides a good description of the 
overall level of aggregation within a sample.  
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BSA is a multi-domain protein and it has been proposed that these domains unfold 
independent of one another and at slightly different temperatures resulting in the 
formation of intermediate states from which aggregation is likely to occur (Fink 1998; 
Michnik 2003; Militello, Vetri et al. 2003). The SE-HPLC of BSA (pH range 6 – 8) did 
detect the formation of small oligomers likely formed as the thermally unfolded subunits 
of one molecule interacted with a matching exposed hydrophobic surface of a 
neighbouring molecule. As the solution pH moves towards the pI of BSA (pH 5), the 
charge distribution on the surface of BSA was reduced and the small soluble oligomers 
further assemble into more disordered aggregates with the loss of electrostatic effect 
stabilisation. Eventually the size of the aggregates exceeds the solubility limit and large 
visible aggregates are formed, as observed visually and with the turbidity assay, 
consistent with previous work (Clark, Judge et al. 1981; Clark, Kavanagh et al. 2001; 
Militello, Casarino et al. 2004; Vetri, Librizzi et al. 2007). 
 
A second high-throughput assay utilising the dye Thioflavin T was assessed. The 
polarised light micrographs of the lysozyme aggregates indicated birefringence leading 
to the assumption some level of ordered structure (possible amyloid aggregates) exists 
within the aggregation, which the BSA aggregates did not show. The fluorescence 
intensity of the ThT with thermally denatured lysozyme did show an increases, indicative 
of association with amyloid structure (Krebs, Bromley et al. 2005; Biancalana and Koide 
2010) consistent with those samples that indicated the presence of precipitated aggregates 
(at pH 8) in the turbidity assay. Taken together, this suggests that lysozyme aggregates 
are amyloid-like to some extent, but TEM images are required to confirm this. Human 
lysozyme is capable of forming amyloid fibrils in individuals suffering from non-
neuropathic systemic amyloidosis as a result of a point mutation in the lysozyme gene. 
HEWL (hen egg white lysozyme), wild-type human and wild-type hen lysozyme have all 
been shown to form amyloid fibrils confirmed by EM, Congo red and ThT fluorescence 
(Krebs, Wilkins et al. 2000; Morozova-Roche, Zurdo et al. 2000; Cao, Hu et al. 2004; 
Frare, Polverino De Laureto et al. 2004). The formation of amyloid fibrils from lysozyme 
has only been reported using only extreme conditions of pH, temperature and incubation 
times, suggesting that the experimental conditions used in our study are likely not harsh 
enough to induced the conformational changes needed to form fibrils. As an example, 
amyloid fibrils of lysozyme were formed by incubating the protein at 81°C for 45 minutes 
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in H2O at pH 3.8, followed by lyophilisation. Samples were then stirred in 32 mM HCl, 
pH 1.5, at 45°C for up to ten days (Frare, Mossuto et al. 2006).  
 
Another point against the assumption of amyloid fibril formation was the comparison to 
the analysis of BSA samples incubated with ThT. The BSA polarised microscopy images 
show that there is no presence of ordered structure in the aggregates formed. However 
the BSA samples in the ThT assay show a higher amount of ThT fluorescence upon 
thermal denaturation than for lysozyme. While the exact mechanism of ThT association 
with amyloid fibrils is still not fully understood it is believed to associate with, (but not 
exclusively), to the crossed-β structure in amyloid fibrils (Krebs, Bromley et al. 2005). 
Protein aggregated into coagulated gel structures is known to involve intermediate protein 
conformations with higher β structure content, compared to native forms (Kelly 1998). 
Thermally denatured irreversible aggregates of BSA have been shown to proceed by a 
conversion of the protein secondary structure from α-helix into well ordered β-sheet rich 
aggregates (Murayama and Tomida 2004). These types of aggregates have been shown 
to bind ThT and Congo red, both indicators of fibrillation and aggregates with amyloid 
properties, however the aggregates didn’t possess the same structural rigidity as classical 
amyloid fibres (Holm, Jespersen et al. 2007). Heat denatured ovalbumin has been shown 
to induced opaque amorphous precipitates that developed cross-β structure as recognised 
by ThT (Azakami, Mukai et al. 2005). These possibility may account for why we see a 
rise in ThT fluorescence within our samples but it is not believed to be a result of fibril 
formation. Typical fibrillation has a sigmoidal profile usually commencing with an initial 
lag time followed by a relatively short elongation growth phase where the fibrils 
accumulate. The ThT intensity values measured by the ThT assay were minimal 
compared to ThT fluorescence intensities characteristic of fibril formation, further 
indicating that the ThT fluorescence is most likely as a result of association with 
aggregated material and not amyloid fibrils (LeVine 1999). Therefore the ThT assay is 
useful in detecting protein aggregates (of both amorphous and amyloid type) and does in 
fact detect aggregation that is not indicated by the % transmission assay. 
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 Conclusions 
High-throughput screening methods have both pros and cons. As a first round, 
positive/negative screening method for solution conditions where high levels of 
aggregation occur, our turbidity assay is suitable and reliable to establish a first-pass 
phase diagram. It can decipher between solution conditions where protein aggregates 
precipitated and those that did not. However analysis of the % transmission data was 
misleading about how much aggregation was occurring. It was also unable to differentiate 
between the different sizes of protein aggregates formed. For this more robust and 
sensitive techniques need to be applied with a sample-by-sample approach. The ThT 
assay for our purposes had inconsistencies, illustrating another downside of relying on 
high throughput screening. Using this assay as a standalone result, both lysozyme and 
BSA would test positive for the presence of amyloid fibrils. By increasing the methods 
of detection and analysis, and comparing the results of BSA to lysozyme a much more 
likely picture of the type of aggregated material for each protein can be concluded. 
Collectively the data for BSA and lysozyme does not point towards fibril formation. 
Hence high throughput technologies do have a role to play in formulation and screening, 
but the results must be viewed in context. An orthogonal approach using a number of 
different techniques (including sample-by-sample measurements) must also be conducted 
if all potentially useful formulations are to be identified.  
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 Oxidation as a 
Pathway to Protein Aggregation 
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 Protein Oxidation 
Protein oxidation occurs as a result of either direct “attack” by a reactive oxidative species 
(ROS) or indirectly through peroxidation of lipids that further degrade and attack proteins 
(Mirzaei and Regnier 2008). The rate of radical attack in proteins is of great interest, due 
to the linkage between oxidative stress and many pathological disorders, the process of 
aging and in biopharmaceuticals. Numerous studies point to the aromatic residues and 
sulphur containing amino acid residues (methionine and cysteine) being most sensitive to 
oxidative attack (Kim, Berry et al. 2001; Lasch, Petras et al. 2001; Guedes, Vitorino et 
al. 2009; Ji, Zhang et al. 2009; Le, Chaffotte et al. 2009). 
 
Hydrogen peroxide is a well-studied oxidizing agent, known to be specific for oxidation 
of methionine and cysteine (Shechter, Burstein et al. 1975; Ji, Zhang et al. 2009). 
Understanding protein sensitivity to H2O2 is of significant value. Proteins are not only 
susceptible to H2O2 attack through cellular process and events but also during process and 
formulation during biopharmaceutical production. Protein formulations containing aged 
polysorbate 80 showed signs of oxidation as a result of H2O2 (Ha, Wang et al. 2002) while 
H2O2 is also used as an aseptic agent for the insolators used in the filling of sterile 
products, consequently increasing the proteins susceptibility to oxidative damage (Ji, 
Zhang et al. 2009). 
 
Chemical modification (Mechanism 4) as a consequence of oxidation leads to alterations 
in the protein structure. The major problem with defining the chemistry arises from the 
complex chemical composition of the protein surface offering a wealth of targets for 
oxidation-induced reactions. Garrison et al. (Garrison 1987), Schuessler and Schilling 
(Schuessler and Schilling 1984), and Kopaldova and Liebster (Kopoldova and Liebster 
1963; Liebster, Kopoldova et al. 1963), all pioneered work on the radical-mediated 
oxidation of proteins noting that it leads to oxidation of amino side chains, fragmentation 
of the polypeptide chain, and the generation of protein-protein cross linkages (Stadtman 
2006). Oxidative modifications leads to a variety of structural conformational changes 
including the formation of higher molecular weight dimer products through mixed 
disulphides, inter- and intra-disulphides, and intramolecular abstraction at the α-carbon 
from the hydrogen of amino acid residues typically resulting in backbone fragmentation 
(Finnegan, Linley et al. 2010). 
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Garison et al. (Garrison 1987), proposed that oxidative cleavage of the protein backbone 
is initiated by the hydroxyl radical ⦁OH, formed during the radiolysis of water or the 
metal-catalysed cleavage of H2O2 as illustrated in Figure 4.1 (reaction a and b). This 
radical is capable of intramolecular α-hydrogen abstraction of amino acid residues, 
leading to the formation of α-amino carbon-centered radicals (reaction c). These radicals 
can undergo rapid addition of O2 to form an alkylperoxy radical derivative (reaction d) 
that is readily converted to the peroxide (reaction f) and subsequently to the alkoxyl 
derivatives (reaction h), that can then be converted to a hydroxyl protein derivative 
(reaction i) mediated by reactions with either HO2⦁ or Fe²⁺ (reaction e, g and j). 
 
  
Figure 4.1: Role of ROS in the oxidation and cleavage of the protein backbone  
(Berlett and Stadtman 1997). 
 
The generation of alkoxly radicals (reactions h and g) sets the stage for peptide bond 
cleavage by one of two pathways; 
1. Diamide (figure 4.2, pathway a); the C-terminal amino acid of the peptide 
fragments derived from the N-terminal portion of the protein is present as a 
diamide derivative, and the N-terminal amino acid of the fragment derived from 
the C-terminal portion of the protein is present as an isocyanate derivative. 
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2. α-amidation (figure 4.2, pathway b); the C-terminal amino acid residue of the 
fragment derived from the N-terminal portion of the protein exists as an amide, 
and the N-terminal amino acid of the fragment derived from the C-terminal 
portion of the protein exists as an N-α–ketoacyl derivative. 
 
With acid hydrolysis, peptide fragments obtained by the diamide pathway will yield CO2, 
NH3, and a free carboxylic acid, whereas hydrolysis of the fragment obtained by the α-
amidation pathway yields NH3 and a free α-ketocarboxylic acid. 
 
 
Figure 4.2: Cleavage of the protein backbone by the diamide pathway (a) and the α-
amidation pathway (b) (Berlett and Stadtman 1997). 
 
This idea of oxidative modification is supported by the work of Davies and co. (Davies, 
Lin et al. 1987). However the Schuessler and Puchalas model of oxidative modification 
of proteins proposes that the fragmentation of BSA involves site specific oxidative 
destruction of proline residues (Puchala and Schuessler 1993). Wolff et al. (Wolff, Garner 
et al. 1986)  further explored the susceptibility of proline to oxidative attack showing that 
peptide bond hydrolysis occurs. However, Dean et al. re-assessed Schuesslers et al. 
fragment size data of BSA to state that it was more likely that glycine is the primary 
residue of attack over proline. They found that over 90% of the terminal amino acids after 
fragmentation by the OH⦁ radical were glycine (Dean, Fu et al. 1997). While there 
appears to be conjecture over the exact mechanism of attack and whether or not it is site 
specific, it is apparent that the primary, secondary and tertiary structure of the protein 
under oxidative attack is modified and that this process can lead to the formation of 
protein aggregates. 
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The amino acid cysteine (Cys) is highly susceptible to oxidative stress; some consider it 
the most potent nucleophile of all amino acids. The cysteine residue is present in most 
proteins and often plays a fundamental role in the tertiary structure through the formation 
of the dimer, cystine. This disulphide (sulphur – sulphur) linkage involves the 
interconversion between thiol and disulphide groups in a redox reaction (figure 4.3); the 
thiol is the reduced state and the disulphide is the oxidised state. In the disulphide state 
each sulphur atom loses an H-bond and gains an S-bond. 
 
Figure 4.3: Disulphide bond formation by the coupling of two thiol groups with the 
formation of S–S bond. 
 
The side group of Cys reacts rapidly with HO⦁ in a one electron oxidation reaction to 
yield Cys thiol radicals (RS*), that can form the disulphide radical anions (RSSR*⁻) 
through a reaction with an additional thiol/thiolate, known as thiol-disulphide exchange: 
 
𝑅𝑆∗ + 𝑅𝑆⁻ = [𝑅𝑆𝑆𝑅]∗⁻                                           4.1 
 
It can also form the thiyl peroxyl radicals (ROSS*) through the reversible reaction with 
O2 and the reaction with ascorbate (Asc⁻); 
 
𝑅𝑆∗ +  𝑂2  = 𝑅𝑆𝑂𝑂
∗                                            4.2 
 
𝑅𝑆∗ + 𝐴𝑠𝑐− → 𝑅𝑆− + 𝐴𝑠𝑐∗                                     4.3 
 
In the case of protein oxidation, reactions (4.1) and (4.3) can be less efficient based on 
the access of CysS* to additional protein Cys residues and/or endogenous glutathione or 
ascorbate. Reaction (4.2) doesn’t represent an efficient pathway for the removal of CysS* 
radicals, specifically at physiological concentrations of O2. Hence competitive reactions 
of CysS* may become important in proteins (Schoneich 2008). Mild oxidation of cysteine 
can generate, inter- or – intra-molecular disulphides, protein mixed disulphides resulting 
in macroscopic variation of protein molecular mass, as well as aggregation. Numerous 
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low resolution techniques have been employed to monitor such structural changes as a 
result of oxidation such as mixtures of protein dimers (S-S linked) and larger aggregates 
including 2D gel electrophoresis (Molinari and Helenius 1999; Lepedda, Zinellu et al. 
2013) and SE-HPLC (Mirzaei and Regnier 2008; Giustarini, Dalle-Donne et al. 2011).  
 
Work by Puchala and Schuessler has added greatly to the understanding of oxidative 
modification to proteins. The aim of their work was to understand the role of oxygen in 
the radiolysis of proteins by comparing and contrasting the degradation and formation of 
products as a result of the process. They have compared four proteins; lactate 
dehydrogenase (Schuessler and Herget 1980), BSA (Schuessler and Schilling 1984), 
haemoglobin (Puchala and Schuessler 1993) and myoglobin (Puchala and Schuessler 
1995) under the same radiolysis conditions using SDS-PAGE and HPLC. They found that 
for all proteins, while being fundamentally different in their structures (number of 
tryptophan residues, disulphide bonds, SH-groups) there was a loss of native protein 
through cleavage of the polypeptide chain, yielding fragments which could be separated 
by electrophoresis. They found that the fragmentation of the protein was not a random 
process, but produced specific fragments, while the degree of aggregated material 
between proteins varied. They also point out that the alteration to protein size varies; in 
the absence of O2 substantial cross-linking occurs resulting in aggregation of the protein, 
while in its presence oxidative modification only yields small fragments. 
 
However, the occurrence of aggregation specifically in the presence of O2 does not appear 
to occur for all proteins. An overview of the literature on protein oxidation modifications 
and the resulting products is diverse and it becomes apparent that it is highly dependent 
on the protein under attack. Studies have shown that H2O2 induced modification of 
proteins can result in the both the formation of higher order aggregated species as a 
consequence of cysteine modification and also in protein fragmentation. Lactoperoxidase 
undergoes  H2O2 dependent formation of dimeric and trimeric products (Lardinois, 
Medzihradszky et al. 1999). H2O2 has also been shown to increase protein cysteine 
disulphides in the lens protein γβ-crystallin (Hanson, Chen et al. 1999). Evidence also 
supports the breakdown of protein as a result of H2O2 modification of cysteine. HSP27, 
S-thiolated during oxidative stress by H2O2, disaggregates from its multimeric native state 
(Eaton, Fuller et al. 2002). Davies and Delsignore have attempted to correlate oxidative 
modification to increased proteolytic susceptibility (Davies 1987; Davies and Delsignore 
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1987; Davies, Delsignore et al. 1987; Davies, Lin et al. 1987). They show that alterations 
to the primary and secondary structure of BSA are severely damaged by the presence of 
the superoxide anion radical, the hydroxyl radical and oxygen. BSA exposed to solely 
HO⦁ underwent progressive crosslinking to form dimers, trimers and tetramers, while 
exposure to HO⦁ and O2⁻ or O2 induced fragmentation of the polypeptide chain at the α-
carbon instead of the peptide bonds. They also linked the formation of bityrosine within 
a protein (intramolecular bonding) or between proteins (intermolecular bonding) as one 
of the processes leading to covalent protein cross-linking. 
 Aims of the study 
The aim of this chapter focuses on understanding how oxidation induced modifications 
to proteins affect protein aggregation. Hydrogen peroxide (H2O2) was used as the oxidant. 
Again, BSA and lysozyme were used as model proteins. Lysozyme has a relatively low 
cysteine content (Cys- 8) and bovine serum albumin (Cys- 35) has a comparatively high 
cysteine content. Both proteins have a low methionine content; BSA contains three, with 
only two in lysozyme. Lysozyme also has 6 tryptophan residues compared to 2 in BSA. 
Hence it may be possible to establish if there is a correlation between the levels of 
oxidation induced aggregation observed for each protein relative to the quantity of 
susceptible amino acids present. Oxidation was induced over a range of mild to extreme 
oxidative stress conditions (dependent on the oxidant concentration). The influence of pH 
on oxidation induced protein aggregation was also explored. The oxidative damage to the 
proteins was evaluated by SE-HPLC, gel electrophoresis, turbidity and ThT assays, while 
intrinsic fluorescence was used to explore changes to the protein structure. 
 
The exact mechanism by which protein induced aggregation is related to oxidative stress 
is still poorly understood. This chapter will address several important questions; how 
easily do proteins aggregate when oxidized using H2O2? Does their amino acid content 
play a role and if so how to what extent? To what degree does aggregation occur through 
the formation of homogenous clusters of monomeric protein, or is it random aggregation 
via heterogeneous aggregates due to the assembly of protein fragments?  
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 Results 
 Oxidation of Lysozyme 
 Oxidative modification of lysozyme secondary structure 
Changes to the secondary structure of lysozyme as a consequence of oxidation was 
monitored by intrinsic fluorescence by measuring the loss in total protein fluorescence 
intensity (excitation at 280 nm and 295 nm). Lysozyme solutions with a fixed 
concentration of 10 mg/ml (pH 5 – 8) were incubated with increasing concentrations of 
H2O2 and their intrinsic fluorescence was measured 1 hour after exposure to H2O2 (figure 
4.4A and B). H2O2 induced clear conformation alterations of both the tyrosine and 
tryptophan fluorescence when the total fluorescence intensity (figure 4.4C and D) and 
λmax (figure 4.4E and F) were monitored with increasing H2O2 concentrations. 
 
Figure 4.4:  Intrinsic fluorescence spectra for lysozyme (pH 5) (A and B), the total 
fluorescence intensity (C and D) and theλmax (E and F) of each individual fluorescence 
signal for lysozyme (pH 5 – 8) excited at 280 nm and 295 nm. 
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The loss in fluorescence intensity is an early phenomenon of radical–mediated protein 
oxidation and confirms alternations of the protein secondary structure (Chao, Ma et al. 
1997; Campos, Lissi et al. 1999; Ma, Chao et al. 1999). The decrease of both the 
tryptophan and tyrosine intrinsic fluorescence indicates both residues are vulnerable to 
oxidative modification and are likely destroyed by the free radicals (Wu, Zhang et al. 
2009). The fluorescence loss for tryptophan residues has been shown to be a direct 
consequence of oxidative degradation (Sun, Zhao et al. 2011). Table 4.1 shows the 
percentage recovery of fluorescence intensity across all solution conditions measured. 
 
Ex 280 nm 
% recovery 
pH 5 pH 6 pH 7 pH 8 
Ex 295 nm 
% recovery 
pH 5 pH 6 pH 7 pH 8 
H2O2 (M)     H2O2 (M)     
0.05 58.46 85.86 83.08 89.51 0.05 78.61 93.85 88.86 93.17 
0.1 48.39 77.27 67.90 80.64 0.1 53.33 84.68 71.40 91.11 
0.2 42.05 74.82 62.77 77.13 0.2 45.64 74.23 62.96 90.50 
0.4 28.75 38.94 57.68 57.96 0.4 32.80 54.23 57.74 79.65 
0.8 19.03 30.01 24.56 38.37 0.8 28.09 43.70 34.20 48.73 
1 11.43 24.05 19.22 30.16 1 22.52 35.17 27.29 34.49 
5 1.92 1.95 1.97 1.94 5 3.22 2.56 1.63 1.05 
Table 4.1: Recovery of intrinsic fluorescence intensity for oxidised lysozyme (pH 5 – 8) 
calculated from the λmax values. 
 
These results suggest that extensive structural changes occurred for oxidised lysozyme. 
The fluorescence intensity was almost completely diminished for the high concentrations 
of H2O2 (1 – 5 M) for all solution conditions. The reduction in fluorescence intensity was 
comparable for pH 6 – 8, while lysozyme pH 5 showed a significantly larger reduction in 
fluorescence intensity, decreased by almost 40% in 0.05 M H2O2 compared to 15 – 20% 
for pH 6 – 8, indicating it’s susceptibly to alteration was more acute. The blue shift in the 
wavelength position (figure 4.4) to shorter wavelengths for oxidised tryptophan is 
indicative of increased burial of the residues in a hydrophobic environment (Keerati-u-
rai, Miriani et al. 2012).  The result of this structural damage was monitored over time to 
assess if changes at the secondary structure due to oxidative damage would result in 
aggregation and/or fragmentation of lysozyme. 
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 Macroscopic changes following oxidation 
Exposure of lysozyme to H2O2 over long periods of time caused clear changes in the 
visual appearance of the protein solutions (figure 4.5). 
 
 
Figure 4.5: SE-HPLC glass vials containing oxidised lysozyme at pH 8, with different 
H2O2 concentrations after 7 days. 
 
Lysozyme in 5 M H2O2, resulted in a solution colour change from clear to an off 
yellow/orange that was visible within 24 hours and no evidence of visible aggregation 
(i.e. turbidity) was observed. From 0.2 – 2.5 M H2O2, visible particles could be seen in 
the glass vials but without a colour change. Lysozyme exposed to lower concentrations 
of H2O2 (0.05 - 0.01 M) remained clear and no obvious particles were observed. 
 Lysozyme turbidity after oxidation 
Exposure of lysozyme to H2O2 resulted in varying levels of turbidity, likely due to the 
formation of large aggregates. In order to discriminate between those samples that formed 
large aggregates and those that remained free from particles (at least sufficient in number 
to result in a measureable change in turbidity), % transmission was recorded in a multi-
well plate over a 160 hour period (figure 4.6).  
 
Highly concentrated solutions of H2O2 can react with plastic. The plates used are made 
from polystyrene. Chemical compatibility charts by both Thermo Scientific (Thermo 
Scientific, 2014)  and JDR Enterprises Inc. (JDR Enterprises Incorporated, 2014) show 
polystyrene has excellent resistance, with “no damage after 30 days of constant exposure” 
to 30% hydrogen peroxide. For this reason it is believed the plates did not have any effect 
on the oxidation and subsequent aggregation of lysozyme. 
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Figure 4.6: Images and turbidity analysis for lysozyme (10mg/ml) incubated with H2O2 
over a 160 hour period. A) pH 5. B) pH 6. C) pH 7. D) pH 8. 
Multi-well plates contain an oxidised lysozyme solution after 160 hours. 
 
The solution turbidity of some samples increased over time due to the formation of large 
aggregates, measured as a change in % transmission. At pH 6 – 8, aggregation was 
observed in all samples and increased with increasing H2O2 concentration. At high 
concentrations of H2O2 (0.8 – 5 M), aggregation was detected after ~20 hours, while the 
lower concentrations of H2O2 (0.1 – 0.4 M) showed a change in solution turbidity after 
longer incubation periods (60 – 80 hours). For lysozyme at pH 5, the lowest levels of 
turbidity were recorded. Only in the high concentrations of H2O2 (0.8 – 5 M) did lysozyme 
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indicate the formation of large aggregated material, and only after 50 – 60 hours of 
incubation. At the lower concentrations of H2O2 (0.1 – 0.4 M), no change in % 
transmission occurred. At 0.05 M H2O2, no change in % transmission occurred at any pH. 
 
 Characterisation of oxidised lysozyme precipitates 
The lysozyme samples were also examined using light microscopy in order to visualise 
the particles formed. All microscopy was performed on samples of oxidised lysozyme on 
day 7 of incubation. Figure 4.7 shows micrographs of aggregated lysozyme at pH 5 and 
pH 8. 
 
Figure 4.7: Micrographs (light microscopy) of oxidised lysozyme aggregates at two 
different pH values. 
 
The aggregates formed at pH 8, appeared to be small clusters of spherical aggregates. The 
protein assemblies formed at pH 5, appeared smaller, less dense and more liable to break 
up. It is unclear from the optical microscopy images if there are differences between the 
aggregate types formed at each pH. It may simply be a concentration effect, since less 
aggregates form at pH 5. 
 
Destabilisation of native lysozyme due to oxidative modification leads to increased 
amounts of protein with altered conformation as suggested with the intrinsic fluorescence 
analysis. Coupled with visual inspection, the turbidity assay and optical microscopy we 
have indicated that this leads to protein aggregation. However the light microscopy 
images cannot distinguish if these are amorphous aggregates or amyloid fibril material. 
The aggregate growth profiles determined by the % transmission measurements were 
similar to profiles expected for fibril formation (Sulatskaya, Turoverov et al. 2010). For 
this reason ThT fluorescence was used to assess if the lysozyme aggregates did have 
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amyloid fibril characteristics. Figure 4.8 shows the relationship between the level of ThT 
fluorescence intensity and solution pH after 180 hours (figure 4.8 A), along with the 
corresponding ThT fluorescence spectra for lysozyme at pH 8 after 180 hours (figure 4.8 
B). 
 
Figure 4.8: ThT assay of oxidised lysozyme solutions after 180 hours effect of solution 
pH on ThT fluorescence. A) Measured ThT fluorescence intensity(λmax 485 nm) for 
oxidised lysozyme pH 5 – 8. B) ThT fluorescence spectra for oxidised lysozyme at pH 8.o 
 
The ThT fluorescence intensities recorded gradually increased with increasing pH. This 
is consistent with the % transmission data. At 5 M H2O2 and at all pH values, a small 
increase in ThT fluorescence was initially measured but decreased after 20 hours. The 
absence of ThT fluorescence correlates with the absence of precipitated material in the 
glass vials under these conditions. It appears that any aggregated particles capable of 
associating with ThT that do form, are quickly lost. 
 
Plotting ThT fluorescence intensity as a function of time produced a sigmoidal plot (figure 
4.9), with a short lag phase (not captured), a growth phase, and a termination phase, 
corresponding to initiation, elongation, and termination phases respectively, which is 
typical of a fibril forming kinetic mechanism (Biancalana and Koide 2010). 
 
After oxidation, lysozyme solutions at pH 5 and pH 8, showed different characteristics in 
their ThT fluorescence curves and TEM images (figure 4.9 and 4.10). At pH 8, there is a 
rapid increase in fluorescence intensity after 20 minutes that reaches a maximum at 60 
minutes for H2O2 concentrations between 0.1 – 1 M. At 0.05 M, a maximum is reached 
at 120 minutes. At the highest peroxide concentration (5 M), an initial increase in intensity 
is followed by a sharp decrease, reaching a minimum at 100 minutes. Transmission 
                  
 
122 
 
electron microscopy was used to confirm the morphology of the oxidised lysozyme 
aggregates. TEM imaging confirmed the presence of fibrillar material for lysozyme at pH 
8 (figure 4.9B). 
 
Figure 4.9: Oxidised lysozyme, pH 8. A) Increase in ThT fluorescence upon association 
with the aggregated material. B) TEM images indicting the presence of fibrillar 
material. 
 
In contrast to this, the ThT assay of oxidised lysozyme at pH 5, indicates slightly lower 
levels of ThT fluorescence while TEM imaging did not indicate the formation of fibrils 
(figure 4.10B). 
 
Figure 4.10: Oxidised lysozyme, pH 5. A) Increase in ThT fluorescence upon association 
with the aggregated material. B) TEM images indicting the presence of amorphous 
aggregated material. 
 
As the TEM did not distinguish any distinct fibrils at this pH, it is more likely that 
amorphous aggregates are formed at pH 5 and that the ThT dye either binds to exposed 
hydrophobic regions of these aggregates or that they have a cross β-structure devoid of 
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fibril morphology. Both types of amorphous aggregates are known to bind ThT at 
significant levels (Chang, Liao et al. 2009; Sen, Fatima et al. 2009). 
 Analysis of small lysozyme aggregates 
Oxidation of lysozyme clearly produces large aggregates (observed visually). Low 
concentrations of H2O2 (0.05 – 0.4 M) that showed no increase in solution turbidity or 
precipitated material but did cause ThT fluorescence. This would suggest the presence of 
a population of small soluble protein aggregates capable of associating with ThT, but not 
detected by the turbidity assay. We know from our analysis in Chapter 3 that the turbidity 
assay is not capable of detecting high proportions small aggregates. Therefore size 
exclusion HPLC was used to detect small lysozyme aggregates not detected by the 
turbidity assay and to monitor the loss in native monomeric lysozyme to possible 
fragmentation. Figure 4.11 shows chromatograms of lysozyme at pH 5 (10 mg/ml), 
incubated with increasing concentrations of H2O2. 
 
 
Figure 4.11: SE-HPLC chromatograms for oxidised lysozyme pH 5 (10 mg/ml) over 15 
days. 
 
The SE-HPLC chromatogram for lysozyme with H2O2 shows two main peaks. The peak 
at 26 minutes is the monomer of lysozyme and the peak at 31 minutes is H2O2. As the 
stability of the monomer becomes compromised as a result of oxidation over time, the 
area under the monomer peak of lysozyme decreases coupled with an increase in peaks 
at shorter retention times indicating higher molecular weight aggregates. The degree to 
which the peak shapes changed was related to the concentration of oxidant and time. 
 
The overlaid SE-HPLC chromatograms for oxidised lysozyme at pH 5, on day 1 and day 
15 are shown in Figure 4.12. The loss in lysozyme concentration was calculated on the 
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basis of a previously calibrated concentration series for lysozyme. Oxidation of the 
monomer occurs quickly. On day one there is an almost 50% loss in monomer 
concentration and a small proportion of higher molecular weight aggregates are observed 
at high oxidant concentrations (2.5 – 5 M). By day 15 all samples show a decrease in 
monomer concentration and an increase in the concentration of higher molecular weight 
aggregates. The decrease in monomer concentration over 15 days is shown in Figure 4.12 
C. By day 15 the high concentrations of H2O2 (2.5 – 5 M) indicate that nearly 90% of 
monomeric protein has been lost to oxidation. None of the oxidised samples showed 
evidence of fragmentation (i.e. peaks associated with lower molecular weight protein 
fragments), a common product of protein oxidation processes (Guedes, Vitorino et al. 
2009). 
 
 
Figure 4.12: SE-HPLC chromatograms of oxidised lysozyme at pH 5on A) day 1 and B) 
day 15 of incubation. C) Loss in lysozyme monomer concentration (mg/ml) as a function 
of time and H2O2 concentration. 
 
Lysozyme at pH 8, treated in the same manner showed similar behaviour (figure 4.13). 
There was an overall reduction in the concentration of lysozyme monomer initially and a 
subsequent increase in higher molecular weight aggregates, which increased over time, 
and with increasing H2O2 concentrations (figure 4.13C). 
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Figure 4.13: SE-HPLC chromatograms of oxidised lysozyme at pH 8 on A) day 1 and B) 
day 15 of incubation. C) Loss in lysozyme monomer concentration (mg/ml) as a function 
of time and H2O2 concentration. 
 
The loss in native monomeric lysozyme (pH 5 and pH 8) into oxidation products was 
calculated after 7 days incubation (table 4.2 and 4.3). The initial concentration of 
lysozyme was 10 mg/ml. From the SE-HPLC chromatograms, the quantity of monomer 
(column 2) and higher molecular weight aggregates (≤ 600 kDa) resolved by HPLC 
(column 3) was calculated. Any precipitated aggregate material was phase separated and 
the concentration of protein remaining in the supernatant was calculated. This allowed us 
to establish the loss of native protein to large protein particles (column 4). The 
concentration of protein unaccounted for was thought to be either made up of fragments 
(so far undetected), or protein aggregates larger than the resolution of the column (> 600 
kDa) but smaller than protein particles removed with the bulk precipitate separated by 
centrifugation (column 5). 
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H2O2 (M) 
SE-HPLC 
monomer 
SE-HPLC 
higher order 
(≤600 kDa) 
Phase separation 
large aggregates 
Not detected 
0.01 7.29 0.93 0.23 1.55 
0.05 6.45 0.87 1.28 1.40 
0.2 5.85 0.14 2.16 1.85 
0.4 4.82 0.31 265 2.22 
0.8 4.47 0.39 2.94 2.17 
1.0 3.87 0.44 3.48 2.21 
2.5 2.29 1.59 1.56 1.56 
5.0 1.68 1.92 1.25 5.15 
 
Table 4.2: Lysozyme at pH 5 (10 mg/ml), concentration of oxidation products (mg/ml) 
after 7 days exposure to H2O2. 
 
H2O2 
(M) 
SE-HPLC 
monomer 
SE-HPLC 
higher order 
(≤600 kDa) 
Phase separation 
large aggregates 
Not detected 
0.01 4.07 1.21 1.04 3.67 
0.05 4.11 1.34 1.97 2.57 
0.2 3.79 0.70 2.12 3.38 
0.4 3.28 0.61 2.45 3.64 
0.8 3.08 0.42 3.86 2.62 
1.0 2.66 0.37 4.15 2.81 
2.5 1.08 0.66 4.72 3.53 
5.0 0.60 1.42 1.14 6.83 
 
Table 4.3: Lysozyme pH 8, concentration of oxidation products (mg/ml) after 7 days 
exposure to H2O2. 
 
SE-HPLC of the supernatant was only able to resolve low levels of molecular weight 
species < 600 kDa. The majority of lysozyme had either formed aggregates > 600 kDa or 
this was an indication that fragmentation was occurring. It was possible that the extent to 
which lysozyme was being fragmented could not be resolved by SE-HPLC because the 
monomer peak (25 min) eluted too close in proximity to the H2O2 peak (31 min) so 
overlapping at the point where the lysozyme peak ended and the H2O2 peak began 
occurred at the elution point where fragments may have been detected (figure 4.14). 
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Figure 4.14: Lysozyme monomer peak along with oxidised lysozyme indicating the 
overlap between protein peak and H2O2 peak. 
 Fragmentation of oxidised lysozyme 
Exposure of lysozyme to H2O2 as analysed by gel electrophoresis indicates fragmentation 
of the protein was occurring (figure 4.15). Non-denaturing PAGE conditions revealed 
both fragmentation and aggregation of lysozyme and that the relative concentration of 
either fragments or aggregates depends on the H2O2 concentration. No distinct bands 
could be resolved except for lysozyme monomer and dimer at 14.7 kDa and 29.4 kDa, 
respectively. 
 
Figure 4.15: 12% SDS PAGE gel of lysozyme A) at pH 5 and B) at pH 8, with increasing 
concentrations of H2O2 day 1.Lane 1- 5 M, lane 2- 2.5 M, lane 3- 1 M, lane 4- 0.8 M, 
lane 5- 0.4 M, lane 6- 0.2 M, lane 7- 0.1 M, lane 8- 0.05 M. 
 
 
Lysozyme at pH 5, lanes 1 – 2 only showed a small portion of fragments at the high 
concentration of H2O2 (2.5 – 5 M). Lysozyme at pH 8, at the same time point indicated 
fragmentation in more of the samples, lanes 1 – 6 (0.2 – 5 M H2O2). Higher molecular 
weight species were also observed. At pH 5 these species were no bigger than 30.1 kDa, 
while they were larger at pH 8 (~ 66 kDa) for higher concentrations of H2O2 (lanes 1 – 
3). It therefore seems reasonable to suggest from the size range of higher molecular 
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weight aggregates observed, that the fragmented protein segments were aggregating 
together, or to remaining monomers. 
 
Lysozyme at pH 5 and at pH 8, incubated with H2O2 showed increased levels of both 
fragmentation and aggregation with time (figure 4.16). For both solution conditions the 
amount of fragments and higher molecular weight species resolved was greater after 3 
days of incubation. The monomer band can still be observed at 14.7 kDa. 
 
Figure 4.16: A) 10% SDS PAGE gel of lysozyme at pH 5 and B) 12% SDS PAGE gel of 
lysozyme at pH 8, with increasing concentrations of H2O2 day 3. Lane 1- 5 M, lane 2- 2.5 
M, lane 3- 1 M, lane 4- 0.8 M, lane 5- 0.4 M, lane 6- 0.2 M, lane 7- 0.1 M, lane 8- 0.05 
M, lane 9- 0 M.  
 
By day 5 for both solution conditions (figure 4.17), almost no fragments were detected 
and there was a reduction in the amount of higher molecular weight species resolved. By 
this time point the many visible aggregates are observed and are too large to penetrate the 
gel network and instead accumulate at the top of the gel (not shown). 
 
Figure 4.17: A) 10% SDS PAGE gel of lysozyme at pH 5 and B) 12% SDS PAGE gel of 
lysozyme with increasing concentrations of H2O2 day 5. Lane 1- 5 M, lane 2- 2.5 M, lane 
3- 1 M, lane 4- 0.8 M, lane 5- 0.4 M, lane 6- 0.2 M, lane 7- 0.1 M, lane 8- 0.05 M, lane 
9- 0 M. 
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 Oxidation of Bovine serum albumin 
Oxidation of BSA was studied following exposure to increasing concentrations of H2O2 
in the same way as was described above for lysozyme. Initial analysis of oxidised BSA 
after one week of incubation did not indicate any change in solution appearance, in % 
transmission or in ThT fluorescence i.e. no aggregation resulting in large protein particles 
was observed. Therefore, analysis focused on a single solution condition; 50 mM sodium 
phosphate buffer, pH 7. 
 Oxidative modification of BSA secondary structure 
Intrinsic fluorescence was used to examine the effect of oxidation on the secondary 
structure of BSA by measuring the loss in total protein fluorescence and λmax. The change 
in intrinsic fluorescence for BSA with increasing H2O2 concentration is shown in Figure 
4.18A and B. Exposure to H2O2 induced a clear decrease in both the tyrosine and 
tryptophan fluorescence intensity. 
 
Figure 4.18: Intrinsic fluorescence spectra for oxidised BSA (pH 7) along with plots of 
theλ max and wavelength shift of each individual fluorescence signal excited at 280 nm 
(A and C) and 295 nm (B and D).  
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Exposure to H2O2 caused a blue shift in the emission wavelength. The fluorescence 
emission spectrum of BSA in the absence of H2O2 (excitation at 280 nm) has a λmax at 
351 nm which becomes slightly blue shifted to 349 nm with increasing oxidant 
concentration. The λmax after excitation at 295 nm had a more significant blue shift from 
355 nm to 350 nm, indicating a substantial alteration to the tryptophan residues between 
0.5 and 0.8 M H2O2 affecting their hydrophobicity. The oxidation of the BSA resulted in 
a progressive decrease in the intrinsic fluorescence signal after excitation at both 280 nm 
and 295 nm (table 4.4). 
 
[H2O2] M 
Ex 280 nm 
% loss 
Ex 295 nm 
% loss 
0.07 55.52 69.87 
0.1 53.97 68.24 
0.15 38.85 55.07 
0.25 32.25 45.99 
0.3 22.38 35.63 
0.39 24.82 24.85 
0.78 11.27 9.9 
1.9 0.89 2.23 
3.9 0.09 0.18 
5.5 0.03 0.05 
Table 4.4: Loss in intrinsic fluorescence intensity for oxidised BSA calculated from the 
λmax values. 
 
At the higher concentrations of H2O2 (1.9 – 5.5 M), the signal intensity was almost 
completely diminished indicating disruption of both the tyrosine and tryptophan residues. 
These observations showed that as a result of oxidative stress, there was significant 
conformational changes and alterations in the solvent environment in the vicinity of the 
tyrosine and tryptophan residues (Chen and Barkley 1998; Lichtman and Conchello 2005; 
Sun, Zhao et al. 2011). 
 Analysis of BSA aggregation and fragmentation 
Monomeric BSA generally exists in equilibrium with dimeric and trimeric forms of the 
protein (figure 4.19). SDS PAGE resolves BSA as three separate bands; monomer (66.5 
kDa), dimer (133 kDa) and a small amount of trimer (199.5 kDa). SE-HPLC only resolves 
both the monomer and dimer form (ratio is 87:13 monomer/dimer). Since SE-HPLC does 
not resolve the trimer, its concentration is less than 0.5% of the total protein content.  
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Figure 4.19: SE-HPLC and gel electrophoresis of BSA before and after addition of 
H2O2. 
 
Oxidation of BSA resulted in the addition of several new protein bands and a spreading 
of the chromatogram peak indicating both aggregation and fragmentation of BSA as a 
consequence of oxidative stress. To monitor changes to the protein, three categories were 
considered; monomer, aggregates (≥ dimer) and fragments (< monomer). The 
concentration in each category was monitored and expressed as a percentage of the total 
protein present. This allowed us to monitor the evolution of the oxidation products of 
BSA over time.  
 
A reduction in the area under the monomer peak was measured as the stability of BSA 
became compromised (figure 4.20). The decrease in BSA concentration was calculated 
on the basis of a previously calibrated concentration series for BSA. By day 2, over 50% 
of protein monomer was lost at the higher concentrations of H2O2 (0.78 – 5.5 M). 
 
Figure 4.20: A) SE-HPLC chromatograms of oxidised BSA at pH 7 after 24 hours. B) 
Loss in BSA monomer concentration (mg/ml) as a function of H2O2 concentration. 
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However the loss in monomer did not correlate with the detected concentration of higher 
molecular weight aggregates or fragments (within the column resolution), suggesting 
significant aggregation and/or fragmentation which remained undetected was occurring 
since only monomer and dimer were observed (figure 4.21). Monitoring both of these 
species with increasing H2O2 concentration showed that at the low concentrations of H2O2 
(0.07 – 0.3 M) the ratio of monomer to dimer remains consistent with native BSA. At 
higher concentrations (0.78 – 5.5 M), the increase in the relative amount of monomer (and 
corresponding decrease in dimer) suggested that the disulphide bridge between the BSA 
dimer was cleaved. 
 
Figure 4.21: SE-HPLC data of BSA at pH 7, indicating the % area under the monomer 
peak, and dimer peaks of the chromatograms in Figure 4.20. 
 
Non-denaturing PAGE of the same samples on day 2 showed a very small degree of 
fragmentation at the higher concentrations of H2O2 (lanes 3 – 6) (figure 4.22). The 
concentration of the dimer band had reduced, an indication that is has been cleaved as the 
HPLC suggests. 
 
Figure 4.22: 12% SDS PAGE 12% gel of BSA with increasing concentrations of H2O2 
day 2. Lane 1- empty, lane 2- 0.3 M, lane 3- 0.78 M, lane 4- 1.9 M, lane 5- 5.5 M, lane 6- 
5.5 M (overloaded). 
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The fragmentation of BSA exposed to H2O2 increased with time. By day three of 
oxidation, fragmentation of the BSA structure had further increased relative to day 2 for 
the high concentrations of H2O2 (lanes 4 – 6), with the low concentrations of H2O2 also 
showing evidence of fragmentation (lanes 1 – 3) (figure 4.23). 
 
Figure 4.23: 12% SDS PAGE gel of BSA with increasing concentrations of H2O2, day 3. 
Lane 1- 0.07, lane 2- 0.1 M, lane 3- 0.25 M, lane 4- 0.78 M, lane 5- 1.9 M, lane 6- 5.5 M. 
Samples were all overloaded so the lower concentrations of fragments present could be 
observed. 
 
Progressive oxidation of BSA resulted in an almost complete loss of monomer. SE-HPLC 
analysis after 8 days of oxidation shows a decrease in monomer concentration at all H2O2 
concentrations concurrent with the formation of fragments and higher molecular weight 
aggregates (figure 4.24). 
 
Figure 4.24: A) SE-HPLC chromatograms of oxidised BSA at pH 7 after 8 days. B) Loss 
in BSA monomer concentration (mg/ml) as a function of H2O2 concentration. 
. 
 
For the higher concentrations of H2O2 (0.78 – 5.5 M) after 8 days of oxidation, the 
monomer peak is replaced with a very broad peak ranging in molecular weight from 10 – 
600 kDa (resolution of the SE-HPLC column), which would include fragments, 
monomers and aggregates. The low concentrations of H2O2 (0.07– 0.3 M) showed a 
reduction in the area under the monomer peak, along with a very slight increase in the 
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amount of higher molecular weight aggregates, believed to be an increase in dimer rather 
than new higher order species as the retention time of the peak was close to dimer 
retention time. However fragments were not detected at these low concentrations (figure 
4.25). 
 
Figure 4.25: SE-HPLC data for BSA at pH 7, day 8 showing the % area under the 
monomer peak, fragment peaks and higher molecular weight aggregate peaks of the 
chromatograms in Figure 4.24. 
 
PAGE of corresponding samples on day 8 does show a very limited amount of 
fragmentation of BSA at these concentrations lanes 5 - 9 (figure 4.26).  
 
Figure 4.26: 10% SDS PAGE gel of BSA with increasing concentrations of H2O2, day 8. 
Lane 1- 5.5 M, lane 2- 3.9 M, lane 3- 1.9 M, lane 4- 0.78 M, lane 5- 0.3 M, lane 6- 0.25 
M, lane 7- 0.15 M, lane 8- 0.1 M, lane 9- 0.07 M. 
 
The size of the fragments between each sample again appeared to be quite uniform, since 
bands of identical molecular weight across all wells were observed at all H2O2 
concentrations. This observation is indicative of site specific oxidation (Hunt, Bottoms et 
al. 1993). A reduction in the monomer band, along with a reduction in the dimer and 
trimer band could also be observed in lanes 1 – 4 compared to lanes 5 – 9. The H2O2 
appeared to be breaking up the dimer and trimer forms of BSA at the high concentration 
of H2O2. 
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 Quantification of oxidation products 
The quantity of BSA that formed different oxidation products after 8 days of exposure to 
H2O2 was calculated (table 4.5). From SE-HPLC the quantity of remaining monomer 
(after removal of large aggregates by centrifugation) (column 2), higher order species (≤ 
600 kDa) and fragments (column 3) detected was calculated. The concentration of protein 
not detected by this technique was assumed to be either fragments, which were undetected 
or protein aggregates, larger than the resolution of the column (> 600 kDa) (column 4). 
 
H2O2 (M) 
SE-HPLC 
monomer 
SE-HPLC 
higher order 
(≤600 kDa) 
SE-HPLC 
fragments 
Not detected 
0.07 2.93 0.26 - 6.81 
0.1 1.93 0.18 - 7.89 
0.15 1.79 0.17 - 8.03 
0.25 1.70 0.23 - 8.07 
0.30 1.76 0.15 - 8.09 
0.78 2.00 0.38 1.01 6.61 
1.9 1.94 0.75 2.24 5.07 
3.9 1.75 0.98 2.08 5.19 
5.5 1.43 1.07 2.54 4.96 
Table 4.5: BSA at pH 7, concentration of oxidation products (mg/ml) after 8 days 
exposure to H2O2. 
 
This showed that the majority of BSA had formed either fragmented products or protein 
aggregates that were larger than 600 kDa but not large enough to alter the appearance of 
the BSA solutions i.e. give rise to solution turbidity and that the total concentration of 
protein left in solution (and hence detected by HPLC and PAGE) was quite low. However 
we known from the gel electrophoresis that only a small proportion of fragments were 
resolved for the low concentrations of H2O2. It is therefore assumed that aggregation was 
the far more likely oxidation product at the low concentrations of oxidant, while at the 
higher concentrations of oxidant greater levels of both fragmentation and aggregation 
were occurring.  
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 Discussion 
Although BSA and lysozyme are very different in their structures, there were some 
similarities in the results of our oxidation study. In both cases under our oxidation 
conditions aggregation of the protein occurs. 
 
The levels of aggregation for lysozyme after exposure to H2O2 was in stark contrast to 
BSA. Within 24 hours of lysozyme oxidation, large protein aggregates were detected, of 
which some showed evidence of fibril formation. The ability of H2O2 to aggregate 
lysozyme is broken down into three oxidation conditions; mild (0.01 – 0.1 M), severe (0.2 
– 1 M) and extreme (5 M) oxidation based on the about of monomer structure retained 
after oxidation. The formation of protein aggregates was observed across all three 
oxidation conditions by the changes in solution appearance (turbidity), ThT assay, SE-
HPLC, and gel electrophoresis. 
 
The most striking feature about the oxidation of BSA is that a large proportion of the 
protein aggregates (up to 80%), but that these aggregates are not large enough to produce 
sample turbidity. Hence, these aggregates are not detected by either of the high throughput 
methods, % transmission or by ThT assay. This again reiterates the point made in Chapter 
3 about the sensitivity of certain high throughput screening methods to detect levels 
aggregation or sizes of aggregates. The high throughput assays cannot detect the level of 
aggregation and fragmentation of BSA. Both SE-HPLC and electrophoresis indicate that 
for the BSA remaining in solution it is mostly composed of small soluble oligomers and 
aggregates. The amount of monomer structure retained is dependent on the concentration 
of H2O2. The total amount of fragments produced as a result of oxidation was quite low, 
but again there was clearly a distinction between the H2O2 concentrations at which 
fragments were resolved (table 4.5). This allowed us to categorise the oxidation of BSA 
into two conditions; mild oxidation conditions (< 0.3 M H2O2), and extreme oxidation 
conditions (> 0.78 M H2O2). 
 
The main difference between BSA and lysozyme (apart from the Mw) is the relative 
amino acid content; in particular, cysteine content, and tryptophan content. It is believed 
that the reason the oxidation products and size of aggregates formed between both 
proteins varies is due to where the radical appears to favour attack and how much this 
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alters the secondary structure of the protein. Oxidation of protein by H2O2 is believed to 
stem from the decomposition of H2O2 into the hydroxyl radical HO⦁, one of the most 
potent radicals. The generation of these radicals is the primary catalyst in the mechanism 
by which oxidative damage leads to protein fragmentation and aggregation (Reubsaet, 
Beijnen et al. 1998). 
 
The identical molecular weight of the fragmented bands identified by gel electrophoresis 
in the early stages of oxidation of BSA, gives support to the assumption that the mode of 
oxidative attack of BSA is at a preferential site (Hunt, Bottoms et al. 1993). BSA showed 
evidence of fragmentation across all H2O2 concentrations. Due to their high abundance, 
regions near the 27 cysteine residues, but more specifically the disulphide bonds and thiol 
groups of BSA are likely to be a major target for the free radical HO⦁, disrupting both the 
tertiary and secondary structure of BSA and resulting in fragmentation as evidenced by 
SE-HPLC (Schuessler and Schilling 1984; Puchala and Schuessler 1993; Guedes, 
Vitorino et al. 2009). This may explain why in the initial stages of oxidation, we saw a 
decrease in the dimeric form of BSA with SE-HPLC; the HO⦁ radical acts to disrupt the 
Cys-Cys bond between the two monomeric forms responsible for the dimer reducing it to 
monomer. 
 
Detection of lysozyme fragments by gel electrophoresis or SE-HPLC was significantly 
lower than for BSA. Only limited fragmentation was detected by gel electrophoresis so 
site specific oxidation could not confirmed or fully interpreted by comparing the 
molecular weight of the fragments. Evidence from gel electrophoresis would also suggest 
that any fragmented protein segments of lysozyme were either aggregating to the 
monomer remaining in the solution. Thus attempts to correlate fragmentation of lysozyme 
with a specific residue modification were challenging. 
 
Both proteins responded to oxidation with a loss in intrinsic fluorescence. The tryptophan 
residues have been shown to be vulnerable to radical attack and loss in intrinsic 
fluorescence is an early occurrence of radical-mediated protein oxidation (Campos, Lissi 
et al. 1999; Ma, Chao et al. 1999; Wu, Zhang et al. 2009; Sun, Zhao et al. 2011). Both 
proteins had a completely diminished fluorescence signal under extreme oxidation 
conditions indicating severe conformation changes relative to mild oxidation conditions. 
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Of the 6 tryptophan residues in lysozyme Trp-62 and -108 make the largest contribution 
to the fluorescence emission (Imoto, Forster et al. 1972; Formoso and Forster 1975). 
Damage to the secondary structure by the HO⦁ radical could have resulted in an opening 
of the folded native conformation of lysozyme exposing Trp-62 and -108 to oxidative 
damage accounting for the loss of fluorescence signal. BSA contains two tryptophan 
residues of which one is buried in a hydrophobic region, Trp-212, while Trp-134 is found 
within a hydrophobic pocket and is more surface exposed. Again damage to the secondary 
structure by radical attack would result in exposure of the buried Trp residue leaving it 
susceptible to attack. It must also be noted that the HO⦁ radical might also be acting to 
directly chemically oxidise tryptophan, forming new molecular entities, accounting for 
the change in its intrinsic fluorescence properties, without inducing a conformational 
change. For the identification of tryptophan degradation compounds in proteins, it would 
be necessary to isolate and characterise them by enzymatic hydrolysis coupled with mass 
spectroscopy or RP-HPLC (Simat and Steinhart 1998). Such tryptophan degradation 
products detected include oxindolylalanine, kynurine and N-formylkynurine (Holt, 
Milligan et al. 1977; Kanner and Fennema 1987; Krogull and Fennema 1987; Itakura, 
Uchida et al. 1994; Simat and Steinhart 1998). 
 
The tryptophan residue is a hydrophobic amino acid known to both red shift and blue shift 
with protein oxidation (Wu, Zhang et al. 2009). Protein hydrophobicity has been the 
object of numerous oxidation studies, where oxidation enhances protein surface 
hydrophobicity by exposure of hydrophobic amino acids, which are buried in native 
protein (Davies and Delsignore 1987; Liang 1999; Sante-Lhoutellier, Aubry et al. 2007; 
Wu, Zhang et al. 2009). Exposure of free hydrophobic tryptophan residues, would 
coincide with a red shift of emission with the changing of the surface hydrophobicity of 
both proteins. Yet we observed a blue shift in our intrinsic fluorescence indicating a more 
buried and nonpolar environment (Lakowicz 2006). It is therefore assumed that the 
exposed tryptophan residues, among others exposed, rapidly attach to other exposed 
hydrophobic residues via non-specific hydrophobic associations, inducing aggregation 
(by Mechanism 2) and further burial of the hydrophobic residues occurs. Aggregation of 
lysozyme and BSA results from the disruption and rearrangement of the secondary 
structure, exposing regions that favourably aggregate. Aggregation due to favourable 
aggregation of exposed hydrophobic regions as a consequence of oxidation has been 
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shown for myofibrils (Sante-Lhoutellier, Aubry et al. 2007) and in the formation of 
visible aggregates of peanut protein isolate (Ye, Liao et al. 2013). 
 
BSA aggregated to a much lesser extent than lysozyme. Again this could be linked to the 
site of oxidative attack or just the overall number of sites available to attack in the peptide 
chain. BSA has 607 amino acid residues (538 in the secreted form) compared to 128 in 
lysozyme, thus BSA becomes more damaged than lysozyme due to the greater number of 
amino acids present and susceptible to attack. This is obvious when we compared the 
relative amounts of monomer of each protein after oxidation. BSA is mainly aggregated 
into small soluble aggregates with very little monomer structure retained. While lysozyme 
forms larger aggregates, there is actually less monomer lost to oxidation with similar 
oxidation conditions (table 4.4, 4.3 and 4.5). 
 
For lysozyme, the solution pH dependence on the degree of oxidation and/or aggregation 
between solution pH 5 and pH 8, may be explained by the charge distribution on the 
surface of lysozyme. Several studies point to the mode of oxidative attack being pH 
dependent (Tien, Berlett et al. 1999; Clague 2013; Lee, Baek et al. 2013). The exact 
reason why solution pH influences the degree of oxidation is speculative but it does imply 
that solvent exposure of particular residues susceptible to oxidation is likely important in 
the mode of modification; residues that are fully solvent exposed will show a maximal 
degree of oxidation compared to residues that may be buried in the native conformation, 
as shown for the oxidation of methionine residues (Manning, Chou et al. 2010).It is also 
possible that the solution pH difference doesn’t influence the action of H2O2 to modify 
lysozyme but it more likely regulates the formation and morphology of the aggregates 
that are formed as a consequence of the structural modifications. The loss in secondary 
structure appears to be greater for lysozyme at pH 5 as indicated by the greater loss in 
intrinsic fluorescence compared to the other solution pH values at equal H2O2 
concentrations (table 4.1). This may account for the lower levels and types of aggregates 
detected at this solution pH, like BSA, the structure is more damaged and thus cannot 
aggregate to the same extent. The formation of lysozyme fibrils at pH 8 compared to the 
formation of amorphous aggregates at pH 5, may also indicated the level of structural 
damge between the two conditions is different. A study on the fibrillation of β-amyloid 
peptide found that differences in secondary structure after shock treatment play a key role 
in the growth of amyloid fibrils and the rate of conversion of monomer to β-sheet dimer 
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is a an important step (Shen and Murphy 1995). The secondary structure of lysozyme at 
pH 8, is obviously less damaged allowing self-association of the β-domain, initiating fibril 
formation providing a template for further deposition of protein and develops a stable 
mainly β-sheet core structure of the fibril β-sheet formation. This mechanism for 
lysozyme amyloid fibril formation through self-assembly of β-domains has been shown 
(Booth, Sunde et al. 1997). 
 
The most obvious case where the level of structural damage links to the amount and 
aggregation is the case of extreme oxidation of lysozyme (5 M H2O2) across all solution 
conditions. These samples showed almost complete loss of monomeric lysozyme by SE-
HPLC and gel electrophoresis and also showed the highest amount of fragments. In the 
very early stages of oxidation the lysozyme solutions indicated the formation of higher 
order species capable of associating with ThT, but after 24 hours the ThT fluorescence 
decreased completely, with only small soluble aggregates and fragments being detected. 
This shows how severe oxidation conditions could actually impede lysozyme aggregation 
relative to the other oxidation conditions. The damage to the protein was more intense, so 
that any protein assemblies initially formed were degraded, the consequence of which 
might account of the high abundance of fragments detected by gel electrophoresis; it’s 
not only the native monomer that was being fragmented but lysozyme aggregates initially 
formed were also being fragmented. 
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 Conclusions 
Both BSA and lysozyme are vulnerable to oxidative attack. Oxidation of both proteins 
was accompanied by a gradual loss in monomer structure to backbone fragmentation, and 
aggregation. By monitoring the chemical modification of both lysozyme and BSA via 
oxidative modification, we can provide insight into the mechanism of protein aggregation 
and also characterise of the types of aggregates produced via different aggregation 
pathways (amorphous versus fibrils). Protein oxidation has been demonstrated to induce 
structural changes to the secondary structure of each protein. The amount of damge 
caused was related to how much each protein aggregated. BSA was severely damaged 
resulting in small soluble protein aggregates, while lysozyme was comparatively less 
damaged and was capable of forming large protein particles, and in certain cases forming 
amyloid fibrils. These results demonstrate that with the same oxidation conditions, 
chemical modification can be protein specific in the types of protein aggregates formed 
i.e. large protein particles and fibrils in lysosome compared to particulate free solutions 
in BSA. 
 
The difference in oxidation products formed between lysozyme and BSA is likely a result 
of accessibility/number of sites for attack. While the exact site of oxidative attack is still 
ambiguous, what is clear is that the extent of aggregation after oxidation is quite different 
and that different modes of detection are required to capture all of this information. 
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 Second Derivative 
Spectroscopy to Monitor Protein 
Unfolding 
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 Introduction 
 Protein unfolding with chemical denaturants 
Upon denaturation, proteins lose secondary and tertiary structure as they unfold resulting 
in exposure of hydrophobic residues to the external solvent environment (Roberts and 
Wang 2010). The mechanism by which a protein acquires its unfolded conformation is a 
major question and is still not fully understood despite several decades of research on this 
topic. The ensemble of unfolding states can be characterised by diverse structural and 
conformational properties.  Any advancement in unravelling this mechanism will include 
detection and characterisation of the folded/unfolded conformation along with any 
partially folded states (intermediates) (Duy and Fitter 2006). 
 
The presence of a chemical denaturant can modify the optical properties of the protein as 
it changes from its native structure to an unfolded state. These observed signal changes 
can vary from changes in intensity of emitted light, fluorescence lifetime, fluorescence 
anisotropy, quantum yield and emission wavelength position (Eftink 1994). By 
monitoring such changes with respect to environment changes, one can begin to reveal 
the protein unfolding pathway (Sancho 2013). 
 
Chemical denaturants such as urea and guanidine hydrochloride (GdmHCl) play a central 
role in protein-unfolding experiments. GdmHCl is capable of unfolding proteins at 
substantially lower concentrations than urea (Greene and Pace 1974). At sufficiently high 
denaturant concentrations, almost all proteins can be unfolded while remaining soluble 
(for both of these denaturants) (Eaton, Munoz et al. 2000).  
 Spectroscopy and protein unfolding 
Protein unfolding due to either chemical or thermal denaturation, is generally performed 
in bulk were the dynamics of the system, averaged over the whole population of 
molecules, is measured (Zocchi 1997). Fluorescence spectroscopy can be used to probe 
global kinetics, solvent exposure, motional anisotropy, the formation of specific tertiary 
contacts and distance correlation functions (Gruebele 1999). In bulk experiments, 
fluorescence intensity measures the ratio of the population in the native state to that in the 
unfolded state as environmental conditions are changed. Parameters such as fluorescence 
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intensities, fluorescence lifetime, spectral shift, and anisotropy can all be used to monitor 
conformational changes indicative of protein unfolding (Valeur 2002; Lakowicz 2006). 
 
The intrinsic fluorescence of proteins arises from the aromatic residues; tryptophan, 
tyrosine and phenylalanine of which tryptophan is the most commonly used probe and 
which has a maximum in the excitation wavelength between 290 – 300 nm, whereas  the 
maximum excitation wavelength for tyrosine occurs at 280 nm (Chen and Barkley 1998). 
The fluorescence spectrum of tryptophan is highly solvent dependent and thus can be 
used to detect the micro-environment of tryptophan residues. If excitation of tryptophan 
at 295 nm is performed, the resulting emission wavelength reflects the polarity of the 
local environment of the indole side chains (Mann, Royer et al. 1993). Changes in the 
emission spectra can reveal the location of tryptophan residues; an exposed surface 
residue will occur at longer wavelengths (red shifted) than that from an interior tryptophan 
residue. Tryptophan fluorescence shifts from λmax ≈ 300 – 350 nm as it moves from the 
hydrophobic core, moving to a more polar exterior (Royer, Mann et al. 1993; Gruebele 
1999). Therefore shifts in tryptophan spectra upon unfolding can indicate exposure of the 
residues to the solvent surrounding it making it a useful probe for monitoring unfolding 
reactions (Lakowicz 2006). In principle, if the structure and location of the intrinsically 
fluorescent residues of a protein are known, then changes in fluorescence properties can 
be interpreted and related to changes in protein conformation and structure (Chen and 
Barkley 1998). 
 
Various spectroscopic techniques have been widely employed to study the changes within 
a protein due to chemical denaturation (Lakowicz 2006; Togashi and Ryder 2006; 
Togashi and Ryder 2008). These are advantageous in their sensitivity and selectivity to 
very low protein concentrations, simplicity of basic data acquisition, temporal resolution 
and the only major requisite is that equimolecular solutions of native and non-
native/unfolded protein must have discernible differences in values of their signals upon 
comparison of their spectra (Eftink 1994; Sancho 2013). 
 Derivative spectroscopy to monitor protein unfolding 
Monitoring structural or conformational changes of a protein as it unfolds in an easy, 
reliable, non-invasive way which has advanced with a new generation of spectrometers 
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equipped with simple and fast microprocessors, allowing interpretation of results from 
classical spectroscopic techniques (Mozo-Villarias 2002). Recently, derivative methods 
have begun to be used in structural studies taking advantage of established fluorescence 
and absorbance techniques (Mozo-Villarias 2002; Kumar, Sharma et al. 2005) and are 
sensitive and dependable tools for monitoring and characterizing the transitions taking 
place in the micro-environments of aromatic residues within the protein structure. These 
methods can monitor minute changes in the protein spectra that may not be as easily 
distinguishable with zero order spectra. Calculating the derivative of an absorbance 
spectrum enhances resolution and facilitates de-convolution of complex zero order 
spectra which are composed of multiple overlapping spectra arising from the absorbance 
of the three aromatic residues (phenylalanine, tyrosine and tryptophan) (Ichikawa and 
Terada 1979; Ojeda and Rojas 2004). Thus, zero order aromatic spectra can contain 
multiple components that can be isolated through the use of resolution-enhancement 
techniques such as derivative analysis (Kueltzo, Ersoy et al. 2003). Numerous studies are 
emerging showing that second derivative spectroscopy of both absorbance and 
fluorescence spectra allow semiquanification of spectral changes and these can be related 
to environmental characteristics of aromatic residues in the proteins and therefore 
conformational changes within the protein (Donovan 1973; Solli and Herskovits 1973; 
Ragone, Colonna et al. 1984; Mach and Middaugh 1994; Mozo-Villarias 2002; Kueltzo, 
Ersoy et al. 2003). Lucas et al. showed second derivative UV absorbance spectroscopy 
provided information regarding features of protein structure through small shifts in the 
magnitude and position of absorbance/fluorescence wavelengths that were influenced by 
protein charge, size and local environment (Lucas, Ersoy et al. 2006). Breydo et al. based 
their method for determining pKa values for tyrosine residues on the decrease in the 
absorption intensity in the second derivative UV spectrum (Breydo, Shevchenko et al. 
1997). While Kumar et al. used second derivative Trp fluorescence spectroscopy to 
identify partially unfolded states of proteins during formulation (Pace 1986; Kumar, 
Sharma et al. 2005).  
 Unfolding of BSA 
BSA is a multi-domain protein (three domains, each with two sub-domains) making 
measurements and analysis of the unfolding process more complex, since each domain is 
capable of dependent or independent unfolding behaviour (Das, Chitra et al. 2004; Batey, 
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Scott et al. 2006). Previous work has shown that the aromatic amino acid residues of BSA 
are not distributed equally throughout the 3 domain protein (Huang, Kim et al. 2004). 
The 27 phenylalanine and the 20 tyrosine residues are found in all three domains in the 
protein structure. There are only two tryptophan residues in the entire protein. One buried 
in a hydrophobic region, Trp-212 situated in subdomain IIA. This Trp is important in the 
hydrophobic interaction between subdomains IIA and IIIA. While Trp-134 is found in 
the second helix of domain I within a hydrophobic pocket that acts as a binding domain 
and is more surface exposed (figure 5.1) (He and Carter 1993; Ma, Nishikawa et al. 2006; 
Majorek, Porebski et al. 2012). Spectroscopic properties of tryptophan residues are 
known to be sensitive to their environment (Eftink 1994; Lakowicz 2006), therefore as 
only two of the three domains contain tryptophan, and one is surface exposed while the 
other is buried in a hydrophobic region, the analysis of the micro-environment of this 
amino acid can prove useful in understanding local changes induced by chemically 
unfolding the protein. The tryptophan residues of BSA has been known to blue shift, 
indicative of an increase in the hydrophobicity of the residues (Sulkowska, Bojko et al. 
2003), while red shifts were attributed to the exposure of BSA residues to a more polar 
environment (Itri, Caetano et al. 2004). 
 
Figure 5.1: Structure of BSA showing the three domains and the location of the two 
tryptophan residues. 
 
The unfolding of BSA and HSA using urea and GdmHCl as chemical denaturants has 
previously been well documented and shown to follow a multi-state transition, forming 
stable intermediates around 4 – 5 M urea and ~2 M GdmHCl (Khan, Agarwal et al. 1987; 
Flora, Brennan et al. 1998; Tayyab, Sharma et al. 2000; Gonzalez-Jimenez and Cortijo 
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2002; Sulkowska, Bojko et al. 2003; Das, Chitra et al. 2004; Ahmad, Ahmed et al. 2005; 
Sulkowska, Rownicka et al. 2005; Adel, Nadia et al. 2008; Togashi, Ryder et al. 2010; 
Anand, Jash et al. 2011). 
Several studies point to domain I undergoing significant unfolding along with domain III 
during early urea denaturation (Tayyab, Sharma et al. 2000; Tayyab, Ahmad et al. 2002). 
While other studies conform to the idea that domain I of BSA does not play a major role 
in the initial unfolding of BSA, but it is in fact domain III which is the least stable domain 
and initially unfolds, followed by domain II and finally domain I (Khan, Agarwal et al. 
1987; Tanaka, Nishizawa et al. 1997; Tayyab, Sharma et al. 2000; Ahmad, Ahmed et al. 
2005; Togashi, Ryder et al. 2010). Therefore, despite many studies, using the most up-
to-date techniques, some debate about the unfolding of BSA remains. 
 Unfolding of lysozyme 
Lysozyme is a small two-domain protein (α- and β- domain), containing six tryptophan 
residues, two of which (Trp-62 and Trp-108) are partially exposed to the solvent, and 
with Trp-62 making the biggest contribution to its intrinsic fluorescence (Formoso and 
Forster 1975). Lysozyme has been extensively studied as a model for understanding the 
mechanism of protein stability, folding and denaturation by a combination of techniques 
including spectroscopic and physiochemical methods, CD, DSC and NMR (Evans, 
Topping et al. 1991; Mckenzie and White 1991; Dobson, Evans et al. 1994; Fink, 
Calciano et al. 1994; Sugai and Ikeguchi 1994; Wilson, Ford et al. 1995; Blumlein and 
McManus 2013).  
 
Unfolding of lysozyme from its native state into a randomly coiled conformation is often 
considered an example of a two-state mechanism under equilibrium conditions (Greene 
and Pace 1974; Sugai and Ikeguchi 1994; Pardon, Haezebrouck et al. 1995; Chang and 
Li 2002; Sassi, Onori et al. 2011); 
 
𝑁 → 𝑈                                                           5.1 
 
The unfolding of lysozyme with GdmHCl has been shown to follow a two-state model, 
being fully unfolded by 6 M GdmHCl (Laurents and Baldwin 1997). The transition region 
for lysozyme unfolding was shown to occur between 1.5 – 5 M GdmHCl (Sirotkin and 
Winter 2010). Lysozyme with GdmHCl up to 5 M has been shown to retain a certain 
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degree of intramolecular order, with the α-helical structure remaining intact, thus not 
forming a completely random coil at 5 M and maintaining up to 70% of its enzymatic 
activity, although denaturation was believed to be complete (Tanford, Pain et al. 1966; 
Hedoux, Krenzlin et al. 2010; Huerta-Viga and Woutersen 2013).  
For urea induced unfolding of lysozyme, a transition region has been shown to occur 
between 2.5 – 5 M urea (Timasheff and Xie 2003) while earlier reports showed with 
addition up to 4 M urea all major conformational changes involving the active site 
(location of Trp-62 and Trp-108) had occurred, with little further change up to 9 M 
(Barnes, Warren et al. 1972; Mcguire and Feldman 1975). Crystallographic studies of 
urea-lysozyme interactions also showed no significant conformational changes with 
increasing urea concentrations (0.7 – 5 M) (Pike and Acharya 1994). Urea has been shown 
to change the tertiary structure into a “softer” structure similar to the molten globule, 
without unfolding of the secondary structure, while comparable studies with GdmHCl 
showed it clearly induced conformational changes (Hedoux, Krenzlin et al. 2010). 
Lysozyme has been shown upon unfolding to blue shift reflecting burial of the tryptophan 
residues into a less polar environment where a more compact conformation is achieved, 
while a red shift with increasing unfolded/denatured structure indicating exposure of 
residues to a more polar environment have also been observed (Mcguire and Feldman 
1975; Pastor, Ferrer et al. 2007; Wu, Ma et al. 2008; Balme, Guegan et al. 2013; 
Esquembre, Sanz et al. 2013). 
 Aims of the study 
The aim of this work was to study the unfolding effects of two denaturants, urea and 
guanidine hydrochloride on the structure of two model proteins, BSA and lysozyme. 
Using UV absorbance, fluorescence spectroscopy and second derivative analysis, a 
system was developed to study the protein structure in solution and the stages involved 
in protein unfolding. The first objective of this study was to replicate previous studies on 
urea and GdmHCl induced unfolding of the model proteins using the well-characterised 
technique of intrinsic fluorescence. This was then used to compare the validity of second 
derivative UV absorbance spectroscopy. 
 
We show how the use of second derivative UV spectroscopy allows the monitoring of the 
individual aromatic amino acids; tyrosine, tryptophan and phenylalanine, while second 
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derivative fluorescence spectroscopy monitors tryptophan and tyrosine residues. Direct 
de-convolution of overlapped spectra of proteins allows us to simultaneously and 
precisely monitor individual amino acids with simple techniques and uncomplicated data 
analysis. This allows for more informative details about the microenvironment of the 
individual residues as they undergo unfolding when compared to the zero order spectra. 
Using this technique we can monitor and characterize spectral changes at a single amino 
acid and relate these to unfolding events at specific regions/domains within the protein 
structure thereby gaining a more detailed picture of the unfolding mechanism of the 
protein.  This study shows that second derivative UV spectroscopy is a sensitive and 
reliable technique and can elucidate further the mechanism by which urea and GdmHCl 
induced unfolding of BSA and lysozyme occurs. We find evidence of a step wise 
unfolding event with intermediate structures, between the fully folded and fully unfolded 
states, for BSA which is consistent with other studies. While a two-state model for 
lysozyme unfolding was also confirmed.  
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 Results 
 Unfolding of BSA 
 Fluorescence spectroscopy of BSA unfolding 
Intrinsic fluorescence was used initially to assess the unfolding of BSA with two 
denaturants, urea (0 – 10.5 M) and guanidine hydrochloride (0 – 7.5 M). Intrinsic 
fluorescence allowed us to monitor characteristic features related to the behaviour of both 
the tyrosine and tryptophan residues as BSA underwent unfolding with increasing 
concentrations of denaturant. The resulting spectra for BSA with increasing 
concentrations of urea are shown in Figure 5.2. 
 
Figure 5.2: Intrinsic fluorescence spectra for BSA with increasing concentrations of 
urea. Excitation at A) 280 nm and B) 295 nm. 
 
Native BSA (50 mM sodium phosphate buffer, pH 8) with excitation at 280 nm gave rise 
to a single peak associated with the fluorescence for tyrosine and tryptophan with a λmax 
at 348 nm and excitation at 295 nm representing the fluorescence of tryptophan alone 
resulted in a λmax at 350 nm. As the molar concentration of denaturant was increased, the 
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fluorescence properties of BSA were altered, implying structural alterations as a result of 
the protein unfolding and exposure of the aromatic residues to the surrounding solvent 
(figure 5.3). Both the intrinsic fluorescence intensity decreased and λmax shifted with 
increasing denaturant concentration. 
 
Figure 5.3: Change in BSA intrinsic fluorescence with increasing urea concentration. A) 
Wavelength shift. B) Intrinsic fluorescence intensity. 
 
The emission peak (Ex at 280 nm) had an initial blue shift from 348 nm to a minimum at 
342 nm between 2.5 – 4 M urea, and from 349 nm to 347 nm between 3 – 4 M when 
excited at 295 nm. These features are usually indicative of an increase in hydrophobicity, 
i.e. that the Trp residues have moved to a less polar inner core due to a partial 
rearrangement of the domains within BSA , or that alteration in the packing structure of 
the domains as the distance of separation between them changed, suggesting the presence 
of a transitional stage during the unfolding process (Sulkowska, Bojko et al. 2003). This 
was followed by a significant red shift between 4 – 5 M urea with an emission maximum 
at 356 nm (Ex 280) and 364 nm (Ex 295) suggesting the exposure of BSA Trp residues 
to a more polar environment (Itri, Caetano et al. 2004). As a result of further domain 
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rearrangement/unfolding, water molecules and/or other amino acids quench the 
fluorescence signal. This was seen as a decrease in the protein fluorescence emission 
intensity, initiated at 2.5 M urea. This indicated the onset of structural re-arrangement and 
at urea concentrations of 8.5 M and higher there was no further change in fluorescence 
intensity or λmax. At this point it is assumed that BSA is fully unfolded and the Trp 
residues are fully exposed to the solvent. 
 
BSA exhibited similar intrinsic fluorescence properties when GdmHCl was used as the 
denaturant (figure 5.4). Both quenching of the fluorescence intensity of both residues and 
shifts in the emission peak wavelength (λmax) were observed. 
 
Figure 5.4: Change in BSA intrinsic fluorescence properties with increasing GdmHCl 
concentration. A) Wavelength shift. B) Intrinsic fluorescence intensity changes. 
 
Again, with GdmHCl, both the fluorescence intensity and λmax change with increasing 
denaturation concentration, again consistent with an initial rearrangement of the BSA 
domain packing followed by exposure of the core amino acids to a more polar 
environment (Togashi, Ryder et al. 2010). Both emission peaks (from excitation at 280 
nm and 295 nm) showed a steady blue shift from 348 nm to a minimum of 342 nm (Ex 
280 nm) and from 349 nm to a minimum of 340 nm (Ex 295 nm), between 0.5 – 1 M as 
domain re-arrangement began. As the concentration of GdmHCl increased, there was a 
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red shift in the emission peak position between 2 – 5 M GdmHCl after which both the 
fluorescence intensity and λmax remained constant, indicating that BSA was fully 
unfolded. This data is consistent with previous measurements using intrinsic fluorescence 
to measure GdmHCl induced BSA unfolding (Togashi, Ryder et al. 2010).  
 Second derivative fluorescence spectroscopy of BSA unfolding 
Second derivative operations were performed on the intrinsic fluorescence spectra of 
BSA since previous work has shown that additional information about the solvent 
environment surrounding tyrosine and tryptophan residues can be observed from this 
analysis (Mozo-Villarias 2002). Figure 5.5 shows the overlapped second derivative 
spectra of the intrinsic fluorescence spectra for BSA with increasing urea concentrations 
(excitation at 280 nm and 295 nm). 
 
Figure 5.5: Second derivative intrinsic fluorescence spectra of BSA with increasing 
concentrations of urea. A) Ex 280 nm. B) Ex 295 nm. 
 
In the second derivative spectrum, native BSA has a minimum at 340 nm (Ex 280 nm) 
and at 338 nm (Ex 295 nm). There was a relatively fixed maximum at 400 nm and a 
shoulder around 360 – 370 nm.  The minima in the second order derivative spectra 
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correspond to peaks in the original spectrum (Gopalan, Golbik et al. 1997) and thus based 
on the position of the minima in the second derivative spectrum, conformational 
information about the protein can be extracted. The positions (red or blue shifts) and 
relative magnitudes of the minima depend on the solvent environment (Mozo-Villarias 
2002; Kumar, Sharma et al. 2005). Previous work has shown that changes in the 
fluorescence emission at these wavelengths are the result of various microstates of 
tryptophan residues with protein unfolding (Gopalan, Golbik et al. 1997). The wavelength 
peak position and intensity of the peak minima were recorded as a means to monitor 
protein conformational changes during urea induced unfolding of BSA (figure 5.6). 
Comparison of the data obtained from the intrinsic fluorescence zero order data with the 
second derivative data indicate that little additional information about the protein 
unfolding pathway can be determined from the second derivative data. 
 
Figure 5.6: Change in BSA second derivative intrinsic fluorescence compared to the 
zero order intrinsic fluorescence with increasing urea concentration. A) Fluorescence 
intensity. B) Wavelength shift. 
 
The change in fluorescence intensity in the second derivative intrinsic fluorescence 
spectra appeared to mirror that of the zero order; initial unfolding by 2 M urea, 
intermediate states from 2.5 – 7 M with no further change in the fluorescence intensity 
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indicating fully unfolded BSA by 8 M. The wavelength shift in the second derivative 
spectrum (for excitation at 295nm) was similar to the zero order data; the characteristic 
blue shift to shorter wavelengths by 3.5 M urea, followed by a red shift at 5 M urea, and 
a levelling off by 7.5 M where BSA was fully unfolded. The emission peak positions for 
excitation at 280 nm appeared more scattered compared to the zero order wavelength 
data. 
 
In the second derivative intrinsic fluorescence spectra (excitation at 280nm), at the higher 
urea concentrations (6.5 – 10. 5 M urea) where BSA is mostly likely fully unfolded there 
was a splitting of the peak minimum into two smaller peaks that successively increased 
with increasing urea concentration (figure 5.7). This change in the peak shape was not 
observed for any of the spectra recorded using 295 nm as the excitation wavelength. 
 
Figure 5.7: Second derivative fluorescence spectra of BSA showing the change in peak 
shape with increasing concentrations of urea. A) Ex 280 nm. B) Ex 295 nm. 
 
The second derivative intrinsic fluorescence spectra of BSA unfolded with GdmHCl were 
also analysed in this manner. Again the second derivative fluorescence emission 
properties of BSA were comparable with the zero order intrinsic fluorescence spectral 
properties. The most striking feature of the second derivative analysis of BSA unfolding 
with GdmHCl, were the alterations to the spectra (Ex at 280 nm) for the high denaturant 
concentrations (5 – 7.5 M) where BSA was believed to be fully unfolded (figure 5.8). 
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Figure 5.8: Second derivative fluorescence spectra of BSA showing the change in peak 
shape with increasing concentrations of GdmHCl. A) Ex 280 nm. B) Ex 295nm. 
 
 Zero order UV absorbance of BSA unfolding 
The zero order UV absorbance of BSA with increasing concentrations of urea and 
GdmHCl were recorded. The normalised spectra overlaid for BSA for urea and GdmHCl 
are shown in Figure 5.9. The zero order UV absorbance spectra obtained show a single 
characteristic protein peak with a maximum at 280 nm. There is considerable overlap in 
the wavelengths at which the three aromatic amino acids absorb and they cannot be 
distinguished clearly in the zero order spectrum. 
 
 
Figure 5.9: Zero order absorbance spectra of BSA with increasing concentrations of 
denaturant. A) GdmHCl. B) Urea. 
 
Monitoring of the λmax intensity values did not reveal any information about the unfolding 
transitions of BSA except for a slight increase in the absorption values with increasing 
denaturant concentration. However a notable shift in λmax was observed (figure 5.10). 
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Figure 5.10: Shift in 𝜆max from the zero order absorbance spectra of BSA with 
increasing concentrations of urea and GdmHCl. 
 
In the absence of denaturant, the 𝜆max for BSA occurs at 278.7 nm. With the addition of 
denaturant the 𝜆max shifts to lower wavelengths. For GdmHCl this shift was initiated at 1 
M GdmHCl and levelled off by 5 – 6 M. For urea induced denaturation the wavelength 
shift was observed at 3 M and was complete at 7.5 M urea. The molar concentrations of 
these events detected by zero order UV absorbance were consistent with the intrinsic 
fluorescence measurements. However no further insight into domain specific unfolding 
can be inferred from this analysis. 
 Second derivative UV absorbance during BSA unfolding 
A second derivative operation was carried out on the zero order spectra of BSA with 
increasing concentrations of urea and GdmHCl. In contrast to the zero order spectrum, 
the second derivative spectrum de-convoluted the single protein associated peak at  ≈ 280 
nm into several peaks (Ichikawa and Terada 1979). Those associated with the three 
aromatic amino acids are shown in Figure 5.11. Tyrosine and tryptophan can be seen at 
strong negative peaks at ~280 nm and ~290 nm respectively. Phenylalanine in proteins 
manifests itself as weak ripples or shoulders within the zero order absorbance spectra 
between 250 – 270 nm region (Schmid 2001), resulting in several negative bands within 
the second derivative spectrum within this region  (Balestrieri, Colonna et al. 1978). 
However it is the strongest band at 259 nm that is monitored for evaluation purposes 
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(Ichikawa and Terada 1977; Mach, Thomson et al. 1991; Lucas, Ersoy et al. 2006).  For 
each of the three residue peaks the wavelength value at the peak minima was recorded 
 
Figure 5.11: Second derivative absorbance spectra of BSA with increasing 
concentrations of denaturant. A) GdmHCl. B) Urea. 
 
The second derivative UV absorbance spectra allow undefined peaks and shoulders from 
the zero order to be transformed into distinct negative peaks having minima centred at 
different wavelengths for each individual aromatic residue thus improving the resolution 
of the overlapping peak at 280 nm. Depending on the concentration of denaturant, the 
shape of the peak and the wavelength minima positions shifted; phenylalanine (259 – 262 
nm), tyrosine (275 – 280 nm) and tryptophan (285 – 290 nm). These changes in the λmin 
with increasing urea concentration are shown in Figure 5.12.  
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Figure 5.12: Effect of urea concentration on the second derivative UV wavelength 
position for the three aromatic amino acid residues in BSA. 
 
The wavelength position for each residue blue shifted with increasing concentrations of 
urea, reflecting exposure of these residues to the solvent as a consequence of the unfolding 
process (Lucas, Ersoy et al. 2006). The second derivative also distinguishes the 
denaturant concentration at which each residue is affected by the structural transitions 
occurring during denaturation. This urea concentration at which this happened was not 
the same for each aromatic amino acid (table 5.1). Phenylalanine exhibits initial changes 
in λmin at a urea concentration of 4 M, with tryptophan and tyrosine indicating signs of 
unfolding at lower urea concentrations, 2.5 and 3.5 M respectively. 
 
Amino acid 
On set of 
unfolding 
Partially unfolded 
intermediates 
Fully unfolded protein 
Trp 0 – 2.5 M 3 – 7 M 8 M 
Tyr 0 – 3.5 M 4 – 7.5 M 8 M 
Phen 0 – 4 M 4.5 – 7 M 8 M 
 
Table 5.1: Urea concentrations of domain unfolding for BSA 
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GdmHCl induced unfolding of BSA showed similar trends (figure 5.13 and table 5.2) 
 
Figure 5.13: Effect of GdmHCl on the second derivative UV spectroscopic wavelength 
position for the three aromatic amino acid residues in BSA. 
 
The tryptophan residue showed the earliest indication of structural alteration at 1 M 
GdmHCl. Unfolding was complete at 3.5 M GdmHCl. Phenylalanine and tyrosine signals 
indicated that unfolding was initiated at 1.5 M GdmHCl and was complete by 3.5 and 4 
M GdmHCl respectively. 
 
Amino acid 
On set of 
unfolding 
Partially unfolded 
intermediates 
Fully unfolded 
protein 
Trp 0 – 1 M 1.5 – 3  M 3.5 M 
Tyr 0 – 1.5 M 2 – 3 M 3.5 M 
Phen 0 – 1.5 M 2 – 3.5 M 4 M 
 
Table 5.2: GdmHCl concentrations of domain unfolding for BSA. 
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 Unfolding of lysozyme 
 Fluorescence spectroscopy of lysozyme unfolding 
Changes in the intrinsic fluorescence of lysozyme were monitored with increasing 
concentrations of urea (figure 5.14). 
  
Figure 5.14: Intrinsic fluorescence spectra for lysozyme with increasing concentrations 
of urea A) Excitation at 280 nm. B) Excitation at 295 nm. 
 
Native lysozyme (50 mM sodium phosphate buffer, pH 8) had a λmax at 345 nm when 
excited at 280 nm, and 343 nm when excited at 295 nm. With increasing concentrations 
of urea, shifts in the wavelength peak position and a loss in the fluorescence intensity 
were observed (figure 5.15). 
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Figure 5.15: Change in lysozyme intrinsic fluorescence properties with increasing urea 
concentration. A) Wavelength shift. B) Intrinsic fluorescence. 
 
For both excitation at 280 nm and 295 nm, the wavelength peak position initially blue 
shifts to shorter wavelengths attributed to the burial of the tryptophan side chains in an 
environment of lower polarity between 1 – 2 M urea (Ex 280 nm) to a minimum of 342 
nm at 6.5 M urea, and at 1.5 M urea (Ex 295 nm) to a minimum at 341 nm at 5 M urea. 
For Ex 295 nm this initial blue shift was then followed by a red shift to a maximum at 
342 nm at 6.5 M urea indicating increasing exposure of the residues to the solvent. For 
Ex 280 nm a slight red shift occurs between 7 – 8 M urea. Again both excitation 
wavelengths show a second blue shift between 8.5 – 10.5 M urea, the concentrations that 
indicate lysozyme is fully unfolded. The fluorescence spectra steadily decreased in 
intensity at both excitation wavelengths as lysozyme goes from its folded conformation 
to an unfolded state. 
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GdmHCl induced unfolding of lysozyme did not result in a significant initial blue shift in 
wavelength position, but had a steady decrease in fluorescence intensity as a function of 
denaturant concentration (figure 5.16).  
 
Figure 5.16: Change in lysozyme intrinsic fluorescence with increasing GdmHCl 
concentration. A) Wavelength shift. B) Intrinsic fluorescence intensity. 
 
Both emission peaks indicate a significant red shift, at 3.5 M urea from 345 nm to a 
maximum of 361 nm at 4.5 M GdmHCl (Ex 280 nm) and from 343 nm to a maximum of 
355 nm at 4 M GdmHCl (Ex 295 nm). No further structural alterations at higher GdmHCl 
concentrations were observed. The fluorescence intensity shows a steady decrease in 
fluorescence intensity that appears to level off by 4.5 or 5 M GdmHCl.  
 Second derivative fluorescence spectroscopy of lysozyme unfolding 
The second derivative of lysozymes intrinsic fluorescence spectra are shown in Figure 
5.17. Again, no additional spectral features were determined from the second order 
fluorescence spectra for either urea or GdmHCl induced unfolding when compared to the 
zero order fluorescence data (not shown). 
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Figure 5.17: Second derivative intrinsic fluorescence spectra for lysozyme with 
increasing concentrations of denaturant (excitation at 280 nm). A) Urea. B) GdmHCl. 
 
The unfolding of lysozyme with GdmHCl second derivative intrinsic fluorescence spectra 
did show a splitting of the Ex 280 nm peak into two minima at 4.5 M GdmHCl, indicative 
of a separation of the tyrosine and tryptophan residues as lysozyme unfolded, consistent 
with the zero order intrinsic fluorescence data. 
 Zero order UV absorbance during lysozyme unfolding 
The second derivative UV spectrum for lysozyme was also investigated to see if it was 
possible to capture a two-state unfolding model with this technique. The zero order UV 
absorbance spectra for lysozyme were collected. The 𝜆max for each zero order spectrum 
was plotted as a function of denaturant concentration in Figure 5.18. Native lysozyme (50 
mM sodium phosphate buffer, pH 8) had a λmax at 281.5 nm. With increasing 
concentrations of denaturant only slight shifts (< 0.5 nm) in the λmax were recorded. 
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Figure 5.18: Shift in 𝜆max from the zero order absorbance spectra for lysozyme with 
increasing concentrations of urea and GdmHCl. 
 
The unfolding transitions for lysozyme were not clearly distinguished from the zero order 
spectra when compared to the same data for BSA, where wavelength shifts of 2.3 nm 
were recorded. 
 Second derivative UV absorbance of lysozyme unfolding 
The second derivative spectra for lysozyme with increasing concentrations of GdmHCl 
and urea were also analysed (figure 5.19). As for BSA, the single protein related 
absorbance peak of the zero order spectrum separates into the three individual aromatic 
residues in the derivative spectrum. 
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Figure 5.19: Second derivative absorbance spectra of lysozyme with increasing 
concentrations of denaturant. A) GdmHCl. B) Urea. 
 
The shape and appearance of both the phenylalanine and tryptophan peaks appeared 
unperturbed by changes to their solvent environment in high denaturant concentrations; 
no significant in λmin (minimum of the peak) was observed. The tyrosine peak however 
did show a slight alteration at the peak minimum with increasing denaturant concentration 
(figure 5.20). 
                  
 
167 
 
 
Figure 5.20: Effect of GdmHCl on the second derivative UV spectroscopic wavelength 
position of the three aromatic residues in lysozyme. 
 
With increasing GdmHCl concentrations, changes in λmin for both tyrosine and tryptophan 
were measured, but no significant trend was seen for phenylalanine. The λmin for tyrosine 
and tryptophan reach a minimum value at 5.5 M GdmHCl (table 5.3), suggesting that 
lysozyme is fully unfolded at this GdmHCl concentration. However, the spectral shifts 
were not as defined as they were for the BSA unfolding curves. The onset of unfolding 
and fully unfolded states can be observed, any intermediate values are assumed to be 
related to the proportion of protein that have unfolded versus those that have not 
(consistent with the two-state unfolding model for lysozyme). 
 
Amino acid 
On set of 
unfolding 
folded –v- unfolded 
Fully unfolded 
protein 
Trp 3.5 M 4 – 5  M 5.5 M 
Tyr 1 M 1.5 – 5 M 5.5 M 
Phen N/A N/A N/A 
 
Table 5.3: GdmHCl concentrations of unfolding events for lysozyme. 
                  
 
168 
 
The urea induced unfolding of lysozyme was investigated by following the shifts in the 
wavelength positions for the three aromatic residues in the second derivative spectra 
(figure 5.21). 
 
Figure 5.21: Effect of urea on the second derivative UV spectroscopic wavelength 
position of the three aromatic residues of lysozyme. 
 
For urea induced unfolding of lysozyme, the phenylalanine residue in the second 
derivative again didn’t give any further insight into the unfolding events. The λmin for 
tryptophan and tyrosine residues did change with increasing urea concentration (table 
5.4). This data is consistent with two-state unfolding. 
 
Amino acid 
On set of 
unfolding 
folded –v- unfolded 
Fully unfolded 
protein 
Trp 0.5  M 1 – 4  M 4.5 M 
Tyr 1.5 M  2 – 5 M 5.5 M 
Phen N/A N/A N/A 
 
Table 5.4: Urea concentrations of unfolding events for lysozyme. 
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 Discussion 
This study focused on the potential of second derivative UV absorbance spectroscopy to 
monitor protein unfolding for BSA and lysozyme using the denaturants, urea and 
GdmHCl. The three dimensional structure is known for these proteins, thus making it 
possible to correlate the changes in the environment around aromatic residues with 
alterations in their spectral properties. 
 Unfolding of BSA 
Our initial study using intrinsic fluorescence analysis found that changes in the λmax and 
total fluorescence intensity occur as BSA is denatured. The unfolding is consistent with 
a two-step unfolding process via three transition states. The concentrations at which each 
unfolding event occurs for both urea and GdmHCl was previously documented and is 
consistent with our measurements (Sulkowska, Bojko et al. 2003; Itri, Caetano et al. 
2004; Sulkowska, Rownicka et al. 2004; Sulkowska, Rownicka et al. 2005; Togashi, 
Ryder et al. 2010). 
 
The zero order absorbance analysis during unfolding for BSA does provide similar data 
to the fluorescence measurements, which agrees with the proposed transitions for BSA 
unfolding; a two-step unfolding process via three transition states (Tayyab, Sharma et al. 
2000; Sulkowska, Bojko et al. 2003; Das, Chitra et al. 2004; Adel, Nadia et al. 2008). 
But from the zero order UV absorbance analysis it is not clear which domain/s are 
involved in each unfolding step. It was however found that the second derivative of the 
UV absorbance spectra were more useful indicators of the unfolding states of BSA as the 
three individual aromatic residues could be monitored independently. Since the structure 
of BSA is known, changes in each of the three aromatic residues could be interpreted and 
related to changes in protein conformation and structure as individual domains begin to 
unfold. 
 
Within the second derivative UV absorbance spectra, the positions of the wavelength 
minima for the three individual peaks associated with the aromatic amino acid residues 
changed with increasing concentration of denaturant. It was also evident that each amino 
acid residue responded independently to the increasing concentrations of denaturant. 
Therefore by using second derivative UV spectra the average local environment of each 
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specific amino acid was monitored to give insight into the effect the denaturant had on 
each separate residue. When this data was plotted against denaturant concentration, 
distinct sequences of events relating to the unfolding of BSA domains were observed 
(figure 5.12 and 5.13). 
 
In our study of urea induced unfolding of BSA, the on-set of unfolding was observed at 
different concentrations for each amino acid. It is known from the literature that a urea 
concentration as low as 2 M is sufficient to instigate BSA unfolding from its native state 
(Tayyab, Sharma et al. 2000; Adel, Nadia et al. 2008). This was also indicated by our 
zero order UV absorbance spectra and intrinsic fluorescence analysis. Most researchers 
believe that the hydrophobic tryptophan residue (Trp-212) is the most sensitive as a 
marker of structural rearrangement. 
 
Our second derivative tryptophan data shows the earliest signs of structural alterations at 
2.5 M urea, suggesting that neither domain I nor domain II undergo any significant 
structural changes until after 2.5 M urea. Therefore domain III containing no tryptophan 
residue was the first of the domains to unfold, followed by rearrangement of domains I 
and II (indicated as three distinct regions in figure 5.1). The buried Trp-212 is involved 
in the hydrophobic interaction between subdomains IIA and IIIA. Therefore the unfolding 
of domain III and the subsequent shift in the tryptophan residue likely reflects a 
rearrangement within domain II. This can be confirmed with the intrinsic fluorescence 
data, where between 2.5 and 3 M urea, a blue shift in wavelength position is observed, 
indicative of partial burial of residues into a less polar inner core due to domain 
rearrangement, or alteration in the packing structure of the domains. Collectively all three 
amino acids indicate a significant structural alteration from 3 – 7 M urea, signalling the 
movement of Trp-212 and other residues out of the non-polar inner core as a consequence 
of domain II being unfolded. Again this coincides with a red shift observed in the intrinsic 
fluorescence data at 4 M urea, clear evidence that Trp-212 is more exposed to a polar 
environment. Lastly the tryptophan signal indicates the final structural alteration occurs 
by 7 M urea with domain I unfolding, beyond which no further structural changes are 
detected indicating the point where all three domains of BSA are fully unfolded and the 
protein adopts an extended conformation. This correlates with the concentration at which 
fully unfolded BSA is indicated by both the intrinsic fluorescence and zero order UV 
absorbance data. 
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Comparable data for the unfolding of BSA with GdmHCl as a denaturant was observed 
by solely examining the three individual aromatic residues in the second derivative UV 
absorbance spectra. The tryptophan residue was first to indicate structural change in the 
wavelength peak position, indicating an unfolding of domain III first at very low GdmHCl 
concentrations, resulting in domain rearrangement that the sensitive Trp-212 residue was 
the first to detect as it moved to a less polar inner core of the hydrophobic cavity of domain 
II, also evidenced by a blue shift observed in the intrinsic fluorescence measurements. 
This was followed by a second unfolding event of domain II at GdmHCl concentration 
greater than 1.5 M whereas tyrosine and phenylalanine don’t indicate domain II unfolding 
until a higher GdmHCl concentration (> 2 M). Again this rearrangement of domain II at 
this GdmHCl concentration is consistent with a red shift observed for both the intrinsic 
fluorescence wavelength position of tyrosine and tryptophan from 2 – 3 M GdmHCl. 
Domain I only begins to unfold after domain II by 4 M GdmHCl, leaving a fully unfolded 
BSA by 6 M GdmHCl, again consistent with both our intrinsic fluorescence and zero 
order absorbance studies. 
 
The unfolding behaviour of BSA with both urea and GdmHCl could also be observed 
with the second derivative fluorescence signals. At the denaturant concentrations at which 
it is likely that all three domains are unfolded (7 M urea and 5.5 M GdmHCl), a splitting 
of the single fluorescence peak occurs. This behaviour was likely due to independent 
signals arising from tyrosine and tryptophan. With excitation at 280 nm the fluorescence 
signal originates from both residues. As the protein becomes unfolded, the distance 
between the residues increases and their individual fluorescence signals became more 
evident in the second derivative spectra. This highlights the advantage of using derivative 
spectroscopy over zero order spectra where it is more difficult to discriminate between 
the tyrosine and tryptophan emissions by excitation at 280 nm. 
 
The order of BSA domain unfolding observed with our second derivative residue peak 
behaviour is consistent with numerous other studies (Khan, Agarwal et al. 1987; Tanaka, 
Nishizawa et al. 1997; Tayyab, Sharma et al. 2000; Ahmad, Ahmed et al. 2005; Togashi, 
Ryder et al. 2010). Our analysis is indicative of a two-step, three state unfolding event 
with the formation of partially unfolded intermediate states as sequential BSA domains 
unfold, thereby confirming the known sequence for BSA unfolding and for the first time, 
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showing that second derivative UV spectroscopy can distinguish this series of events. It 
was also found that the structural alterations detected by the tryptophan residue, 
specifically Try-212, alone are more representative of the unfolding of BSA domains, 
rather than the global unfolding of the protein as observed with the zero order UV 
absorbance spectra. The second derivative unfolding curves for both phenylalanine and 
tyrosine while also indicative of a two-step, three state transition unfolding mechanism, 
the denaturant concentration of each domain unfolding was slightly greater than for 
tryptophan. Since these residues are more abundant and spread throughout BSAs structure 
they are less sensitive to slight structural alterations compared to tryptophan. Modelling 
of these unfolding events in their correct sequence is an interesting, but a difficult problem 
hence the advantage of being able to monitor the tryptophan residue alone, that is known 
to be a sensitive probe for the monitoring of protein unfolding. 
 
Figure 5.22: Schematic for the mechanism of urea induced unfolding of BSA as derived 
from second derivative wavelength position of the tryptophan residue 
 
 Unfolding of lysozyme 
The unfolding curves of lysozyme in this study were derived from the structural analysis 
of denatured lysozyme with increasing concentrations of urea and GdmHCl. Comparison 
of the lysozyme data with that of BSA reveals that both proteins do not share a common 
mechanism during the process of unfolding. For BSA, unfolding is characterised by 
distinctive wavelength shifts for domain unfolding representative of a two-step unfolding 
process via three transition states. Unlike BSA, no obvious domain unfolding transitions 
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could be extracted from either the zero order or the second derivative UV absorbance 
spectra for unfolded lysozyme. The unfolding curves for lysozyme were all consistent 
with a two-state unfolding mechanism, thus confirming a two state model stated in the 
literature of lysozyme unfolding (Greene and Pace 1974; Sugai and Ikeguchi 1994; Chang 
and Li 2002; Sassi, Onori et al. 2011). The use of second derivative UV absorbance of 
lysozyme for creating unfolding curves was able to illustrate the concentrations where 
lysozyme begins to unfold and the point at which it is a fully unfolded structure. This was 
seen to be applicable to the tyrosine and tryptophan residues only. The signal arising from 
the phenylalanine residue did not appear to be sensitive to structural alterations nor did it 
indicate any changes within its solvent environment and was therefore difficult to discern 
clear trends in that data with respect to lysozyme unfolding. 
 
As proposed for GdmHCl unfolding of lysozyme, all structural alterations have occurred 
by 6 M GdmHCl, the point at which no further alterations of the tryptophan or tyrosine 
residues are recorded in its second derivative wavelength position. The wavelength 
position of tryptophan remains steady up until 3.5 – 5.5 M GdmHCl where a large shift 
in the absorbance band was recorded. As proposed for lysozyme unfolding with GdmCl 
(Laurents and Baldwin 1997) the more surface exposed tryptophan active site residues 
(Trp-62 and 63) do not respond to lysozyme unfolding, instead it is the buried 
hydrophobic Trp residues (Trp- 123, 111 and 108) that indicate the unfolding of 
lysozyme. These three tryptophan residues do not show significant shifts during the 
unfolding process indicating they are tightly packed within their hydrophobic 
environment, and it’s not until the global unfolding reaction occurs (> 3.5 M) that they 
become solvent exposed. This was also apparent in the intrinsic fluorescence of the same 
data, no blue shifts in the wavelength positions were recorded, but a large red shift was 
observed at 3 M GdmHCl, indicative of exposure of the hydrophobic residues to a more 
polar environment. 
 
The second derivative unfolding curve of lysozyme with urea is not fully consistent with 
this opinion; while both the tyrosine and tryptophan residues propose a two-state 
unfolding model as seen in their unfolding curves (figure 5.20 and figure 5.21), they 
appear to respond during the initial stages of unfolding. This could be due to the 
interaction of urea with the surface exposed Trp residues. A steady shift in the tryptophan 
wavelengths is recorded between 0.5 – 4 M urea signifying the initiation unfolding as the 
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tight packing loosens and the hydrophobic residues gradually but simultaneously become 
more solvent exposed with the global unfolding event (fully unfolded conformation) 
occurring by 4 M urea. The fluorescence wavelength shift pattern appeared to fluctuate 
with an initial blue shift, followed by a red shift and another blue shift indicative of 
residue movement into and out of hydrophobic environments. Since lysozyme is neither 
fully folded nor unfolded within this concentration range it is possible the wavelength 
shift reflects differences in the populations of lysozyme structures. 
 
The second derivative unfolding curves for urea induced unfolding, would suggest 
progressive expansion of the protein conformation toward its linear shape, while GdmHCl 
induced unfolding of lysozyme would suggest a tightly packed conformation with global 
unfolding event upon which hydrophobic residues become solvent exposed. Therefore 
GdmHCl studies capture the fully unfolded form of lysozyme while the urea studies 
appears to detect the process of unfolding for lysozyme. It is known that both urea and 
GdmHCl both induced unfolding of protein it different ways (Halim, Kadir et al. 2008; 
Lim, Rosgen et al. 2009; Hedoux, Krenzlin et al. 2010). Despite extensive studies, the 
exact mechanism by which urea or GdmHCl denature proteins is still divided between 
the “indirect” (Frank 1968; Bennion and Daggett 2003) and “direct” (Robinson and 
Jencks 1965; Wallqvist, Covell et al. 1998; Hua, Zhou et al. 2008)  mechanisms. Based 
on the “direct” mechanism, it has been shown that both while denaturants directly bind 
to lysozyme, GdmHCl is believed to interact with the hydrophobic groups, with urea 
mainly interacting with the hydrophilic residues transforming the tertiary structure into a 
softer structure similar to a molten globule without unfolding of the secondary structure 
(Pike and Acharya 1994; Gao, She et al. 2010; Hedoux, Krenzlin et al. 2010). It’s possible 
that the second derivative data reflects this. It is also possible that because lysozyme is 
unfolding in a two-state manner (either unfolded or fully unfolded), the residues mainly 
reflect the most populated form, and for urea and GdmHCl induced unfolding of 
lysozyme this was different. This behaviour could be extracted out of the second 
derivative fluorescence spectra. For GdmHCl at the higher concentrations a splitting of 
the peaks occurs at the point which global unfolding of the protein is likely to have 
occurred. As the protein is fully unfolded, the individual tyrosine and tryptophan 
fluorescence signals became more evident in the second derivative spectra. 
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 Conclusions 
It has been demonstrated here that second derivative values extracted from zero order 
spectra are a meaningful parameters to characterise the unfolding states of proteins. We 
have shown how monitoring the second derivative UV absorbance spectra of a protein is 
a reliable method of indication of the conformational transitions of the protein as it is 
unfolded, establishing a connection between the three aromatic residues and the unfolding 
dynamics of a protein with respect to changes in their microenvironment. It has been 
shown to be highly sensitive to detecting minute changes in spectra characteristics that 
may go undetected in classical absorbance or fluorescence spectroscopy. It is also highly 
specific for resolving spectra with strongly overlapped emission/absorbance bands. 
 
The second derivative spectrum serves as a useful indicator of the unfolding state of the 
three individual aromatic residues of BSA. The unfolding transitions occurred at different 
denaturant concentrations for each of the three aromatic residues. This made it possible 
to reconstruct which regions of the protein are more stable, and which are first disrupted 
during protein unfolding. The second derivative spectra were also capable of detecting 
the two-state unfolding events of lysozyme, with the tyrosine and tryptophan proving 
most valuable for monitoring the unfolding of lysozyme. It was found for both proteins 
specifically the hydrophobic tryptophan residues, are most sensitive for detecting 
unfolding transitions, and for BSA it allowed monitoring of specific domain unfolding. 
Second derivative UV absorbance spectra appears to be more sensitive to detecting 
changes to the solvent environment around the residues that undergo significant solvent 
changes i.e. movement of residues into and out of polar environments. 
 
This study illustrates two important concepts. Firstly, it shows that measurement of the 
individual aromatic residues provides a means of following the transitions between the 
denatured and native states of proteins. Secondly, it shows how knowledge of protein 
structure coupled with a simple laboratory technique can give just as detailed information 
about the unfolding process of multi-domain proteins compared to more expensive and 
technically demanding techniques such as Raman spectroscopy, MS and AFM. The 
second derivative of UV absorbance spectra, which isolates the three aromatic residues 
allows excellent monitoring of protein unfolding-refolding process for BSA and 
lysozyme. The speed and efficiency with which we can collect, process and interpret 
                  
 
176 
 
second derivative data from simple techniques like fluorescence and UV-absorbance 
using small sample volumes without expensive detection equipment highlights the 
advantage of this technique. 
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 Purification and 
Characterisation of IgG1 
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 Introduction 
The use of monoclonal antibodies (mAbs) as therapeutic agents is widespread in the 
biopharmaceutical industry. Humanised monoclonal antibodies are the fastest-growing 
category entering clinical study (Casi and Neri 2012; Scott, Allison et al. 2012). The 
global market for pharmaceuticals as of 2010 was $597 billion, of which mAbs accounted 
for 7%. By this time 10 mAbs had acquired blockbuster status as they generated in excess 
of $1 billion. The top five selling mAbs generated over €32 billion between them; 
bevacizumab (Avastin®) (16% market share), rituximab (Rituxan®) (16% market share), 
adalimumab (Humira®) (15% market share), infliximab (Remicade®) (15% market 
share), and trastuzumab (Herceptin®) (13% market share) (Elvin, Couston et al. 2013).  
As such, it is of vital importance that key features such as quality and safety is secured 
and approved to make them commercially viable and available for market. The most 
tedious challenge to this is ensuring antibody stability. This is mainly due to the choice 
of delivery, via subcutaneous injection (Jiskoot, Randolph et al. 2012; Lee, Perchiacca et 
al. 2013). Therapeutic formulations of mAbs have to be delivered in high concentration 
(> 100 mg) and in small volumes (< 2 ml) for intravenous administration. These highly 
concentrated formulations (50 mg/ml and higher) are susceptible to aggregation, that not 
only decreases the mAbs activity and efficiency, but may also be highly toxic and 
immunogenic to the patient (Harding, Stickler et al. 2010). It is widely accepted that 
injection of a foreign protein into humans can elicit an immune reaction (Rosenberg 2006; 
Zolls, Tantipolphan et al. 2012). Patient reactions can range from local skin irritation at 
the injection site, pyrexia and influenza-like symptoms, to acute anaphylaxis and systemic 
inflammatory response syndrome, which could be fatal (Hansel, Kropshofer et al. 2010; 
Jiskoot, Randolph et al. 2012). Therefore the development of these new types of therapies 
is highly dependent on understanding the molecular characteristics of the mAbs and what 
makes them unsafe. Despite great advancement in improving the safety of mAbs, adverse 
effects can still occur and steps to identify and minimize the risks are a necessity. 
 
During the production and processing of mAbs designed as therapeutics aimed for 
market, concerns with the stability of the mAbs must be overcome. Problems such as 
aggregation due to physical instability, deamidiation or oxidation due to chemical 
instability have to be addressed. One such proposed method is the engineering of 
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glycoforms expressed in the cell lines that produce the mAbs (Li, Vijayasankaran et al. 
2010).  
For therapeutic proteins it is important to understand both the biological function, 
typically defined by its amino acid component, and also the glycan component. A major 
proportion of biotherapeutic products are glycoproteins (Jefferis 2009). Control of 
glycosylation is of key concern during the development of therapeutic proteins because 
glycan chains play an important role in determining and maintaining the proteins 
conformation, activity and stability, in protein protection from proteolytic degradation, in 
intracellular trafficking and antigenicity (Bertozzi, Freeze et al. 2009; Roth and Khalaila 
2012). Engineering glycoforms to increase the biological activity of mAbs allows 
optimisation of their roles and enhances the functional diversity of the proteins. 
Glycosylation achieves this as every aspect of glycosylation can be modified from the 
glycosidic linkage, the glycan composition, structure and shape (Teillaud 2005). For these 
reasons, the ability to determine the glycosylation pattern of antibodies is garnering 
increasing interest and importance as it is fundamentally linked to the activity, solubility, 
interactions, folding, stability, pharmacokinetics and immunogenicity of the antibody 
(Igawa, Tsunoda et al. 2011). Establishing connections between glycan structures and 
their functionality or monitoring glycosylation in disease diagnosis and prognosis are 
important research areas and give more control over protein quality (Li and d'Anjou 
2009). 
 
One of the key goals of recombinant glycoprotein production is to achieve consistent 
glycosylation. The cell lines used to produce IgG mAbs also play a significant role in the 
synthesis of the glycan chain. Therefore it is advantageous to make the cell lines able to 
produce recombinant IgG with a well-defined pattern of glycosylation in their Fc region, 
or with the ability to express excess levels of the glycoenzymes (glycosyltranferase, 
glycosylhyrolases) needed to perform glycosylation (Teillaud 2005). Glycans can be 
modified by sialylation, fucosylation, sulphatation, methylation or acetylation all of 
which can greatly affect their efficacy including their biological activity and clearance 
rate.  Example include Chinese hamster ovary (CHO) cell lines that are engineered to 
express high levels of human β–1, 4–galactosyltransferase (GT) to reduce the rate of 
terminal GlcNac (Jones, Papac et al. 2007). Glycoproteins exposing glycans that end in 
Man, GlcNAc or Fuc residues are believed to be more rapidly removed from circulation. 
CHO cells were also modified to express ST6GalI, not naturally expressed in CHO cells, 
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to increase the α-2,6-linked sialic acid over α-2,3-linked sialic acid, a link that is known 
to increase sialylation of the oligosaccharides and shown to improve protein half-life 
(Bragonzi, Distefano et al. 2000).   
No straightforward technique to sequence glycans has been developed but instead relies 
on the multi-step combination of electrophoresis to isolate the glycan linked protein, 
enzymatic cleavage to release the glycan, chromatography for separation and finally mass 
spectroscopy and chemical digestion to study individual glycans. Obtaining sufficient 
quantities of a given glycan for analysis, especially with structures that are in low 
abundance, is also a problem. Once a structure has been solved, duplicating that structure 
artificially is difficult as the synthesis of each structure has to be designed (Costa, 
Rodrigues et al. 2013). 
 
As glycobiology aims to develop precise, robust and sensitive approaches for glycan 
production and analysis to meet the growing therapy demands, it needs to optimise and 
safeguard proper process control to ensure product efficacy and consistency. However, 
the problems faced include, heterogeneity of sugar structures that arise from the vast 
variety and diversity of glycan structures, sequences and linkages (Marino, Bones et al. 
2010). A relatively simple set of sugars can form a huge number of complex structures 
and any defects in their structure can have disastrous consequences. 
 
It must also be pointed out that while cell lines have been engineered to produce 
recombinant mAbs with a well-defined pattern of glycosylation in their Fc region, that 
the molecule being modified itself can show signs of unusual behaviour during 
production. Glycoforms can actually alter the structure and stability of the mAbs in a 
negative way (Zheng, Bantog et al. 2011). Focusing on the mAb IgG, numerous studies 
have looked at the solution solubility and stability of both glycosylated and aglycosylated 
mAbs to try find correlation between mAb glycosylation and aggregation (Arnold, 
Wormald et al. 2007; Wang, Antonsen et al. 2008; Kayser, Chennamsetty et al. 2011; 
Zheng, Bantog et al. 2011). The general consensus from the many reviews on the 
glycosylation of therapeutic proteins is that there are pros and cons to both methods. Sola 
and Griebenow have reviewed the effects that glycosylation has on the therapeutic 
efficacy of protein drugs and looks at both the instabilities of glycosylation on protein 
such as irreversible conformational changes and unfolding that can result in aggregation, 
but also highlights the effective long term stability glycosylation can bring by increasing 
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internal non-covalent forces and rigidifying the protein structure (Sola and Griebenow 
2009). While recently Jung et al. (Jung, Kang et al. 2011) have highlighted the advantages 
and benefits of producing aglycosylated mAbs including simplified bioprocessing 
development, shortened running times and high yields in bacteria, overcoming issues 
associated with glycan heterogeneity. They also noted that aglycosylated mAbs can 
display novel therapeutic effector functions and the probability of them having a higher 
degree of conformational mobility then glycosylated mAbs. 
 Aims of the study 
The objective of this chapter is to isolate, purify and characterise a monoclonal antibody, 
IgG1, from cell culture medium. Purified protein can be characterised by gel 
electrophoresis and SE-HPLC. Methods and procedures for both of these techniques need 
to be optimised to ensure accurate identification of the purified product. Two growth 
conditions were used in growing the cells producing the protein, Batch 1 (shake flasks) 
and Batch 2 (bio-reactor). It was important to analyse the different effects that these two 
culture conditions had on the production of the protein of interest. Initial stability studies 
on the purified protein were also conducted to assess the effect storage conditions had on 
the protein.  
 
Changes in the growing conditions of the cell lines producing the protein can result in 
degradation of the protein and thus result in changes to the glycosylation pattern. 
Monitoring the glycoform can ensure product efficacy and consistency. There is 
enormous diversity in the type of glycan structures that can attach to IgG. Variation or 
change to the glycoform attached to a protein can lead to numerous alterations in the 
protein structure that in turn can affect the proteins stability & ability to function (Zheng, 
Bantog et al. 2011). The glycoform attached to the IgG1 was isolated and its fingerprint 
identified. Stability studies on the short and long term storage conditions were conducted 
to assess changes in the isolated glycoform. 
 
While there is still some debate about the optimal glycoform required for stability, there 
is a general consensus that glycosylation does indeed lead to enhanced molecular stability 
and has therapeutic advantages for the pharmaceutical industry (Sola and Griebenow 
2010). However, reliable techniques to fingerprint glycoforms for a particular mAb or 
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therapeutic protein are required and in-fact, this information is often not available during 
formulation, in particular. Hence, there remains a need for a comprehensive perspective 
on the subject and for increased understanding of this aspect of protein post translation 
modification to aid in the design of successful protein-based therapeutics. 
 Results 
 Purification of monoclonal antibody. 
The monoclonal antibody IgG1 was expressed in CHO (DP12v2) cell line and grown in 
either shake flasks or a 2.5 L bioreactor by Ian Marison’s group at DCU. The cell culture 
medium was kindly gifted to us. Purification of IgG1 from the cell medium was 
performed by affinity-purification using an immobilized Protein A column. Figure 6.1 
shows the binding and elution of the protein to and from the column. Fractions are 
collected within the time indicated and pooled. 
 
Figure 6.1:  Elution profile of IgG1 after passage through a Protein A column. The 
black line represents loading the cell culture medium onto the column, the red line is the 
binding buffer while the green line is the elution of protein. 
 
To ensure that only the desired protein, IgG1, was purified in its native monomeric form, 
the pooled fractions were subjected to SE-HPLC and gel electrophoresis as indicators of 
the protein purity obtained. 
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 SE-HPLC 
Depending on the protein class, the isoelectric point of IgG1 can range from 6.3 to 8.1 
(Abraham, Podell et al. 1979). As the protein was eluted from the column, fractions are 
collected into tubes containing 1 M Tris-HCl, pH 9. This is to ensure that the final pH of 
the protein solution is neutral, since the elution buffer is an acidic buffer, 0.1 M citric 
acid, pH 4. The effects of leaving purified protein overnight in this neutral Tris-HCl buffer 
can be seen with SE-HPLC (Figure 6.2). The chromatogram shows several peaks 
corresponding to a range of molecular weights, the majority of which are lower in 
molecular weight than protein monomer. In fact, a protein monomer peak is not present. 
There appears to be excessive degradation of the protein. 
 
Figure 6.2: SE-HPLC of purified sample IgG1 left in 1 M Tris-HCl overnight compared 
to purified IgG1. 
 
For this reason the pooled fractions had their buffer exchanged into 50 mM sodium 
phosphate, pH 8 using Amicon ultra 0.5ml 100K membrane centrifugal filter units 
immediately after collection. A chromatogram of IgG1 in this buffer condition is shown 
in Figure 6.3. The IgG1 in sodium phosphate shows a major peak at 8.58 minutes. From 
the calibration of the TSK 300 SWxl column used to separate the protein, a peak at this 
retention time corresponds to a molecular weight of 150 kDa, which is the expected 
molecular weight for an IgG1.  
                  
 
184 
 
 
Figure 6.3: SE-HPLC of different purified samples of IgG1 in 50 mM sodium phosphate, 
pH 8, showing a single monomeric protein peak along with a small portion of higher and 
lower molecular weight species (less than 0.7%). 
 
The chromatogram also shows a small fraction of higher and lower molecular weight 
species, less than 0.7% of the total protein in the sample. These peaks were attributed to 
a dimer species of the IgG with a molecular weight of 300 kDa and the presence of a 
lower molecular weight species of 50 kDa, possibly the heavy chain of IgG1. 
 Gel electrophoresis 
Gel electrophoresis was used as a second method to confirm the purity of the IgG1 
collected. To achieve this two gel types were utilized; Native and SDS-PAGE. Native gel 
electrophoresis allows for detection of proteins in their native form, in our case IgG1 as 
an intact 150 kDa monomeric protein, visualised as a single protein band at a molecular 
weight of 150 kDa, while reducing SDS-PAGE would allow us to break the IgG1 into its 
characteristic heavy and light chains via reduction of the disulphide linkages between 
light and heavy chains, another method of identifying if the correct protein had been 
purified. 
 Identifying intact monomeric IgG1 
The preparation of IgG1 samples for gel electrophoresis had to be optimised. The 
progression of the protocol optimisation is shown in Figure 6.4. In our initial experiments 
the gels were prepared from 12% polyacrylamide solutions. This was reduced to 7% to 
prevent protein retention in the stacking gel. Concurrent with this there was aggregation 
of the protein upon mixing with the sample buffer. Originally, sample buffers were 
prepared with 0.5 M Tris-HCl, pH 6.8. While more protein was resolved with the 7% 
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SDS-PAGE, it resulted in gels with smeared bands. Different samples buffers were 
prepared with a range of pHs. Upon mixing with IgG1, a colour change from the normal 
blue, to yellow/green solution could be observed, a possible indication of aggregation of 
the sample. It was found that at pH 8, matching that of the protein buffer, no visual 
aggregation could be observed and the sample buffer retained its blue colour. It seems 
likely that pH 6.8 is close to the isoelectric point of the IgG1 and that resulted in 
aggregation. However on the 7% SDS-PAGE even with sample buffer at pH 8, the IgG 
still showed band smearing and protein aggregates trapped in the wells of the gel. SDS-
PAGE gels were used with a non-reducing sample buffer (no 2-mercaptoethanol) to 
isolate the intact monomeric protein. However, it was also likely that the SDS present in 
the sample buffer and running buffer was possibly affecting the IgG1 stability. It was 
apparent that SDS-PAGE could not be used to isolate the intact monomeric IgG1. Instead, 
native gels were used, free from SDS to ensure that denaturation or aggregation did not 
occur. Using this method a single strong monomeric protein band at the correct molecular 
weight was observed. 
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Figure 6.4: Isolation of intact IgG1 using gel electrophoresis. The evolution of gel 
preparation to obtain a clear monomeric band of IgG1 using native gels without any 
signs of aggregation or degradation to confirm the purity of the desired protein. 
 
 Identifying heavy and light chains of IgG1 
IgG is made up of two heavy chains (50 kDa each) and two light chains (25 kDa each) 
that are held together by covalent cysteine bonds. Therefore SDS-PAGE with reducing 
conditions was used to separate and identify the heavy and light chains at the correct 
molecular weights, as another means to confirm the purification of IgG1 (figure 6.5). The 
pores in a 12% polyacrylamide gel were of sufficient size to resolve protein within the 
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molecular weight range of the heavy and light chains. The pH of the sample buffer was 
adjusted from the standard protocol of pH 6.8 to pH 8 to match that of the protein sample 
buffer to avoid aggregation of the IgG1. The sample buffer also contained 2-
mercaptoethanol to break the cysteine bond between the two chain types. 
 
Figure 6.5: Separation of the heavy chain and light chain of IgG1 using gel 
electrophoresis. 12% SDS-PAGE gel using reducing conditions (2-mercaptoethanol) to 
break the cysteine bonds that hold the IgG1 intact. Two clear separate bands can be seen 
representing the heave chain at 50 kDa and the light chain at 25 kDa. 
 
 Batch to batch variation 
 Protein yield 
The electrophoresis confirmed that for both batches, IgG1 was isolated, but there were 
clear differences in the quality of product purified from each batch. This was analysed in 
greater detail.  Table 6.1 illustrates the concentration of IgG retrieved after three separate 
purifications from each batch of IgG1 after buffer exchange in 50 mM sodium phosphate, 
pH8. Each batch had an initial volume of 50 ml for Batch 1 and 30 ml for batch 2. Batch 
1 had a much lower yield compared to Batch 2. 
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Batch # 
Purified IgG1 
(mg/ml) 
Volume 
(ml) 
Total yield 
(mg) 
1 2.82 8.5 23.97 
1 2.59 8 20.72 
1 1.25 8.5 10.63 
    
2 5.9 8.5 47.2 
2 5.47 8.5 43.82 
2 4.43 8.5 37.69 
Table 6.1: Concentration analysis of purified IgG 
 Gel Electrophoresis 
The variation between the batches was detected by gel electrophoresis. Gel 
electrophoresis on Batch 1 (flasks) showed that the purified IgG1 had aggregated and was 
unable to be resolved on the gel, even in the optimised conditions (Figure 6.6). It was 
likely that the protein had aggregated prior to purification as the same large band can be 
seen in the well of the gel in both of the native gels, before and after purification. Bands 
at the molecular weights consistent with heavy and light chains can also be observed in 
the unpurified sample indicting possible degradation of the native protein prior to 
purification. The protein was confirmed however as IgG1 through identification of the 
heavy and light chains on the reducing gel. This also confirms that the type of aggregate 
formed was by covalent attachment as the aggregates could be broken up by 2-
mercaptoethanol. 
 
Figure 6.6: Batch 1 of IgG1 characterised by gel electrophoresis. The 7% native 
purified gel shows a faint band at 150 kDa the molecular weight of IgG1 but the majority 
of the material is aggregated in the wells of the gel. The reduced gel confirms IgG1 was 
purified. 
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Gel electrophoresis of Batch 2 (bioreactor) showed a strong, single intact band at 150 kDa 
in the native purified gel indicating purification of monomeric IgG1. This was also 
confirmed using a reducing SDS-PAGE showing the two characteristic bands, one for 
each of the heavy and light chains (Figure 6.7). 
 
 Figure 6.7: Batch 2 of IgG1 characterised by gel electrophoresis. The 7% native 
purified gel shows a strong band at 150 kDa the molecular weight of IgG1. The reduced 
gel confirms IgG1 was purified. 
 
 SE-HPLC 
SE-HPLC also detected variation between the two protein batches (Figure 6.8). A 1 
mg/ml solution of IgG1 from each batch was compared by SE-HPLC (injection volume 
= 40 μl). Batch 1 had a much lower monomer yield compared to batch 2. Batch 2 had a 
99% yield of monomeric IgG1 with only 1% of dimer and higher molecular weight 
species. In Batch 1 a high proportion of lower molecular weight species, nearly 88% of 
the total sample detected. 
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Figure 6.8: SE-HPLC analysis of Batch 1 (A) and Batch 2 (B) of purified IgG1. The 
amount of monomer protein between each batch varied greatly. 
 
There was clearly significant differences in the protein material taken from shake flasks 
(Batch 1) versus the protein material grown in the bio-reactor (Batch 2). Further 
discussion with our colleagues at DCU revealed that cells were grown longer than is 
optimal during production in shake flasks (batch 1) and some cell death occurred. We 
speculate that this resulted in enzymatic damage to the IgG1 in the culture medium as a 
result of this cell death. Therefore, for our study, IgG1 from Batch 2 was used for further 
analysis. All of the electrophoresis experiments indicate a protein with a molecular weight 
consistent with IgG1 (150 kDa) and reducing conditions show the characteristic heavy 
and light chain bands. SE-HPLC indicates that the protein is very pure. 
 Stability of purified IgG1 
The monomeric IgG1 from Batch 2 was used to evaluate the stability of the purified 
protein, in 50 mM sodium phosphate buffer at pH 8. The protein was monitored using 
SE-HPLC over a two week period. Two different storage conditions were examined. One 
sample set was stored at 24°C, and the other at 4°C. Figure 6.9 shows the chromatograms 
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of the two sample sets along with the positions of the three major peaks identified in the 
chromatogram in Figure 6.8. 
 
Figure 6.9: SE-HPLC of IgG1 in 50 mM sodium phosphate, pH 8. A) IgG1 stored at 4°C 
and B) at 24°C at day 1 just after purification, washed into 50 mM sodium phosphate, 
pH 8, on day 7 and on day 14. 
 
There is no significant migration in peak positions, change in peak shape or the 
appearance of new peaks that could indicate aggregation or degradation (within the 
column resolution) of the protein due to a decrease in protein stability. However, there 
does appear to be a decrease in the area under the peak with increasing time. The area 
under each peak was monitored over time to see if there was any loss in protein that might 
indicate the formation of larger aggregates that would not have been observed on the SE-
HPLC column (Figure 6.10). 
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Figure 6.10: SE-HPLC calculated % area under the three main peaks of IgG stored at 
4°C and 24°C over 14 days. A) Shows the change in monomer. B) Higher order species. 
C) Lower order species. 
 
From Figure 6.11 we see that a significant decrease in protein monomer concentration 
and corresponding decrease in the already low proportions of the other species in solution. 
Between 12 - 18% of the monomer is lost by day 7, and this increases to nearly 30% by 
day 14. This loss is likely attributed to the formation of higher molecular weight 
aggregates, too large to be resolved on the SE-HPLC column. The column resolution is 
only up to 500 kDa, too low to resolve protein much larger than a trimer of IgG1. The 
way in which the samples were stored will also play a role. The IgG1 was transferred to 
a HPLC vial on day 1. If large aggregates form (by Mechanism 1, 2 or 4, and in the 
absence of external stress, mechanism 1 is most likely), they will sediment in the vial and 
will therefore, not be injected onto the column during subsequent runs. It is also probable 
that some portion of the material became irreversibly absorbed on the glass surface (by 
Mechanism 5), which would account for some portion of the loss of protein. 
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 Identifying the glycoform of IgG1 
The glycosylation pattern for this IgG1 was determined and the stability of the sugars 
against degradation was assessed for samples stored in different conditions and over a 
range of time scales. Four sets of sample conditions were examined: 
1. IgG1 at time zero (Frozen -80°C directly after purification) 
2. IgG1 stored at 24°C over 7 days 
3. IgG1 stored at 4°C over 7 days 
4. Year old sample of IgG1 stored at 4°C 
 
Prior to enzymatic cleavage to release the glycan, the glycosylated heavy chain (50 kDa) 
of the purified IgG1 was isolated on a SDS reducing gel (Figure 6.11). Gel pieces were 
chopped up and incubated with the enzyme to allow sufficient release of the N-linked 
glycan. 
 
Figure 6.11: SDS-PAGE reducing gel of IgG1 for glycosylation analysis. Lane 1- IgG 
year old, lane 2-3 IgG stored at 4°C over 7 days, lane 4-5 IgG stored at 24°C over 7 
days, lane 6-7 IgG at time zero. 
 
N-glycans were then analysed using ultra-high pressure liquid chromatography (UPLC). 
This was chosen over HPLC as it offers increased separation efficiency, and has 
significantly reduced separation times and higher peak capacity (Tharmalingam, 
Adamczyk et al. 2013). 
 Undigested samples 
Four IgG samples from a single batch (Batch 2) of purified protein had their undigested 
glycoform analysed. All four conditions were analysed in duplicate. Using UPLC and 
standardised against a dextran ladder. Once the elution profile for each sample was 
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obtained, the glucose unit (GU) value was determined for each identifiable peak (Figure 
6.12). This involved comparing the elution of the dextran ladder (with each successive 
peak in the ladder adding a GU) to the profile of our sample. The retention times of the 
glycan peaks were compared to the retention times of the standard dextran ladder to assign 
a glucose unit. The assigned value could be compared to a database of known glycan 
structures to tentatively assign glycan structures, GlycoBase 3.0+. 
 
Figure 6.12: Dextran ladder standard profile obtained from separation using UPLC. 
Each peak represents the retention of a polysaccharide of glucose, where the first peak 
represents 1 glucose, the second 2 glucose units etc. This is then used to assign GU 
values to the glycoform of our IgG1. 
 
Once GU values had been assigned, the % area under each peak was calculated for both 
samples under the same storage condition to ensure consistency in the glyco profile. 
Figure 6.13 shows the UPLC glycosylation profile of the different IgG1 sample sets. Each 
peak represents a type of oligosaccharide moiety present in the glycoform. The areas 
under each peak were integrated to show the relative amounts of a glycan type compared 
to that of the overall glycoform. Therefore by monitoring the % area of each individual 
peak, we can relate a % loss to degradation of that glycan in the glycoform.  
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Figure 6.13: Elution profile for IgG time zero (-80°C) along with bar chart comparing 
the % area under each peak for duplicate samples. 
 
 
 
Figure 6.14: Elution profile for IgG day 7 (24°C) along with bar chart comparing the % 
area under each peak for duplicate samples. 
 
 
                  
 
196 
 
 
Figure 6.15: Elution profile for IgG day 7 (4°C) along with bar chart comparing the % 
area under each peak for duplicate samples. 
 
 
 
Figure 6.16: Elution profile for IgG year old (4°C) along with bar chart comparing the 
% area under each peak for duplicate samples. 
 
It’s important to ensure that similar glycan profiles for two identical samples are obtained. 
In each case there was little variation in GU values or peak % area between each sample 
per storage condition, thus indicating good release of the sugars from the protein and 
consistent profiling of the glycoform. 
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The stability of the glycoforms was examined by comparing the individual glyco profiles 
from the four storage conditions to each other (Figure 6.17). For each sample set, the 
glyco-profiles and the average % area under each peak were compared. This was to assess 
if the different storage conditions had an effect on the glycan profile. 
 
 
Figure 6.17: Comparison of the glycan profile from four different storage conditions. 
A) Elution profile for the glycoform distribution of the four storage conditions of IgG. 
B) Bar chart indicating the % area under each peak for the four different storage 
conditions. 
 
From this data it appears that each of the four sample sets have considerable overlap and 
uniformity between their glyco profiles and in their retention behaviour, indicating that 
all samples still have the same glycoform attached to the Fc portion of the IgG1. The loss 
in % area between each sample is also minimal, signifying that the glycoform stored under 
the four different conditions remained completely stable with no degradation. This 
indicates that the storage conditions used did not impact on the glycoform structure. From 
this work it was established that the glycosylation of this particular IgG1 is very stable at 
different storage temperatures and over prolonged periods of time. 
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 Digested samples 
In order to fully understand the stability of the IgG protein, it was important to decipher 
its glyco form distribution. This detailed structural analysis involves the separation of a 
glycan pool to provide a signature profile that gives an overview of the individual glycan 
moieties present. Intact glycans released from purified IgG1, were broken down into a 
specific oligosaccharide units by enzymatic cleavage and analysed by NP-HPLC. 
 
After release of the glycoform from the protein, prior to examination by chromatography, 
the samples underwent treatment with enzymes known as exoglycosidases. This step 
yields information about both the sugar sequence and linkages between the sugar units. 
Specific enzymes are chosen to systematically cleave off oligosaccharide units with 
defined linkages. After the initial analysis of the undigested samples, an array of different 
enzyme combinations were chosen to progressively break down the individual elements 
in the glyco pool. These enzymes do not cleave internal bonds between carbohydrates but 
remove terminal carbohydrates from the non-reducing end of a glycan. Using this 
techniques, the removal of glycan residues can be identified by linkage as well as sugar. 
 
The 2AB labelled N-glycans were treated sequentially with exoglycosidase enzymes. The 
exoglycosidases and their role used in this digest include (Marino, Bones et al. 2010); 
1. Arthrobacter ureafaciens sialidase (ABS) – releases α(2-6/3/8) –linked 
nonreducing terminal N- acetylneuraminic acid (NANA, Neu5Ac) and N-
glycolylneuraminic acids (NANA, Neu5Gc) 
2. Bovine kidney alpha-fucosidase (BFK) – releases α(1-2/6) –fucose linked 
nonreducing terminal fucose residues more efficiently than α(1-3/4) –linked 
fucose. 
3. Bovine testes β-galactosidase (BTG) – hydrolyzes nonreducing terminal galactose 
with β(1-3/4) linkages. 
4. Β-N-acetylgucosaminidase cloned from S. pneumonia, expressed in Escherichia 
coli – digests β(1-4) –linked GlcNAc to mannose but not a bisecting GlcNAc β(1-
4) linked to mannose. 
5. Jack Bean α(1-2,3,6)-Mannosidase (JBM) – releases non-reducing terminal α(1-
2,6)-linked mannose residues more efficiently than α(1-3). 
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Data analysis of glyco profiles can be complex and difficult due to differences between 
the various platforms of analysis. Interpretation of results is a challenging task, so reliance 
on a comprehensive and accessible database is a necessity. For this reason this data was 
interpreted using a bioinformatic tool, GlycoBase 3.0+ to establish the glycan 
composition for the IgG1. This database is continually being developed at NIBRT and 
branched off from EurocarbDB. It is a novel HPLC/UPLC resource that contains elution 
positions for more than 650 2AB-labeled N-linked and O-linked glycan structures 
determined by a combination of HPLC, UPLC, exoglycosidase sequencing and mass 
spectrometry (Tharmalingam, Adamczyk et al. 2013).  
 
Three different pieces of information allow the glycan structure to be predicted 
1. Change in peak area – as parts of the glycan are cleaved off, the % area of the 
remaining peaks in the profile increases, while the overall number of peaks 
decreases. The % area in the UND sample peaks in Figure 6.18 is spread over 7 
peaks totalling the whole glycan profile. Peaks disappear with successive digests 
indicating loss of that structure and the % area of the remaining peaks increases. 
The purple bar in Figure 6.18 shows that with that combination of exoglycosidases 
all of the glycan structures apart from one moiety have been cleaved off and so 
the single peak left accounts for 100% of the area resolved. 
2. The shift in retention time – as parts of the glycan are cleaved off, you decrease 
the overall size of the glycan causing the retention time to shift slightly. Specific 
shifts in retention times in combination with the enzyme used, are characteristic 
of certain glycan structures e.g. cleavage of galactose can result in two changes: 
6-linked Gal shows a peak shift to lower retention time compared to cleavage of 
a 3-linked Gal. 
3. The GU values – Glycobase3.0+ has GU values assigned to known structures. 
 
                  
 
200 
 
 
Figure 6.18: Exogylcosidase digest of the 2-AB labelled N- glycan of IgG1. % area 
under each peak of the glycan profiles after successive addition of enzymes. 
 
The combination of the specificity of the exoglycosidase used and a knowledge of the 
incremental value of each moiety facilitates the analysis of the glycan sequence and 
linkage assignment. With these three factors in conjunction with the database it was 
possible to predict the glycan structures present in our IgG1 glyco profile. Figure 6.19 
shows the NP-HPLC glycosylation profile of IgG1 in its undigested form (UND) along 
with the profiles of the glycans successively treated with different exoglycosidases. The 
confirmation of the structure using exoglycosidase digestions is important to confirm the 
heterogeneity of the glycans profiles obtained. 
                  
 
201 
 
 
Figure 6.19: NP-HPLC Glycan profiles of 2AB labelled N-glycans from IgG1 (A) with 
(B) Arthrobacter ureafaciens sialidase (ABS) (C) Bovine kidney alpha-fucosidase (BFK) 
(D) Bovine testes β-galactosidase (BTG) (E) Β-N-acetylgucosaminidase (GUH) (F) Jack 
Bean α(1-2,3,6)-Mannosidase (JBM) along with their predicted glycan structure. 
 
The major peak was assigned as the structure F(6)A2G(4)S2(6)1 at 8.13 GU, with all 
other structures shown in Table 6.2. With the addition of the ABS the peak was reduced 
to a major peak at 6.76 GU, which confirmed the presence sialic acids [S2(6)]. This peak 
was further reduced to just 5.8 GU with the addition of BTG, which confirmed the 
presence of terminal galactose [G(4)] on the glycans.  BFK releases the terminal fucose 
[F(6)] to give a peak at 5.3 GU, while the GUH will digest BGlcNac [A2G1] to give a 
peak at 4.3 GU. Finally profile (F) shows the peak at 2.7 GU as JBK releases the mannose 
[M3-M1] to leave just the N-Acetyl-Glucosamine, GlcNac –GlcNac- mannose moiety. 
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Nomenclature Glucose units Proposed glycan GlycoBase I.D 
M1 2.7 
 
530 
M3 4.3 
 
597 
A2G1 5.3 
 
759 
F(6)A2(6)G1 5.8 
 
735 
    
F(6)A2(6)G(4)1 6.76 
 
634 
    
F(6)A2G(4)S2(6)1 8.13 
 
683 
 
Table 6.2: Exoglycosidase digestions of IgG1. The Nomenclature abbreviations include 
M (mannose), A (antennae), G (galactose), F (fucose), and S (sialic acid). The structures 
contain sugars including GlcNAc (⧠), Man (○), Gal (◊), Fuc (⟐) and NeuAc (⋆).  
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 Discussion 
Non-optimal conditions during protein expression, purification, handling and storage can 
severely alter the protein conformation, resulting in aggregation and loss of activity 
(Bondos and Bicknell 2003). Therefore optimisation of the purification process is an 
extremely important step in any protein purification work to guarantee isolation of the 
correct protein without adverse effects on its structure. Controlling the environment and 
purification strategies can minimised the extent of aggregation (Cromwell, Hilario et al. 
2006). This was evident in our batch to batch variation analysis. We could see the effect 
that growth conditions had on the quality and stability of protein product. Batch 1 grown 
in shake flasks showed evidence of protein aggregation and degradation even before 
purification as evidenced by gel electrophoresis. It also gave much lower purified protein 
yields compared to Batch 2. It was difficult to get consistent data from this material. Upon 
consultation with Prof. Ian Morrison’s group it appeared there was difficulties with 
growing the cells that produced the cell medium for Batch 1. This would account for the 
observed batch to batch variation. 
 
Another step to control aggregation of protein involves optimising the purification 
process (Roberts and Wang 2010; Mach and Arvinte 2011). This also aids in optimising 
additional sample preparations steps such as buffer exchange and filtering, necessary to 
get protein samples ready for downstream analytical methods of characterisation. To 
achieve this, buffer conditions were controlled so that optimum purity and stability of 
IgG1 could be achieved. It was found that washing the protein into 50mM sodium 
phosphate, pH 8, buffer the protein could maintain its monomeric form, compared to 
being left in the purification protocol buffer, Tris-HCl. Excessive damage to the protein 
was detected by SE-HPLC when the protein was left in this buffer. 
 
The buffer conditions play a significant role in the shelf-life of therapeutic proteins. 
Buffers are used to maintain the pH of the protein formulation and thereby help stabilise 
the protein. One of the first steps in the formulation process is to determine the pH and 
ionic strength where the protein is natively folded, and minimal amount of 
degradation/aggreagtion events will occur (Daugherty and Mrsny 2006). Numerous 
studies have detailed both improved stability and aggregation of monoclonal antibodies 
under various storage buffers, temperatures and length scales (Sarciaux, Mansour et al. 
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1999; Arosio, Jaquet et al. 2012; Majumdar, Manikwar et al. 2013). Initial stability tests 
were performed assessing the long term storage of IgG1 in the buffer condition (50 mM 
sodium phosphate, pH 8), analysed over a two week period, at two different storage 
temperatures, 4 ○C and 24 ○C. It was observed that there was a significant loss of 
monomeric protein, presumed to be higher order aggregates (~30%) through either self-
association, or surface induced aggregation. This was not explored further. Continuation 
or additional stability optimisation experiments could not be carried out to due to a 
shortage of sample. It was not possible to obtain addition cell culture medium to continue 
the stability tests it was hoped could be performed. 
 
There is enormous variability in the glycosylation site of IgG in that they can contain 
different patterns of glycans which could affect their biological function along with their 
stability (Raju, Briggs et al. 2000; Bertozzi, Freeze et al. 2009). In order to fully 
understand the stability of the IgG1 protein purified, it was important to identify its 
glycoform. Glycosylation is an important step in the recombinant expression of mAbs 
and is therefore a significant variable to monitor, especially where the stability of the 
mAbs is being considered (Sola and Griebenow 2010; Costa, Rodrigues et al. 2013). 
Glycan heterogeneity can be altered by many cell culture environmental factors including 
nutrient starvation, metabolic waste accumulation, culture viability, pH and temperature 
(Andersen, Bridges et al. 2000; Yang and Butler 2000; Kontoravdi, Asprey et al. 2007). 
Thus there is a requirement to monitor variables in the attachment of a glycan in order to 
ensure consistent glycosylation and glycoprotein formation. 
 
In this study it was confirmed that the IgG1 purified had a high degree of homogeneity 
of N-glycans within its glycan pool. The structure of the carbohydrate chain of the FC 
region of all the IgG1 samples was found to contain N-Acetyl-Glucosamine (GlcNAc), 
mannose (Man), galactose (Gal), sialic acid (Sia) and fucose (Fuc) with no variations 
occurring This shows there was batch-to-batch consistency in the protein formulation and 
glycosylation of the IgG1, signifying that the culture conditions and the culture medium 
used to grow the transfected cells produced well defined glycan chains. This glycoform 
was seen to be stable over a prolonged time period (up to 1 year). Storage temperature 
also had no apparent effect on the glycan profile. 
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 Conclusions and future work 
This study has highlighted the importance of cell culture conditions in the formulation of 
IgG1. We have shown that IgG1 grown in shake flasks caused undesirable damage to the 
protein believed to be caused by non-optimal growth conditions. IgG1 grown from 
bioreactor conditions was purified with a high monomer content. The buffer and storage 
conditions also play a role on maintaining the stability of protein and conditions need to 
be optimised at the early stages of purification to prevent unwarranted damage to the 
protein. 
 
One of the original aims of this work was to assess the structural stability of the purified 
IgG1. It was hoped to evaluate the behaviour of the protein when subjected to different 
stress mechanisms by completing different forced degradation studies. Having a detailed 
characterisation of the purified protein product was a key achievement towards this goal. 
Future work would include further characterisation of the physicochemical properties of 
the protein including sequencing of the primary structure by mass spectroscopy. A more 
detailed assessment of buffer conditions where optimal stability is achieved giving 
potential to determine the isoelectric point of the protein would prove highly useful. 
 
Homogeneous glycosylation of the IgG1 purified was confirmed. The glycosylation of 
the IgG1 also appeared to be stable over an extended time period with different storage 
conditions. The results of this study will enhance our understanding of the IgG1 protein. 
While the stability of the glycoform has been confirmed, its impact on the stability and 
the activity of this IgG1 is yet to be tested. This analysis would prove highly useful when 
exploring the stability of the protein. 
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Summary and Concluding Remarks 
The aggregation of proteins formed by a number of distinct mechanisms has been 
examined using a range of chemical and biophysical techniques. Care must be taken when 
interpreting the results of such studies. We have shown that protein aggregates, resulting 
from a single stress (thermal or oxidation) can range from nanometres to many microns 
in size and can even result in fragmentation of the protein (oxidation) with these 
fragments also aggregating. We have shown that the type and quantity of aggregation can 
vary greatly with just a single solution condition, for example, the thermal denaturation 
of BSA at pH 5 (large protein assemblies) versus pH 6 (small oligomeric aggregates). It 
was also shown that the same stress mechanism can result in protein aggregates with 
different morphologies (oxidised lysozyme at pH 5 (amorphous) versus lysozyme at pH 
8 (fibrils). This shows how two proteins in the same solution conditions and with the same 
stress mechanism can react very differently. 
 
Here in lies the challenge of analysing and characterising protein aggregation. It is the 
variety in the types of aggregates formed in addition to the range in particle sizes means 
that no single technique can monitor the whole aggregation pathway. Also it appears that 
no specific mechanism produces a specific aggregate type. This is of significant 
importance given the intensive drive towards high-throughput screening within the 
biopharmaceutical industry to speed up the generation of lead candidates as drug targets 
or therapeutic proteins. With the aim of improving the time cycle for introducing targets 
and reducing production costs, are they compromising at the cost of accuracy, efficiency 
and safety? As we have shown with the assessment of two high-through put screening 
assays, while useful as a first pass screening platform, it also has major drawbacks. A 
more detailed assessment of the data obtained using high throughput methods can be 
misleading and not representative of the true aggregation levels. While the use of 
orthogonal high throughput techniques will be more discriminating than the limited 
number of assays used in this study, it is unlikely that in-depth sample-by-sample analysis 
will become obsolete, since it is still the best way to fully characterise protein aggregation.  
The use of second derivative UV absorbance was demonstrated to be a reliable tool for 
the characterisation of unfolding states of protein as a result of chemical denaturation. 
The second derivative unfolding curves for lysozyme with two denaturants, urea and 
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GdmHCl correctly indicated a two-state unfolding mechanism. For BSA, which is known 
to unfold via intermediate states, it was possible to identify the concentrations of 
denaturants at which specific domain unfolding occurred by monitoring the second 
derivative absorbance of tryptophan. The data agrees with previous work on the unfolding 
of BSA measured with a variety of techniques. This was a surprising level of 
sophistication for such a simple technique. Second derivative UV absorbance could be 
further explored by looking at other proteins with known unfolding mechanisms to further 
establish its usefulness and sensitivity at monitoring unfolding transitions.  
 
The final objective of this work was to be able to compare the model proteins (lysozyme 
and BSA) to a more biologically relevant therapeutic glycoprotein, IgG. Due to the 
structural complexity of IgG, it is a challenge to preserve its biological activity and 
stability throughout upstream processing (formulation and purification) along with 
downstream processing (storage and administration). A more thorough understanding of 
the aggregation mechanisms and pathways for therapeutic proteins encountered during 
their development is needed to enhance their formulation. Initial studies assessing the 
stability of the IgG1 protein were performed, however no further optimisation 
experiments could be carried out due to a shortage of sample. However, significant 
progress was made towards this aim. Protocols were developed for the purification and 
characterisation of the protein and a glycosylation fingerprint was measured for the 
protein. Therefore a platform from which a more detailed analysis of the stability of this 
IgG1 against aggregation can be performed in the future.  
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